Jaffer A. Ajani, M.D.

Peer-Reviewed Articles

1. Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, Pavese J, Matsangou M, Bhattacharya P, Ueno Y, Wang X, Shah MA. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. e-Pub 2024. PMID: 38954176.
2. Sewastjanow-Silva M, Kwiatkowski E, Yamashita K, Abdelhakeem A, Yoshimura K, Vicentini ER, Pizzi MP, Jin J, Fan Y, Zou G, Wang L, Yin F, Dhar SS, Blum Murphy M, Mares JE, Li JJ, Gan Q, Waters RE, Rogers JE, Ajani JA. Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience. Int J Cancer. e-Pub 2024. PMID: 38995150.
3. Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol 8(1):166, 2024. e-Pub 2024. PMID: 39085400.
4. Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Blum Murphy M, Amaya-Chanaga C, Patel A, Hu N, Matsumura Y, Kitagawa Y, Ajani J. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med 13(9):e7235, 2024. PMID: 38716626.
5. Shitara K, Shah MA, Lordick F, Bang YJ, Ilson D, Cutsem EV, Enzinger P, Kim SS, Klempner SJ, Moran D, Park JW, Bhattacharya P, Ajani JA, Xu RH. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary. Future Oncol:1-17. e-Pub 2024. PMID: 38861294.
6. Zou G, Huang Y, Zhang S, Ko KP, Kim B, Zhang J, Venkatesan V, Pizzi MP, Fan Y, Jun S, Niu N, Wang H, Song S, Ajani JA, Park JI. E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming. J Exp Med 221(4), 2024. e-Pub 2024. PMID: 38411616.
7. Rogers JE, Ajani JA. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies. Curr Opin Oncol. e-Pub 2024. PMID: 38726797.
8. Strickland MR, Lander EM, Gibson MK, Ilson DH, Ajani JA, Klempner SJ. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management. J Natl Compr Canc Netw:1-8. e-Pub 2024. PMID: 38503041.
9. Sewastjanow-Silva M, Xiao L, Gonzalez GN, Wang X, Hofstetter W, Swisher S, Mehran R, Sepesi B, Bhutani MS, Weston B, Coronel E, Waters RE, Rogers JE, Smith J, Lyons L, Reilly N, Yao JC, Ajani JA, Murphy MB. Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study. Cancers (Basel) 16(7), 2024. e-Pub 2024. PMID: 38611056.
10. Yamashita K, Sewastjanow-Silva M, Yoshimura K, Rogers JE, Rosa Vicentini E, Pool Pizzi M, Fan Y, Zou G, Li JJ, Blum Murphy M, Gan Q, Waters RE, Wang L, Ajani JA. SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel. Cancers (Basel) 16(7), 2024. e-Pub 2024. PMID: 38610978.
11. DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. e-Pub 2024. PMID: 38358339.
12. Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol:JCO2301601. e-Pub 2024. PMID: 38382001.
13. Rogers JE, Ajani J. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma. Curr Oncol 31(2):769-777, 2024. e-Pub 2024. PMID: 38392051.
14. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. e-Pub 2024. PMID: 38297981.
15. Badgwell B, Estrella J, Roy-Chowdhuri S, Ikoma N, Blum Murphy M, Ajani J, Mansfield P. Updated Analysis of a Phase 2 Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Peritoneal Carcinoma from Gastric Cancer. Ann Surg Oncol. e-Pub 2024. PMID: 38286882.
16. Yonemura A, Semba T, Zhang J, Fan Y, Yasuda-Yoshihara N, Wang H, Uchihara T, Yasuda T, Nishimura A, Fu L, Hu X, Wei F, Kitamura F, Akiyama T, Yamashita K, Eto K, Iwagami S, Iwatsuki M, Miyamoto Y, Matsusaki K, Yamasaki J, Nagano O, Saya H, Song S, Tan P, Baba H, Ajani JA, Ishimoto T. Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment. Cell Rep:113613. e-Pub 2023. PMID: 38232734.
17. Kim SB, Van Cutsem E, Ajani J, Shen L, Barnes G, Ding N, Tao A, Xia T, Zhan L, Kato K. Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health related quality of life in Asian patients. Curr Med Res Opin:1-10. e-Pub 2023. PMID: 37846080.
18. Rogers JE, Yamashita K, Sewastjanow-Silva M, Trail A, Waters RE, Ajani J. Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target. Cancers (Basel) 15(21), 2023. e-Pub 2023. PMID: 37958354.
19. Hirata Y, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum Murphy M, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma. Cancers (Basel) 15(21), 2023. e-Pub 2023. PMID: 37958312.
20. Jeong YS, Eun YG, Lee SH, Kang SH, Yim SY, Kim EH, Noh JK, Sohn BH, Woo SR, Kong M, Nam DH, Jang HJ, Lee HS, Song S, Oh SC, Lee J, Ajani JA, Lee JS. Clinically conserved genomic subtypes of gastric adenocarcinoma. Mol Cancer 22(1):147, 2023. e-Pub 2023. PMID: 37674200.
21. Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol:JCO2300170. e-Pub 2023. PMID: 37713657.
22. Fan Y, Song S, Li Y, Dhar SS, Jin J, Yoshimura K, Yao X, Wang R, Scott AW, Pool Pizzi M, Wu J, Ma L, Calin GA, Hanash S, Wang L, Curran M, Ajani JA. Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T cell Immunity in Gastric Cancer Peritoneal Metastases. Cancer Res. e-Pub 2023. PMID: 37738407.
23. Jin J, Yoshimura K, Sewastjanow-Silva M, Song S, Ajani JA. Challenges and Prospects of Patient-Derived Xenografts for Cancer Research. Cancers (Basel) 15(17), 2023. e-Pub 2023. PMID: 37686627.
24. Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. e-Pub 2023. PMID: 37524953.
25. Trail A, Rogers J, Ajani J. Can You Establish the Cause of This Patient's Shortness of Breath?. J Adv Pract Oncol 14(5):440-443, 2023. e-Pub 2023. PMID: 37576362.
26. Hirata Y, Noorani A, Song S, Wang L, Ajani JA. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat Rev Clin Oncol. e-Pub 2023. PMID: 37264184.
27. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Ileana Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. e-Pub 2023. PMID: 37279095.
28. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. e-Pub 2023. PMID: 37339271.
29. Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. e-Pub 2023. PMID: 37329891.
30. Zhao S, Wang R, Song S, Hao D, Han G, Song X, Zhang J, Pizzi MP, Shanbhag N, Futreal A, Badgwell B, Harada K, Calin G, Vykoukal J, Yu CY, Katayama H, Hanash SM, Wang L, Ajani JA. Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases. iScience 26(6):106913, 2023. e-Pub 2023. PMID: 37305699.
31. Wang R, Song S, Qin J, Yoshimura K, Peng F, Chu Y, Li Y, Fan Y, Jin J, Dang M, Dai E, Pei G, Han G, Hao D, Li Y, Chatterjee D, Harada K, Pizzi MP, Scott AW, Tatlonghari G, Yan X, Xu Z, Hu C, Mo S, Shanbhag N, Lu Y, Sewastjanow-Silva M, Fouad Abdelhakeem AA, Peng G, Hanash SM, Calin GA, Yee C, Mazur P, Marsden AN, Futreal A, Wang Z, Cheng X, Ajani JA, Wang L. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell. e-Pub 2023. PMID: 37419119.
32. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet, 2023. e-Pub 2023. PMID: 37068504.
33. Hirata Y, Agnes A, Estrella JS, Blum M, Das P, Minsky BD, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. ASO Visual Abstract: Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. e-Pub 2023. PMID: 37193894.
34. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. e-Pub 2023. PMID: 37248301.
35. Li JJ, Rogers JE, Yamashita K, Waters RE, Blum Murphy M, Ajani JA. Therapeutic Advances in the Treatment of Gastroesophageal Cancers. Biomolecules 13(5), 2023. e-Pub 2023. PMID: 37238666.
36. Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut 72(4):624-637, 2023. PMID: 36002248.
37. Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21(4):393-422, 2023. PMID: 37015332.
38. Rogers JE, Yamashita K, Sewastjanow-Silva M, Rosa Vicentini E, Waters R, Ajani JA. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma. Expert Rev Anticancer Ther. e-Pub 2023. PMID: 37122102.
39. Hirata Y, Agnes A, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. e-Pub 2023. PMID: 37106276.
40. Mitchell KG, Bayley EM, Ikoma N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Erasmus JJ, Weston BR, Ajani JA, Badgwell BD, Hofstetter WL. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. e-Pub 2023. PMID: 37080372.
41. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus. Future Oncol 19(11):739-752, 2023. e-Pub 2023. PMID: 36919706.
42. De Silva Sewastjanow M, Rogers JE, Hofstetter WL, Ajani JA. Esophageal cancer: Is the CROSS strategy ready for history books?. J Thorac Cardiovasc Surg 22(S0022-5223):00095-2, 2023. e-Pub 2022. PMID: 35184889.
43. Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene-Nzelu CG, Razavi-Mohseni M, Abdul Ghani SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P, Singapore Gastric Cancer Consortium. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. e-Pub 2023. PMID: 36918265.
44. Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Oncologist. e-Pub 2023. PMID: 36940261.
45. Yoon HH, Shi Q, Ajani JA. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply. JAMA Oncol 9(2):280-281, 2023. e-Pub 2022. PMID: 36547945.
46. Jin J, Huo L, Fan Y, Wang R, Scott AW, Pizzi MP, Yao X, Shao S, Ma L, Da Silva MS, Yamashita K, Yoshimura K, Zhang B, Wu J, Wang L, Song S, Ajani JA. A new intronic quantitative PCR method led to the discovery of transformation from human ascites to murine malignancy in a mouse model. Front Oncol 13:1062424, 2023. e-Pub 2023. PMID: 36865791.
47. Rogers JE, Ajani JA. Recent advances in the management of gastric adenocarcinoma patients. Fac Rev 12:2, 2023. e-Pub 2023. PMID: 36873983.
48. Vassilakopoulou M, Chen HC, Wang X, Harada K, Iwatsuki M, Das P, Blum Murphy M, Matamoros A, Sagebiel T, Devine C, Thomas I, Sanders EM, Shanbhag N, Rogers JE, Lee JH, Weston B, Bhutani MS, Hofstetter W, Nguyen QN, Badgwell BD, Ajani JA. Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment?. Oncology 101(3):153-158, 2023. e-Pub 2022. PMID: 36412619.
49. Kharofa JR, Yothers G, Kachnic LA, Ajani J, Meyer JE, Augspurger ME, Okawara GS, Garg MK, Schefter TE, Swanson TA, Doncals DE, Kim H, Zaki BI, Narayan S, Lee RJ, Mamon HJ, Schwartz MA, Moughan J, Crane CH. Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529. Am J Clin Oncol 45(12):534-536, 2022. e-Pub 2022. PMID: 36413683.
50. Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, Prokop LJ, Moehler M, Kang YK, Shi Q, Ajani JA. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol 8(10):1456-1465, 2022. e-Pub 2022. PMID: 36006624.
51. Sewastjanow-Silva M, Yamashita K, Rosa Vicentini E, Hirschmann M, Pool Pizzi M, Trail AM, Waters RE, Rogers JE, Ajani JA. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives. Expert Rev Anticancer Ther. e-Pub 2022. PMID: 36266061.
52. Rogers JE, Ajani JA. Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?. Expert Opin Pharmacother. e-Pub 2022. PMID: 36286544.
53. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol 6(1):78, 2022. e-Pub 2022. PMID: 36302890.
54. Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E, RATIONALE-302 Investigators. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol:JCO2101926, 2022. PMID: 35442766.
55. Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol, 2022. e-Pub 2022. PMID: 36000541.
56. Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S. Preclinical Characterization and Phase 1 Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunol Res. e-Pub 2022. PMID: 36129967.
57. Rogers JE, Yamashita K, Sewastjanow Silva M, Ajani JA. Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors. Cancers (Basel) 14(19), 2022. e-Pub 2022. PMID: 36230726.
58. Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O, Das P. Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. JCO Precis Oncol 6:e2200049, 2022. PMID: 35952321.
59. Li Y, Fan Y, Xu J, Huo L, Scott AW, Jin J, Yang B, Shao S, Ma L, Wang Y, Yao X, Pool Pizzi M, Sewastjanow Da Silva M, Zhang G, Zhuo L, Cho EJ, Dalby KN, Shanbhag ND, Wang Z, Li W, Song S, Ajani JA. GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma. J Exp Clin Cancer Res 41(1):257, 2022. e-Pub 2022. PMID: 35996148.
60. Rha SY, Ku GY, Kim HS, Chung HC, Amlashi FG, Maru DM, Fein CA, Tang LH, Zhou W, Wu T, Peter SA, Kelsen DP, Ajani JA. PD-L1 expression and overall survival in Asian and western patients with gastric cancer. Future Oncol 18(21):2623-2634, 2022. e-Pub 2022. PMID: 35616013.
61. Ajani JA, Leung L, Singh P, Kurt M, Kim I, Pourrahmat MM, Kanters S. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis. Eur J Cancer 170:119-130, 2022. e-Pub 2022. PMID: 35605522.
62. Van Cutsem E, Kato K, Ajani J, Shen L, Xia T, Ding N, Zhan L, Barnes G, Kim SB. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open 7(4):100517. e-Pub 2022. PMID: 35785595.
63. Kumar S, Bahdi F, Emelogu IK, Yu AC, Coronel M, Ge PS, Coronel E, Ajani JA, Weston B, Lynch P, Ross WA, Lee JH. How much progress have we made?: a 20-year experience regarding esophageal stents for the palliation of malignant dysphagia. Dis Esophagus 35(6), 2022. PMID: 34937091.
64. Rogers JE, Ajani JA. Defining the role of upfront immune checkpoint inhibition in advanced HER-2 negative gastric or gastroesophageal junction adenocarcinoma. Ann Palliat Med. e-Pub 2022. PMID: 35695051.
65. Fu L, Yonemura A, Yasuda-Yoshihara N, Umemoto T, Zhang J, Yasuda T, Uchihara T, Akiyama T, Kitamura F, Yamashita K, Okamoto Y, Bu L, Wei F, Hu X, Liu Y, Ajani JA, Tan P, Baba H, Ishimoto T. Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer. Gastric Cancer 25(3):542-557, 2022. e-Pub 2022. PMID: 35166958.
66. Rogers JE, Sewastjanow D Silva M, Waters RE, Ajani JA. Pharmaceutical advances in the treatment of gastric adenocarcinoma. Expert Opin Pharmacother 23(5):611-621, 2022. e-Pub 2022. PMID: 35098851.
67. Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603(7903):942-948, 2022. e-Pub 2022. PMID: 35322232.
68. Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y, CheckMate 648 Trial Investigators. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386(5):449-462, 2022. PMID: 35108470.
69. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(2):167-192, 2022. PMID: 35130500.
70. Rogers JE, Sewastjanow-Silva M, Waters RE, Ajani JA. Esophageal cancer: emerging therapeutics. Expert Opin Ther Targets 26(2):107-117, 2022. e-Pub 2022. PMID: 35119973.
71. Rogers JE, Trail A, Ajani JA. Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?. J Natl Compr Canc Netw 20(2):100-101, 2022. PMID: 35130497.
72. Shah MA, Udrea AA, Bondarenko I, Mansoor W, Sánchez RG, Sarosiek T, Bozzarelli S, Schenker M, Gomez-Martin C, Morgan C, Özgüroglu M, Pikiel J, Kalofonos HP, Wojcik E, Buchler T, Swinson D, Cicin I, Joseph M, Vynnychenko I, Luft AV, Enzinger PC, Salek T, Papandreou C, Tournigand C, Maiello E, Wei R, Ferry D, Gao L, Oliveira JM, Ajani JA. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267477.
73. Harada K, Yamashita K, Iwatsuki M, Baba H, Ajani JA. Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis. Expert Rev Clin Pharmacol 15(1):43-49, 2022. e-Pub 2022. PMID: 35184625.
74. Charalampakis N, Tsakatikas S, Schizas D, Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G, Katsaros I, Abdelhakeem AAF, Sewastjanow-Silva M, Rogers JE, Ajani JA. Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. World J Gastrointest Oncol 14(1):181-202, 2022. PMID: 35116110.
75. Rogers JE, Wang X, Trail A, Ajani JA. Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?. Oncology 100(3):182-187, 2022. e-Pub 2021. PMID: 34969028.
76. Davis CH, Ikoma N, Mansfield PF, Das P, Minsky BD, Blum MA, Ajani JA, Bass BL, Badgwell BD. Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. Surg Endosc 35(12):6577-6582, 2021. e-Pub 2020. PMID: 33170336.
77. Song S, Chen Q, Li Y, Lei G, Scott A, Huo L, Li CY, Estrella JS, Correa A, Pizzi MP, Ma L, Jin J, Liu B, Wang Y, Xiao L, Hofstetter WL, Lee JH, Weston B, Bhutani M, Shanbhag N, Johnson RL, Gan B, Wei S, Ajani JA. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut 70(12):2238-2248, 2021. e-Pub 2021. PMID: 33487592.
78. Fan Y, Ajani JA, Song S. Proteomic profiling of key signatures from gastric lesions to early gastric cancer. EBioMedicine 74:103744. e-Pub 2021. PMID: 34902787.
79. Zhou N, Hofstetter WL, Esophageal Squamous Cell Carcinoma Working Group, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg. e-Pub 2021. PMID: 34883083.
80. Corsini EM, Foo WC, Mitchell KG, Zhou N, Maru DM, Ajani JA, Hofstetter WL, Esophageal Adenocarcinoma Working Group, Correa AM, Antonoff MB, Lin SH, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg 162(5):1404-1412.e2, 2021. e-Pub 2020. PMID: 33010880.
81. Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, Wang L, Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut 70(11):2055-2065, 2021. e-Pub 2020. PMID: 33334899.
82. VanderWalde N, Moughan J, Lichtman SM, Jagsi R, Ballo M, VanderWalde A, Mohiuddin M, Meropol NJ, Kachnic L, Berger A, Ajani J, Anne R, Hopkins JL, Arora A, Meyer J, Ellsworth SG, Lee RJ, Green N, Crane CH. The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. J Geriatr Oncol S1879-4068(21):00240-X. e-Pub 2021. PMID: 34756496.
83. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. J Natl Compr Canc Netw:1-12. e-Pub 2021. PMID: 34678759.
84. Allen CJ, Pointer DT, Blumenthaler AN, Mehta RJ, Hoffe SE, Minsky BD, Smith GL, Blum M, Mansfield PF, Ikoma N, Das P, Ajani J, Dineen SP, Fleming JB, Badgwell BD, Pimiento JM. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg 274(4):544-548, 2021. PMID: 34132693.
85. Zhou N, Mitchell KG, Corsini EM, Truong VTT, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Ajani JA, Hofstetter WL. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg 108(10):1207-1215, 2021. PMID: 34095952.
86. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery 170(4):1231-1239, 2021. e-Pub 2021. PMID: 34059344.
87. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD, Ikoma N. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Ann Surg Oncol 28(11):6638-6648, 2021. e-Pub 2021. PMID: 33754224.
88. Cameron RB, Ajani JA, Wu AJ. Adjuvant nivolumab after preoperative chemoradiotherapy and surgery in esophageal cancer: A shifting paradigm. J Thorac Cardiovasc Surg S0022-5223(21):01372-6. e-Pub 2021. PMID: 34663521.
89. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
90. Jin Z, Shen J, Wang C, Chen D, Zhang B, Zhang J, Ajani JA, Bennouna J, Chao J, Yoon HH, Zhu H, Ruan Y, Zhu C, Xu A. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. Ann Transl Med 9(14):1189, 2021. PMID: 34430630.
91. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27-40, 2021. e-Pub 2021. PMID: 34102137.
92. Jabbour SK, Williams TM, Sayan M, Miller ED, Ajani JA, Chang AC, Coleman N, El-Rifai W, Haddock M, Ilson D, Jamorabo D, Kunos C, Lin S, Liu G, Prasanna PG, Rustgi AK, Wong R, Vikram B, Ahmed MM. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. J Natl Cancer Inst 113(6):665-679, 2021. PMID: 33351071.
93. Shin MK, Kim J, Kim D, Lee SH, Shin JH, Jeong YS, Sohn BH, Kim J, Kim SR, Ajani JA, Lee JS, Cheong JH. Long non-coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer. Clin Transl Med 11(6):e421, 2021. PMID: 34185430.
94. Song S, Xu Y, Huo L, Zhao S, Wang R, Li Y, Scott AW, Pizzi MP, Wang Y, Fan Y, Harada K, Jin J, Ma L, Yao X, Shanbhag ND, Gan Q, Roy-Chowdhuri S, Badgwell BD, Wang Z, Wang L, Ajani JA. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res 40(1):207, 2021. e-Pub 2021. PMID: 34162421.
95. Rogers JE, Trail A, Ajani JA. Why should localized gastric adenocarcinoma patients fare poorly after adjunctive therapy compared to surgery alone?. Chin Clin Oncol 10(3):32, 2021. e-Pub 2020. PMID: 33222442.
96. Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Mansfield P, Ajani JA, Badgwell BD. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg 25(6):1380-1387, 2021. e-Pub 2020. PMID: 32542556.
97. van der Wilk BJ, Eyck BM, Hofstetter WL, Ajani JA, Piessen G, Castoro C, Alfieri R, Kim JH, Kim SB, Furlong H, Walsh TN, Nieboer D, Wijnhoven BPL, Lagarde SM, Lanschot JJBV. Chemoradiotherapy followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-Analysis. Ann Surg. e-Pub 2021. PMID: 34191461.
98. Chen HY, Feng LL, Li M, Ju HQ, Ding Y, Lan M, Song SM, Han WD, Yu L, Wei MB, Pang XL, He F, Liu S, Zheng J, Ma Y, Lin CY, Lan P, Huang MJ, Zou YF, Yang ZL, Wang T, Lang JY, Orangio GR, Poylin V, Ajani JA, Wang WH, Wan XB. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. Oncologist 26(5):e780-e793, 2021. e-Pub 2021. PMID: 33543577.
99. Corsini EM, Mitchell KG, Zhou N, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Lin SH, Ajani JA, Hofstetter WL. Modified En bloc Esophagectomy Compared to Standard Resection after Neoadjuvant Chemoradiation. Ann Thorac Surg 111(4):1133-1140, 2021. e-Pub 2020. PMID: 32857997.
100. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M, CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 384(13):1191-1203, 2021. PMID: 33789008.
101. Liu Y, Baba Y, Ishimoto T, Tsutsuki H, Zhang T, Nomoto D, Okadome K, Yamamura K, Harada K, Eto K, Hiyoshi Y, Iwatsuki M, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ohmuraya M, Wang X, Ajani JA, Sawa T, Baba H. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer 124(5):963-974, 2021. e-Pub 2020. PMID: 33299132.
102. Cascinu S, Bodoky G, Muro K, Van Cutsem E, Oh SC, Folprecht G, Ananda S, Girotto G, Wainberg ZA, Miron MLL, Ajani J, Wei R, Liepa AM, Carlesi R, Emig M, Ohtsu A. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist 26(3):e414-e424, 2021. e-Pub 2020. PMID: 33274542.
103. Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi MP, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson RL, Wang L, Wang Z, Peng G, Ajani JA. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut. e-Pub 2021. PMID: 33785559.
104. Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer 20(1):56, 2021. e-Pub 2021. PMID: 33766033.
105. Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol 39(9):990-1000, 2021. e-Pub 2021. PMID: 33577358.
106. Mehrvarz Sarshekeh A, Alshenaifi J, Roszik J, Manyam GC, Advani SM, Katkhuda R, Verma A, Lam M, Willis J, Shen JP, Morris J, Davis JS, Loree JM, Lee HM, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res 27(6):1663-1670, 2021. e-Pub 2021. PMID: 33414133.
107. Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol 123(4):911-922, 2021. e-Pub 2021. PMID: 33400838.
108. Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, Morinaga T, Nakao Y, Harada K, Eto K, Kurashige J, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Ajani JA, Baba H. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. Br J Cancer 124(3):595-603, 2021. e-Pub 2020. PMID: 33100329.
109. Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal 19(1):19, 2021. e-Pub 2021. PMID: 33588867.
110. Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol 28(2):758-765, 2021. e-Pub 2020. PMID: 32696305.
111. Ajani JA. Impediments to therapeutic advances for patients with gastroesophageal adenocarcinoma. Transl Gastroenterol Hepatol 6:49, 2021. e-Pub 2021. PMID: 34423170.
112. Abdelhakeem A, Patnana M, Wang X, Rogers JE, Murphy MB, Sagebiel T, Ikoma N, Badgwell BD, Trail A, Estrella JS, Lu Y, Devine C, Ajani JA. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. Oncology 99(10):659-664, 2021. e-Pub 2021. PMID: 34352788.
113. Abdelhakeem AA, Wang X, Waters RE, Patnana M, Estrella JS, Blum Murphy M, Trail AM, Lu Y, Devine CE, Ikoma N, Das P, Badgwell BD, Rogers JE, Ajani JA. Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers (Basel) 13(3), 2021. e-Pub 2021. PMID: 33498613.
114. Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med 27(1):141-151, 2021. e-Pub 2021. PMID: 33398161.
115. Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, Pizzi MP, Scott A, Harada K, Ma L, Yao X, Jin J, Zhao W, Dong X, Badgwell BD, Shanbhag N, Tatlonghari G, Estrella JS, Roy-Chowdhuri S, Kobayashi M, Vykoukal JV, Hanash SM, Calin GA, Peng G, Lee JS, Johnson RL, Wang Z, Wang L, Song S. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut 70(1):55-66, 2021. e-Pub 2020. PMID: 32345613.
116. Badgwell B, Ikoma N, Murphy MB, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Lano E, Song S, Mansfield P, Ajani J. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Ann Surg Oncol 28(1):258-264, 2021. e-Pub 2020. PMID: 32556731.
117. Siegel EM, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney RM, Magliocco A, Riggs B, Winter K, Simko JP, Ajani JA, Guha C, Okawara GS, Abdalla I, Becker MJ, Pizzolato JF, Crane CH, Brown KD, Shibata D. Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One 16(12):e0260857, 2021. e-Pub 2021. PMID: 34882728.
118. Blumenthaler AN, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol 122(7):1373-1382, 2020. e-Pub 2020. PMID: 32810292.
119. Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka K. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs 38(6):1763-1773, 2020. e-Pub 2020. PMID: 32377978.
120. Blumenthaler AN, Allen CJ, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. Ann Surg Oncol 27(13):5047-5056, 2020. e-Pub 2020. PMID: 32737700.
121. White MG, Kothari A, Ikoma N, Murphy MB, Song S, Ajani J, Mansfield P, Badgwell B. Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. Ann Surg Oncol 27(13):4963-4969, 2020. e-Pub 2020. PMID: 32648181.
122. Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, De Los Santos MC, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology 159(6):2146-2162.e33, 2020. e-Pub 2020. PMID: 32805281.
123. Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, Yap TA, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest 130(11):5951-5966, 2020. PMID: 33016929.
124. He F, Yu L, Ding Y, Li ZH, Wang J, Zheng J, Chen HY, Liu S, Pang XL, Ajani JA, Wan XB. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. Cancer Sci 111(11):4205-4217, 2020. e-Pub 2020. PMID: 32860448.
125. Ignatova E, Seriak D, Fedyanin M, Tryakin A, Pokataev I, Menshikova S, Vakhabova Y, Smirnova K, Tjulandin S, Ajani JA. Epstein-Barr virus-associated gastric cancer: disease that requires special approach. Gastric Cancer 23(6):951-960, 2020. e-Pub 2020. PMID: 32514646.
126. Kim BJ, Chiang YJ, Das P, Minsky BD, Blum MA, Ajani JA, Estrella JS, Hofstetter WL, Tzeng CD, Badgwell BD, Mansfield PF, Ikoma N. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med 9(11), 2020. e-Pub 2020. PMID: 33138060.
127. Harada K, Patnana M, Wang X, Iwatsuki M, Murphy MAB, Zhao M, Das P, Minsky BD, Weston B, Lee JH, Bhutani MS, Estrella JS, Shanbhag N, Ikoma N, Badgwell BD, Ajani JA. Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. Surg Today 50(10):1223-1231, 2020. e-Pub 2020. PMID: 32409870.
128. Li Y, Song S, Pizzi MP, Han G, Scott AW, Jin J, Xu Y, Wang Y, Huo L, Ma L, Vellano C, Luo X, MacLeod R, Wang L, Wang Z, Ajani JA. LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33076512.
129. He F, Ju HQ, Ding Y, Jiang Z, Li Z, Huang B, Wang X, Zhao Y, Li Y, Qi B, Luo W, Zhang Z, Pei Q, Chen H, Liu S, Pang X, Zheng J, Wang J, Ajani JA, Wan XB. Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. Br J Cancer 123(8):1244-1252, 2020. e-Pub 2020. PMID: 32724220.
130. Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer 20(3):313-327, 2020. e-Pub 2020. PMID: 33024587.
131. Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol 122(3):422-432, 2020. e-Pub 2020. PMID: 32462681.
132. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Murphy MAB, Maru DM, Weston B, Lee JH, Rogers JE, Trail A, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Das P, Hofstetter WL, Badgwell BD, Ajani JA. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer 23(5):904-912, 2020. e-Pub 2020. PMID: 32347396.
133. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg 272(2):311-318, 2020. PMID: 32675544.
134. Zafar SN, Blum M, Chiang YJ, Ajani JA, Estrella JS, Das P, Minsky BD, Hofstetter WL, Mansfield P, Badgwell BD, Ikoma N. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg 110(2):398-405, 2020. e-Pub 2020. PMID: 32289300.
135. Blum Murphy M, Ikoma N, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Song S, Mansfield P, Ajani J, Badgwell B. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol 27(8):2806-2811, 2020. e-Pub 2020. PMID: 31974712.
136. Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Yasuda T, Arima K, Harada K, Eto K, Hayashi H, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Yashiro M, Masuda M, Ajani JA, Tan P, Baba H, Ishimoto T. Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing β1 Integrin, Enhancing Drug Resistance. Cancer Res 80(16):3222-3235, 2020. e-Pub 2020. PMID: 32605995.
137. Harada K, Zhao M, Shanbhag N, Baba H, Ajani JA. Palliative care for advanced gastric cancer. Expert Rev Anticancer Ther 20(7):575-580, 2020. e-Pub 2020. PMID: 32543938.
138. Yamashita K, Iwatsuki M, Ajani JA, Baba H. Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. Ann Gastroenterol Surg 4(4):369-378, 2020. e-Pub 2020. PMID: 32724880.
139. Song S, Li Y, Xu Y, Ma L, Pool Pizzi M, Jin J, Scott AW, Huo L, Wang Y, Lee JH, Bhutani MS, Weston B, Shanbhag ND, Johnson RL, Ajani JA. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Mol Oncol 14(6):1410-1426, 2020. e-Pub 2020. PMID: 32175692.
140. Duleba M, Yamamoto Y, Neupane R, Rao W, Xie J, Qi Y, Liew AA, Niroula S, Zhang Y, Mahalingam R, Wang S, Goller K, Ajani JA, Vincent M, Ho KY, Hou JK, Hyams JS, Sylvester FA, Crum CP, McKeon F, Xian W. Cloning of ground-state intestinal stem cells from endoscopic biopsy samples. Nat Protoc 15(5):1612-1627, 2020. e-Pub 2020. PMID: 32238950.
141. Ikoma N, Agnes A, Chen HC, Wang X, Blum MM, Das P, Minsky B, Estrella JS, Mansfield P, Ajani JA, Badgwell BD. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg 24(5):1018-1025, 2020. e-Pub 2019. PMID: 31754987.
142. Moningi S, Ajani JA, Badgwell BD, Murphy MB, Ikoma N, Mansfield PF, Ho JC, Suh Y, Crane C, Herman JM, Holliday EB, Koay E, Koong AC, Krishnan S, Minsky B, Smith G, Taniguchi C, Das P. IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol 5(3):369-376, 2020. e-Pub 2019. PMID: 32529130.
143. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol 38(14):1569-1579, 2020. e-Pub 2020. PMID: 32160096.
144. Yang Lu , Linghua Wang, Jaffer A Ajani. Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. Clin Nucl Med, 2020. PMID: 31977493.
145. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut 69(4):748-763, 2020. e-Pub 2020. PMID: 32034004.
146. Van Cutsem E, Muro K, Cunningham D, Bodoky G, Sobrero A, Cascinu S, Ajani J, Oh SC, Al-Batran SE, Wainberg ZA, Wijayawardana SR, Melemed S, Ferry D, Hozak RR, Ohtsu A, RAINBOW Investigators. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer 127:150-157, 2020. e-Pub 2020. PMID: 32014812.
147. Song S, Wang Z, Li Y, Ma L, Jin J, Scott AW, Xu Y, Estrella JS, Song Y, Liu B, Johnson RL, Ajani JA. PPARδ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. Mol Cancer Res 18(3):390-402, 2020. e-Pub 2019. PMID: 31796534.
148. Jane E Rogers, Lianchun Xiao , Allison Trail , Mariela Blum Murphy , Melissa Palmer , Jaffer A Ajani. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology, 2020. e-Pub 2020. PMID: 32097933.
149. Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H, Gan B. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res 30(2):146-162, 2020. e-Pub 2020. PMID: 31949285.
150. Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Chin FW, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore) 99(9):e19295, 2020. PMID: 32118743.
151. Allen CJ, Blumenthaler AN, Das P, Minsky BD, Blum M, Roy-Chowdhuri S, Ajani JA, Ikoma N, Mansfield PF, Badgwell BD. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol 18(1):39, 2020. e-Pub 2020. PMID: 32066454.
152. Allen CJ, Vreeland TJ, Newhook TE, Das P, Minsky BD, Blum M, Ajani J, Ikoma N, Mansfield PF, Badgwell BD. Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Ann Surg Oncol 27(2):534-542, 2020. e-Pub 2019. PMID: 31552618.
153. Schizas D, Charalampakis N, Kole C, Mylonas KS, Katsaros I, Zhao M, Ajani JA, Psyrri A, Karamouzis MV, Liakakos T. Immunotherapy for esophageal cancer: a 2019 update. Immunotherapy 12(3):203-218, 2020. e-Pub 2020. PMID: 32208794.
154. Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res 9, 2020. e-Pub 2020. PMID: 33042518.
155. Yao X, Ajani JA, Song S. Molecular biology and immunology of gastric cancer peritoneal metastasis. Transl Gastroenterol Hepatol 5:57, 2020. e-Pub 2020. PMID: 33073052.
156. Abdelhakeem A, Wang X, Rogers JE, Trail A, Zhao M, Blum-Murphy M, Estrella JS, Ajani JA. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology 98(12):884-888, 2020. e-Pub 2020. PMID: 32998149.
157. Zou J, Qin W, Yang L, Wang L, Wang Y, Shen J, Xiong W, Yu S, Song S, Ajani JA, Lin SY, Mills GB, Yuan X, Chen J, Peng G. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res 10(11):3947-3972, 2020. e-Pub 2020. PMID: 33294279.
158. Jin J, Xu Y, Huo L, Ma L, Scott AW, Pizzi MP, Li Y, Wang Y, Yao X, Song S, Ajani JA. An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue. PLoS One 15(2):e0228910, 2020. e-Pub 2020. PMID: 32053639.
159. Mizrak Kaya D, Nogueras González GM, Harada K, Blum Murphy MA, Lee JH, Bhutani MS, Weston B, Thomas I, Rogers JE, Das P, Badgwell BD, Ajani JA. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology 98(8):542-548, 2020. e-Pub 2020. PMID: 32434189.
160. Wang L, Ajani JA. Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats. Clin Cancer Res 25(23):6887-6889, 2019. e-Pub 2019. PMID: 31527165.
161. Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M, Song S, Ajani J, Ikoma N, Mansfield PF, Roy-Chowdhuri S, Badgwell BD. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol 120(8):1350-1357, 2019. e-Pub 2019. PMID: 31612494.
162. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech 12(12), 2019. e-Pub 2019. PMID: 31732509.
163. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol 5(11):1597-1604, 2019. PMID: 31529018.
164. Rivin Del Campo E, Matzinger O, Haustermans K, Peiffert D, Glynne-Jones R, Winter KA, Konski AA, Ajani JA, Bosset JF, Hannoun-Levi JM, Puyraveau M, Chakravarthy AB, Meadows H, Northover J, Collette L, Christiaens M, Maingon P. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). Eur J Cancer 121:130-143, 2019. e-Pub 2019. PMID: 31574418.
165. Xu Y, Song S, Wang Z, Ajani JA. The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective. Cell Commun Signal 17(1):157, 2019. e-Pub 2019. PMID: 31775795.
166. Ahmed O, Ajani JA, Lee JH. Endoscopic management of esophageal cancer. World J Gastrointest Oncol 11(10):830-841, 2019. PMID: 31662822.
167. Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer 18(1):141, 2019. e-Pub 2019. PMID: 31601234.
168. Sonoda K, Samdani RT, Ikoma N, Kaya DM, Blum-Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS.. Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. J Surg Oncol. e-Pub 2019. PMID: 31498442.
169. Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD.. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. e-Pub 2019. PMID: 31350645.
170. Rogers JE, Ajani JA.. Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy. J Clin Oncol. e-Pub 2019. PMID: 31465257.
171. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I.. The Immune Landscape of Cancer. Immunity. e-Pub 2019. PMID: 31433971.
172. Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H.. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cance. e-Pub 2019. PMID: 31451991.
173. Yin Y, Liu W, Shen Q, Zhang P, Wang L, Tao R, Li H, Ma X, Zeng X, Cheong JH, Song S, Ajani JA, Mills GB, Tao K, Peng G.. The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Mol Cancer The. e-Pub 2019. PMID: 31142662.
174. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM.. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol. e-Pub 2019. PMID: 31384313.
175. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA.. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. e-Pub 2019. PMID: 31319389.
176. Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL.. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. e-Pub 2019. PMID: 31313820.
177. Yamashita K, Iwatsuki M, Harada K, Koga Y, Kiyozumi Y, Eto K, Hiyoshi Y, Ishimoto T, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H.. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?. Br J Cancer. e-Pub 2019. PMID: 31285589.
178. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget 10(45):4703-4718, 2019. e-Pub 2019. PMID: 31384397.
179. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA.. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. e-Pub 2019. PMID: 31188215.
180. Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA.. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. e-Pub 2019. PMID: 31171626.
181. Madoka Takeuchi , Jaffer A Ajani , Xuemin Fang , Per Pfeiffer , Masahiro Takeuchi , Hanneke W M van Laarhoven. Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin. Cancers (Basel), 2019. PMID: 31234436.
182. Harada K, Zhao M, Baba H, Ajani JA.. Endoscopic resection for esophageal or gastroesophageal junction adenocarcinoma. Dig Med Res. e-Pub 2019. PMID: 31179442.
183. Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pizzi MP, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA.. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res, 2019. PMID: 30563933.
184. Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA.. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology. e-Pub 2019. PMID: 30893708.
185. Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T, Eto K, Iwagami S, Harada K, Ishimoto T, Baba Y, Yoshida N, Miyanari N, Takamori H, Ajani JA, Baba H.. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. e-Pub 2019. PMID: 30854619.
186. Esophageal Cancer Study Group Participating Centers. Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus. J Thorac Cardiovasc Surg, 2019. e-Pub 2018. PMID: 30558879.
187. van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM.. SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. Cancers (Basel). e-Pub 2019. PMID: 30764578.
188. Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA.. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer, 2019. PMID: 30592991.
189. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA.. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. e-Pub 2019. PMID: 30720506.
190. Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer. e-Pub 2019. PMID: 30706247.
191. Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, Ajani JA, Minsky BD, Mansfield P, Badgwell BD.. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. e-Pub 2019. PMID: 30680477.
192. Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA.. Targeting Angiogenesis in Colorectal Carcinoma. Drugs. e-Pub 2019. PMID: 30592991.
193. Harada K, Abdelhakeem AAF, Ajani JA.. A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. Nat Rev Clin Oncol, 2019. PMID: 30291292.
194. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
195. Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA. Targeting Angiogenesis in Colorectal Carcinoma. Drugs 79(1):63-74, 2019. PMID: 30617958.
196. Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H. Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. Ann Gastroenterol Surg 3(1):43-49, 2019. e-Pub 2018. PMID: 30697609.
197. Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer 21(6):1004-1013, 2018. e-Pub 2018. PMID: 29730720.
198. Ikoma N, Estrella JS, Hofstetter WL, Ajani JA, Fournier KF, Mansfield PF, Skibber JM, Badgwell BD. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg 22(11):2013-2019, 2018. e-Pub 2018. PMID: 30054780.
199. Harada K, Abdelhakeem AAF, Ajani JA. A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. Nat Rev Clin Oncol. e-Pub 2018. PMID: 30291292.
200. Harada K, Pool Pizzi M, Baba H, Shanbhag ND, Song S, Ajani JA. Cancer stem cells in esophageal cancer and response to therapy. Cancer 124(20):3962-3964, 2018. e-Pub 2018. PMID: 30368777.
201. O'Brien J, Reid CM, Andrianopoulos N, Ajani AE, Clark DJ, Krum H, Loane P, Freeman M, Sebastian M, Brennan AL, Shaw J, Dart AM, Duffy SJ; Melbourne Interventional Group Investigators.. Heart Rate as a Predictor of Outcome Following Percutaneous Coronary Intervention. Am J Cardiol. 2018 Oct 1;122(7):1113-1120. doi: 10.1016/j.amjcard.2018.06.042. Epub 2018 Jul 4. e-Pub 2018. PMID: 30107905.
202. Biswas S, Andrianopoulos N, Papapostolou S, Noaman S, Duffy SJ, Lefkovits J, Brennan A, Walton A, Shaw JA, Ajani A, Clark DJ, Freeman M, Hiew C, Oqueli E, Reid CM, Stub D, Chan W.. Does the subtype of acute coronary syndrome treated by percutaneous coronary intervention predict long-term clinical outcomes?. Eur Heart J Qual Care Clin Outcomes. 2018 Oct 1;4(4):318-327. doi: 10.1093/ehjqcco/qcy009. e-Pub 2018. PMID: 30191840.
203. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Syst 7(4):422-437.e7, 2018. e-Pub 2018. PMID: 30268436.
204. Vicente D, Ikoma N, Chiang YJ, Fournier K, Tzeng CD, Song S, Mansfield P, Ajani J, Badgwell BD. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol 25(9):2720-2730, 2018. e-Pub 2018. PMID: 29987602.
205. Song S, Ajani JA. Reply. Gastroenterology 155(3):934-935, 2018. e-Pub 2018. PMID: 30098926.
206. Ajani JA, Bhutani MS, Swisher SG. Oesophageal preservation in locally advanced oesophageal cancer. Lancet Oncol 19(9):e430, 2018. PMID: 30191840.
207. Gu J, Zhang J, Zheng L, Ajani JA, Wu X, Ye Y. Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Sci Rep 8(1):14006, 2018. e-Pub 2018. PMID: 30228315.
208. Nelson DB, Dhupar R, Katkhuda R, Correa A, Goltsov A, Maru D, Sepesi B, Antonoff MB, Mehran RJ, Rice DC, Vaporciyan AA, Davila M, Davila R, Betancourt S, Ajani J, Hofstetter WL. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg 156(1):406-413.e3, 2018. e-Pub 2018. PMID: 29605441.
209. Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA, Fournier KF, Mansfield P, Badgwell BD. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol 25(7):2012-2017, 2018. e-Pub 2018. PMID: 29748883.
210. Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, Devine CE, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer 98:23-29, 2018. e-Pub 2018. PMID: 29859338.
211. Harada K, Song S, Ajani JA. Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. Oncoscience 5(7-8):214-215, 2018. e-Pub 2018. PMID: 30234141.
212. Thiels CA, Ikoma N, Fournier K, Das P, Blum M, Estrella JS, Minsky BD, Ajani J, Mansfield P, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. e-Pub 2018. PMID: 29878364.
213. Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. e-Pub 2018. PMID: 29949666.
214. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 9(1):1777, 2018. e-Pub 2018. PMID: 29725014.
215. Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. e-Pub 2018. PMID: 29736026.
216. Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev 66:104-113, 2018. e-Pub 2018. PMID: 29730461.
217. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology:1-10. e-Pub 2018. PMID: 29843157.
218. Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, Song S. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling. Gastroenterology 154(5):1524-1537.e6, 2018. e-Pub 2017. PMID: 29274868.
219. Blum Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, Ajani J. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol 41(4):321-325, 2018. PMID: 26908161.
220. Ikoma N, Estrella JS, Blum M, Das P, Chen HC, Wang X, Fournier K, Mansfield P, Ajani J, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. e-Pub 2018. PMID: 29679346.
221. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94(6):345-353. e-Pub 2018. PMID: 29705797.
222. Mizrak Kaya D, Nogueras-González GM, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A, Thomas I, Lin Q, Badgwell BD, Ajani JA. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol 117(4):678-684, 2018. e-Pub 2017. PMID: 29205363.
223. Ikoma N, Cloyd J, Badgwell BD, Agnes A, Rodriguez-Bigas M, Ajani JA, You YN. Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. J Surg Oncol 117(4):707-709, 2018. e-Pub 2017. PMID: 29228462.
224. Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K, Royal R, Mansfield P, Badgwell BD. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer 124(5):998-1007, 2018. e-Pub 2018. PMID: 29393964.
225. Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H. Pyloroplasty may reduce weight loss 1 year after esophagectomy. Dis Esophagus 31(3), 2018. PMID: 29579257.
226. Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, Skinner HD, Johnson RL, Ding S, Ajani JA. A Novel YAP1 Inhibitor targets CSCs-enriched Radiation Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer Ther 17(2):443-454, 2018. e-Pub 2017. PMID: 29167315.
227. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol 13(1):99-106, 2018. e-Pub 2017. PMID: 29218623.
228. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer 118(3):331-337, 2018. e-Pub 2017. PMID: 29235564.
229. Lopez A, Harada K, Mizrak Kaya D, Ajani JA. Current therapeutic landscape for advanced gastroesophageal cancers. Ann Transl Med 6(4):78, 2018. PMID: 29666801.
230. Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA. Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. Ann Transl Med 6(4):80, 2018. PMID: 29666803.
231. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 21(1):74-83, 2018. e-Pub 2017. PMID: 28643144.
232. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, Johnson RL, Wang Z, Song S, Ajani JA. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer 21(1):31-40, 2018. e-Pub 2017. PMID: 28801853.
233. In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer 21(1):1-9, 2018. e-Pub 2017. PMID: 28948368.
234. Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer 118(1):52-61, 2018. e-Pub 2017. PMID: 29136404.
235. Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA. Liquid biopsies in gastrointestinal malignancies: when is the big day?. Expert Rev Anticancer Ther 18(1):1-20, 2018. e-Pub 2017. PMID: 29202614.
236. Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med 7(1):123-133, 2018. e-Pub 2017. PMID: 29239137.
237. Badgwell B, Blum M, Das P, Estrella J, Wang X, Fournier K, Royal R, Mansfield P, Ajani J. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc 32(1):512, 2018. e-Pub 2017. PMID: 28643069.
238. Vali Pasha K, Ratnavathi CV, Ajani J, Raju D, Manoj Kumar S, Beedu SR. Proximate, mineral composition and antioxidant activity of traditional small millets cultivated and consumed in Rayalaseema region of south India. J Sci Food Agric 98(2):652-660, 2018. e-Pub 2017. PMID: 28665516.
239. Casamayor M, Morlock R, Maeda H, Ajani J. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience 12:883, 2018. e-Pub 2018. PMID: 30679950.
240. Iwatsuki M, Harada K, Baba H, Ajani JA. Higher rate of colon polyp detection aided by an artificial intelligent software. Transl Gastroenterol Hepatol 3:106, 2018. e-Pub 2018. PMID: 30701213.
241. Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol 8(6):1009-1017, 2017. PMID: 29299361.
242. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. e-Pub 2017. PMID: 29248170.
243. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer 123(21):4106-4113, 2017. e-Pub 2017. PMID: 28885712.
244. In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol 24(12):3683-3691, 2017. e-Pub 2017. PMID: 28895113.
245. Ikoma N, Das P, Blum M, Estrella JS, Devine CE, Wang X, Fournier K, Mansfield P, Minsky BD, Ajani J, Badgwell BD. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys 99(3):660-666, 2017. e-Pub 2017. PMID: 29280460.
246. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 99(3):667-676, 2017. e-Pub 2017. PMID: 29280461.
247. Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M. Efficacy of Sequential Ipilimumab Monotherapy vs Best Supportive Care For Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Cancer Res 23(19):5671-5678, 2017. e-Pub 2017. PMID: 28655793.
248. Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther 16(10):2215-2222, 2017. e-Pub 2017. PMID: 28716815.
249. Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, Fournier K, Royal R, Mansfield P, Ajani J. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol 24(11):3338-3344, 2017. e-Pub 2017. PMID: 28799004.
250. Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg 21(10):1563-1570, 2017. e-Pub 2017. PMID: 28819789.
251. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget 8(45):79356-79365, 2017. e-Pub 2017. PMID: 29108314.
252. Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget 8(46):81430-81440, 2017. e-Pub 2017. PMID: 29113402.
253. Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun 8(1):1050, 2017. e-Pub 2017. PMID: 29051489.
254. Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, Ajani J, Badgwell BD. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol 24(9):2679-2687, 2017. e-Pub 2017. PMID: 28332034.
255. Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G, DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol 28(9):2142-2148, 2017. PMID: 28911091.
256. Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Ann Oncol 28(9):2077-2085, 2017. PMID: 28430862.
257. Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Harada K, Rogers JE, Mares J, Amlashi FG, Minsky BD, Das P, Hofstetter WL, Matamoros A, Sagebiel TL, Blum-Murphy MA, Lee JH, Weston B, Bhutani MS, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol 24(8):2291-2301, 2017. e-Pub 2016. PMID: 27770339.
258. Elimova E, Lin Q, Song S, Ajani JA. Current status of ramucirumab in gastroesophageal adenocarcinoma. Future Oncol 13(18):1585-1592, 2017. e-Pub 2017. PMID: 28436242.
259. Mizrak Kaya D, Dong X, Nogueras-González GM, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol 34(8):135, 2017. e-Pub 2017. PMID: 28685276.
260. Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol 10(1):149, 2017. e-Pub 2017. PMID: 28810883.
261. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer 117(5):648-655, 2017. e-Pub 2017. PMID: 28728163.
262. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. e-Pub 2017. PMID: 28683449.
263. Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res. e-Pub 2017. PMID: 28747339.
264. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers 3:17036, 2017. e-Pub 2017. PMID: 28569272.
265. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. e-Pub 2017. PMID: 28628563.
266. Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18(5):640-653, 2017. e-Pub 2017. PMID: 28343975.
267. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget. e-Pub 2017. PMID: 28611281.
268. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol 13(10):919-934, 2017. e-Pub 2017. PMID: 28067073.
269. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani J, Badgwell BD. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol 24(4):960-965, 2017. e-Pub 2016. PMID: 27778127.
270. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget 8(17):28696-28710, 2017. PMID: 28404924.
271. Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer 20(Suppl 1):92-101, 2017. e-Pub 2016. PMID: 27718136.
272. Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol 10(3):1-9, 2017. e-Pub 2017. PMID: 28094573.
273. Betancourt Cuellar SL, Sabloff B, Carter BW, Benveniste MF, Correa AM, Maru DM, Ajani JA, Erasmus JJ, Hofstetter WL. Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved?. Eur J Radiol 88:56-60, 2017. e-Pub 2017. PMID: 28189209.
274. Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol 12(2):368-374, 2017. e-Pub 2016. PMID: 27729298.
275. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol 12(2):375-382, 2017. e-Pub 2016. PMID: 27794500.
276. Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol 35(4):475-477, 2017. e-Pub 2016. PMID: 28129519.
277. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(4):446-464, 2017. e-Pub 2016. PMID: 28129524.
278. DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of esophageal cancer?. World J Gastroenterol 23(5):751-762, 2017. PMID: 28223720.
279. Gu J, Liang D, Pierzynski JA, Zheng L, Ye Y, Zhang J, Ajani JA, Wu X. D-mannose: a Novel Prognostic Biomarker for Patients with Esophageal Adenocarcinoma. Carcinogenesis. e-Pub 2017. PMID: 28062409.
280. Bartley AN, Washington MK, Ismaila N, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. J Oncol Pract 13(1):53-57, 2017. e-Pub 2016. PMID: 27907277.
281. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res 6:501, 2017. e-Pub 2017. PMID: 28491289.
282. Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, Peng G. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res 7(3):473-483, 2017. e-Pub 2017. PMID: 28401005.
283. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol 23(13):4332-4337, 2016. e-Pub 2016. PMID: 27384751.
284. Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Cheong JH, Cho JY, Lim JY, Park ES, Kim SC, Kang YK, Noh SH, Ajani JA, Lee JS. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res 22(24):6228-6235, 2016. e-Pub 2016. PMID: 27654712.
285. Mizrak Kaya D, Harada K, Ajani JA. Is targeted therapy possible for patients with gastric adenocarcinoma?. Expert Opin Pharmacother 17(18):1-4, 2016. e-Pub 2016. PMID: 27652930.
286. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 140(12):1345-1363, 2016. e-Pub 2016. PMID: 27841667.
287. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol 146(6):647-669, 2016. e-Pub 2016. PMID: 28077399.
288. Badgwell B, Blum M, Estrella J, Ajani J. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. Lancet Oncol 17(12):1628-1629, 2016. e-Pub 2016. PMID: 27776842.
289. Elimova E, Song S, Shimodaira Y, Lin Q, Ajani JA. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Ann Surg Oncol 23(12):3786-3791, 2016. e-Pub 2016. PMID: 27503493.
290. Yi J, Lu L, Yanger K, Wang W, Sohn BH, Stanger BZ, Zhang M, Martin JF, Ajani JA, Chen J, Lee JS, Song S, Johnson RL. LATS1 and LATS2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology 64(5):1757-1772, 2016. e-Pub 2016. PMID: 27531557.
291. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol 114(5):602-606, 2016. e-Pub 2016. PMID: 27439746.
292. Fuchs CS, Tabernero J, Tomášek J, Chau I, Melichar B, Safran H, Tehfe MA, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Emig M, Melemed SA, Hozak RR, Ferry D, Caldwell CW, Ajani JA. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer 115(8):974-982, 2016. e-Pub 2016. PMID: 27623234.
293. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14(10):1286-1312, 2016. PMID: 27697982.
294. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Rev Proteomics. e-Pub 2016. PMID: 27718753.
295. Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D, Goblirsch M, Stiegelbauer V, Shigeyasu K, Zhang X, Chen M, Vidhu F, Bartholomeusz GA, Toiyama Y, Kusunoki M, Doki Y, Mori M, Song S, Gunther JR, Krishnan S, Slaby O, Goel A, Ajani JA, Radovich M, Calin GA. H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer. EBioMedicine. e-Pub 2016. PMID: 27789274.
296. Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 91(9):1307-18, 2016. PMID: 27594190.
297. Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, Blum MA, Estrella J, Matamoros A, Sagebiel T, Devine CE, Badgwell BD, Lin QD, Das P, Ajani JA. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol 7(4):499-505, 2016. PMID: 27563438.
298. Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P, Mansfield P, Ajani J. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol 23(6):1948-55, 2016. e-Pub 2016. PMID: 26868957.
299. Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. e-Pub 2016. PMID: 27120436.
300. Blum Murphy MA, Elimova E, Ajani JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol 10(3):1-10, 2016. e-Pub 2015. PMID: 26560689.
301. Sepesi B, Schmidt HE, Lada M, Correa AM, Walsh GL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Ajani JA, Watson TJ, Swisher SG, Low DE, Hofstetter WL. Survival in Patients with Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg 101(3):1075-81, 2016. e-Pub 2015. PMID: 26680311.
302. Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw 14(2):173-9, 2016. PMID: 26850487.
303. Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?. Ann Surg Oncol 23(2):626-32, 2016. e-Pub 2015. PMID: 26564243.
304. Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, Ajani JA. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology 90(1):10-20, 2016. e-Pub 2015. PMID: 26492090.
305. Shiozaki H, Elimova E, Slack RS, Chen HC, Staerkel GA, Sneige N, Shimodaira Y, Sagebiel T, Lee JH, Bhutani MS, Das P, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol 113(1):29-35, 2016. e-Pub 2015. PMID: 26603684.
306. Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology 90(5):239-47, 2016. e-Pub 2016. PMID: 27046280.
307. Shiozaki H, Shimodaira Y, Elimova E, Wadhwa R, Sudo K, Harada K, Estrella JS, Das P, Badgwell B, Ajani JA. Evolution of gastric surgery techniques and outcomes. Chin J Cancer 35(1):69, 2016. e-Pub 2016. PMID: 27460019.
308. Shimodaira Y, Harada K, Lin Q, Ajani JA. The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. Ann Transl Med 4(2):38, 2016. PMID: 26889491.
309. Lee J, Bass AJ, Ajani JA. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. Am Soc Clin Oncol Educ Book 35:104-11, 2016. PMID: 27249691.
310. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 64(11):1721-31, 2015. e-Pub 2014. PMID: 25385008.
311. Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology 89(6):305-10, 2015. e-Pub 2015. PMID: 26393501.
312. Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K. Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. Gastroenterology 149(6):1599-606, 2015. e-Pub 2015. PMID: 26296479.
313. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 51(17):2545-52, 2015. e-Pub 2015. PMID: 26321501.
314. Sanchez-Espiridion B, Liang D, Ajani JA, Liang S, Ye Y, Hildebrandt MA, Gu J, Wu X. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clin Gastroenterol Hepatol 13(10):1730-1737.e9, 2015. e-Pub 2015. PMID: 25998788.
315. Elimova E, Ajani JA. Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options?. J Clin Oncol 33(28):3085-91, 2015. e-Pub 2015. PMID: 26324361.
316. Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. e-Pub 2015. PMID: 26482869.
317. Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, Jin J, Ma L, Zhu H, Skinner HD, Johnson RL, Ajani JA. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget 6(28):25883-96, 2015. PMID: 26317542.
318. Elimova E, Ajani JA. Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be?. J Clin Oncol 33(21):2410, 2015. e-Pub 2015. PMID: 26077236.
319. Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients - Does It Make a Difference?. Oncology. e-Pub 2015. PMID: 26159599.
320. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemo-resistance in esophageal cancer. Clin Cancer Res 21(11):2580-90, 2015. e-Pub 2015. PMID: 25739674.
321. Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol 111(7):875-81, 2015. e-Pub 2015. PMID: 25872485.
322. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. e-Pub 2015. PMID: 26059652.
323. Charalampakis N, Elimova E, Shimodaira Y, Shiozaki H, Wadhwa R, Ajani JA. Biologics in combination with chemotherapy for gastric cancer: is this the answer?. Expert Opin Pharmacother 16(7):955-60, 2015. e-Pub 2015. PMID: 25850442.
324. Ajani JA, Song S, Hochster HS, Steinberg IB. Introduction. Semin Oncol 42 Suppl 1:S1-2, 2015. e-Pub 2015. PMID: 25839663.
325. Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol 42 Suppl 1:S3-17, 2015. e-Pub 2015. PMID: 25839664.
326. Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros A, Song S, Ajani JA. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw 13(4):e19-29, 2015. PMID: 26052595.
327. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. e-Pub 2015. PMID: 26002780.
328. Neishaboori N, Wadhwa R, Nogueras-González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. e-Pub 2015. PMID: 25765719.
329. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 13(2):194-227, 2015. PMID: 25691612.
330. Bodoky G, Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, Vynnychenko I, Prausová J, Van Laethem JL, Cascinu S, Ajani JA. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. e-Pub 2015. PMID: 25707610.
331. Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 6(1):45-52, 2015. PMID: 25642337.
332. Ajani JA. After local therapy for esophageal cancer, should we continue to survey patients and, if so, why and how?. J Natl Compr Canc Netw 13(1):2-3, 2015. PMID: 25583763.
333. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology 88(6):332-6, 2015. e-Pub 2015. PMID: 25765098.
334. Skinner HD, Lee JH, Bhutani MS, Weston B, Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, Song S, Ye Y, Huang M, Ajani J, Wu X. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer 120(23):3635-41, 2014. e-Pub 2014. PMID: 25091571.
335. Dhupar R, Correa AM, Ajani J, Betancourt S, Mehran RJ, Swisher SG, Hofstetter WL. Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer. Dis Esophagus 27(8):770-6, 2014. e-Pub 2013. PMID: 24152134.
336. Sun Y, Gu J, Ajani JA, Chang DW, Wu X, Stroehlein JR. Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: A case-control study. Cancer 120(19):3040-8, 2014. e-Pub 2014. PMID: 24962126.
337. Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 20(38):13637-13647, 2014. PMID: 25320502.
338. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 32(30):3400-5, 2014. e-Pub 2014. PMID: 25225435.
339. Ajani JA, Swisher SG. Three Angels are Dancing on the Head of the Esophageal Cancer Pin, but Shouldn't We Not Topple One or Two?. Ann Surg Oncol 21(9):2815-6, 2014. e-Pub 2014. PMID: 24756809.
340. Li Y, Liu Z, Liu H, Wang LE, Onodera H, Suzuki A, Suzuki K, Wadhwa R, Elimova E, Sudo K, Shiozaki H, Estrella J, Lee JS, Song S, Tan D, Ajani JA, Wei Q. Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. Carcinogenesis 35(9):2031-8, 2014. e-Pub 2014. PMID: 24990617.
341. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg 98(3):1064-71, 2014. e-Pub 2014. PMID: 25038008.
342. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol 45(2):567-74, 2014. e-Pub 2014. PMID: 24859412.
343. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Stroehlein JR, Martin JF, Hung MC, Johnson RL. Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties. Cancer Res 74(15):4170-82, 2014. e-Pub 2014. PMID: 24906622.
344. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw 12(8):1139-44, 2014. PMID: 25099446.
345. Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical Staging of Patients with Early Esophageal Adenocarcinoma: Does FDG-PET/CT Have a Role?. J Thorac Oncol 9(8):1202-6, 2014. PMID: 25157774.
346. Sudo K, Elimova E, Skinner HD, Hofstetter WL, Ajani JA. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. J Clin Oncol 32(19):2112-3, 2014. e-Pub 2014. PMID: 24868018.
347. Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Anti-angiogenic agent ramucirumab: meaningful or marginal?. Expert Rev Anticancer Ther 14(4):367-79, 2014. e-Pub 2014. PMID: 24605771.
348. Shen R, Liu H, Wen J, Liu Z, Wang LE, Wang Q, Tan D, Ajani JA, Wei Q. Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. Mol Carcinog. e-Pub 2014. PMID: 24756984.
349. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. e-Pub 2014. PMID: 24742823.
350. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus 27(2):168-75, 2014. e-Pub 2013. PMID: 23621168.
351. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol 8(1):142-9, 2014. e-Pub 2013. PMID: 24210755.
352. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors Associated with Local-Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer. Ann Surg Oncol 21(1):306-14, 2014. e-Pub 2013. PMID: 24197760.
353. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology 86(5-6):336-9, 2014. e-Pub 2014. PMID: 24925190.
354. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 31(34):4306-10, 2013. e-Pub 2013. PMID: 24145339.
355. Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 34(12):2750-6, 2013. e-Pub 2013. PMID: 23996928.
356. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 24(11):2844-9, 2013. e-Pub 2013. PMID: 23975663.
357. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol 24(11):2854-9, 2013. e-Pub 2013. PMID: 23994746.
358. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31(31):3935-43, 2013. e-Pub 2013. PMID: 24043745.
359. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 10(11):643-55, 2013. e-Pub 2013. PMID: 24061039.
360. Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin 23(4):551-8, 2013. PMID: 24199704.
361. Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys 87(4):638-45, 2013. e-Pub 2013. PMID: 24035327.
362. Xu E, Gong Y, Gu J, Jie L, Ajani JA, Wu X. Risk assessment of esophageal adenocarcinoma using γ-H2AX assay. Cancer Epidemiol Biomarkers Prev 22(10):1797-804, 2013. e-Pub 2013. PMID: 23904462.
363. Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut 62(8):1100-11, 2013. e-Pub 2012. PMID: 22735568.
364. Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg 17(8):1359-69, 2013. e-Pub 2013. PMID: 23715646.
365. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 86(5):885-91, 2013. PMID: 23845841.
366. Ajani JA. Challenges imposed by the complexity of cancer genome. Lancet Oncol 14(8):e291-2, 2013. PMID: 23816294.
367. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation. Oncology 85(2):95-99. e-Pub 2013. PMID: 23860252.
368. Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. e-Pub 2013. PMID: 23899532.
369. Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis. e-Pub 2013. PMID: 23803692.
370. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-9, 2013. e-Pub 2012. PMID: 22950385.
371. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am 42(2):359-69, 2013. e-Pub 2013. PMID: 23639645.
372. Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani JA. Ramucirumab: a novel antiangiogenic agent. Future Oncol 9(6):789-95, 2013. PMID: 23718298.
373. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 24(5):1262-6, 2013. e-Pub 2012. PMID: 23247658.
374. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 11(5):531-46, 2013. PMID: 23667204.
375. Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach?. Curr Oncol Rep 15(2):146-51, 2013. PMID: 23355076.
376. Song S, Maru DM, Ajani JA, Chan CH, Honjo S, Lin HK, Correa A, Hofstetter WL, Davila M, Stroehlein J, Mishra L. Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res 73(7):2159-69, 2013. e-Pub 2013. PMID: 23536563.
377. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. J Surg Oncol 107(3):265-70, 2013. e-Pub 2013. PMID: 23303654.
378. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) 6(3):196-205, 2013. PMID: 23466817.
379. Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol 10(2):109-18, 2013. e-Pub 2012. PMID: 23165235.
380. Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw 11(1):60-6, 2013. PMID: 23307982.
381. Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, Muddasani R, Lu V, Ajani JA, Wang Y, Wei Q. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One 8(5):e64973, 2013. e-Pub 2013. PMID: 23724109.
382. Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. e-Pub 2013. PMID: 23350713.
383. Li Y, Liu Z, Liu H, Wang LE, Tan D, Ajani JA, Wei QY. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One 8(9):e71994, 2013. e-Pub 2013. PMID: 24023723.
384. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer 48(18):3396-404, 2012. e-Pub 2012. PMID: 22853875.
385. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 84(5):1078-85, 2012. e-Pub 2012. PMID: 22867894.
386. Murphy MA, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense?. J Natl Compr Canc Netw 10(12):1590-2, 2012. PMID: 23221793.
387. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 48(16):2941-53, 2012. e-Pub 2012. PMID: 22921186.
388. Thosani N, Lee JH, Hofstetter WL, Ajani JA, Guha S, Bhutani MS. Response. Gastrointest Endosc 76(5):1073-5, 2012. PMID: 23078931.
389. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-Term Update of US GI Intergroup RTOG 98-11 Phase III trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin. J Clin Oncol. e-Pub 2012. PMID: 23150707.
390. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg 94(4):1126-33, 2012. e-Pub 2012. PMID: 22921233.
391. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638-2642, 2012. e-Pub 2012. PMID: 22831985.
392. Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A, Blum MA, Ajani JA, Onodera H. Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. Clin J Gastroenterol 5(5):355-60, 2012. e-Pub 2012. PMID: 26181075.
393. Pan JY, Ajani JA, Gu J, Gong Y, Quin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 118(17):4346-53, 2012. e-Pub 2011. PMID: 22213102.
394. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. Oncology 83(5):300-304. e-Pub 2012. PMID: 22964903.
395. Swisher S, Ajani J, Correa A, Komaki R, Hofstetter W. Minimally invasive versus open oesophagectomy for oesophageal cancer. Lancet 380(9845):883; author reply 885-6, 2012. PMID: 22959377.
396. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-22, 2012. e-Pub 2011. PMID: 22150920.
397. Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer-is CROSSing over so hard to do?. Nat Rev Clin Oncol 9(9):493-4, 2012. e-Pub 2012. PMID: 22825372.
398. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection. J Clin Oncol 30(19):2327-33, 2012. e-Pub 2012. PMID: 22585691.
399. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 83(3):e345-51, 2012. e-Pub 2012. PMID: 22417808.
400. Jiang Y, Ajani JA. Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol 24(4):448-53, 2012. PMID: 22581355.
401. Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy as Preoperative Treatment for Localized Gastric Adenocarcinoma. Int J Radiat Oncol Biol Phys 83(2):581-6, 2012. e-Pub 2011. PMID: 22137021.
402. Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys 83(2):e231-9, 2012. e-Pub 2012. PMID: 22436793.
403. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118(10):2632-40, 2012. e-Pub 2011. PMID: 22565611.
404. Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II Study of a Paclitaxel-based Chemoradiation Regimen with Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 82(5):1967-72, 2012. e-Pub 2011. PMID: 21507583.
405. Blum MA, Ajani JA. Therapy: Localized gastric cancer-a CLASSIC shift in the paradigm?. Nat Rev Gastroenterol Hepatol 9(4):194-5, 2012. e-Pub 2012. PMID: 22392288.
406. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric Cancer: Apples Will Always Be Apples. J Clin Oncol 30(9):1017-8; author reply 1019-20, 2012. e-Pub 2012. PMID: 22331947.
407. Kountourakis P, Ajani JA, Davila M, Lee JH, Bhutani MS, Izzo JG. Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. Gastrointest Cancer Res 5(2):49-57, 2012. PMID: 22690258.
408. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21(3):374-87, 2012. PMID: 22439934.
409. Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, Swisher SG, Hofstetter WL, Guha S, Bhutani MS. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc 75(2):242-53, 2012. e-Pub 2011. PMID: 22115605.
410. Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: Significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg 143(2):412-20, 2012. e-Pub 2011. PMID: 22172216.
411. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal Cancer Dose Escalation using a Simultaneous Integrated Boost Technique. Int J Radiat Oncol Biol Phys 82(1):468-74, 2012. e-Pub 2010. PMID: 21123005.
412. Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the Timing of Esophagectomy After Chemoradiation Affect Outcome?. Ann Thorac Surg 93(1):207-13, 2012. e-Pub 2011. PMID: 21962263.
413. Ajani JA, Swisher SG. Preoperative Chemotherapy for Localized Squamous Cell Carcinoma of the Esophagus? We Should Go Back to the Drawing Board!. Ann Surg Oncol 19(1):3-4, 2012. e-Pub 2011. PMID: 21989665.
414. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for Prognostication of Outcome in Patients with Esophageal and Gastroesophageal Carcinoma Undergoing Definitive Chemoradiotherapy. Oncology 82(2):108-113, 2012. e-Pub 2012. PMID: 22328056.
415. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized Gastric Cancer Treated with Chemoradation without Surgery: UTMD Anderson Cancer Center Experience. Oncology 82(6):347-351, 2012. e-Pub 2012. PMID: 22677933.
416. Hayashi Y, Blum MA, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie 35(4):204-9, 2012. e-Pub 2012. PMID: 22488092.
417. Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-Modulated Proton Therapy Further Reduces Normal Tissue Exposure During Definitive Therapy for Locally Advanced Distal Esophageal Tumors: A Dosimetric Study. Int J Radiat Oncol Biol Phys 81(5):1336-42, 2011. e-Pub 2011. PMID: 21470796.
418. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual inhibition of Tumor Energy Pathway by 2-deoxy glucose and metformin Is Effective Against a Broad Spectrum of Preclinical Cancer Models. Mol Cancer Ther 10(12):2350-62, 2011. e-Pub 2011. PMID: 21992792.
419. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-33, 2011. e-Pub 2011. PMID: 21456015.
420. Ajani JA, Mangu PB, Burstein HJ. Peek before you treat? Is it a fantasy or reality?. J Oncol Pract 7(5):338-9, 2011. PMID: 22211134.
421. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology 141(2):476-485.e11, 2011. e-Pub 2011. PMID: 21684283.
422. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA, American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays. J Clin Oncol 29(24):3328-30, 2011. e-Pub 2011. PMID: 21788567.
423. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 9(8):830-87, 2011. PMID: 21900218.
424. Glasgow RE, Ilson DH, Hayman JA, Gerdes H, Mulcahy MF, Ajani JA. Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw 9(8):902-11, 2011. PMID: 21900220.
425. Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated Muscularis Mucosae Invasion has Similar Risk of Lymph Node Metastasis and Recurrence-free Survival as Intramucosal Esophageal Adenocarcinoma. Am J Surg Pathol 35(7):1045-53, 2011. e-Pub 2011. PMID: 21602659.
426. Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 13(3):157-67, 2011. PMID: 21365188.
427. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol 7(6):715-26, 2011. PMID: 21675835.
428. Khokhar NZ, Jiang Y, Benson AB, Ajani JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res 4(3):96-105, 2011. PMID: 22043325.
429. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, Noh SH, Park ES, Chu IS, Hong WK, Ajani JA, Lee JS. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 17(7):1850-7, 2011. e-Pub 2011. PMID: 21447720.
430. Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer 117(5):925-30, 2011. e-Pub 2010. PMID: 20960497.
431. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 128(1):132-43, 2011. e-Pub 2010. PMID: 20309880.
432. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11. J Clin Oncol 28(34):5061-6, 2010. e-Pub 2010. PMID: 20956625.
433. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Lee JH, Bhutani MS, Dekovich A, Swisher SG, Ajani JA. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer 116(24):5619-27, 2010. e-Pub 2010. PMID: 21136578.
434. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 26(6):640-6, 2010. PMID: 20827183.
435. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 116(19):4487-94, 2010. PMID: 20629031.
436. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 116(17):4007-13, 2010. PMID: 20564111.
437. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) 3(9):1176-86, 2010. e-Pub 2010. PMID: 20651033.
438. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg 90(3):884-90; discussion 890-1, 2010. PMID: 20732513.
439. Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg 90(3):892-8; discussion 898-9, 2010. PMID: 20732514.
440. Jiang Y, Mackley H, Cheng H, Ajani JA. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med 4(4):535-41, 2010. PMID: 20701442.
441. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 116(11):2511-8, 2010. PMID: 20301114.
442. Ajani JA. Resectable Esophageal Cancer: Surgery As Primary Therapy Is Not the Answer, but Then, What Is and Why?. J Clin Oncol 28(15):e243-4, 2010. e-Pub 2010. PMID: 20368554.
443. Shah MA, Ajani JA. Gastric cancer--an enigmatic and heterogeneous disease. JAMA 303(17):1753-4, 2010. PMID: 20442394.
444. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation. Dig Dis Sci 55(4):1098-105, 2010. e-Pub 2009. PMID: 19399614.
445. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 116(7):1656-63, 2010. e-Pub 2010. PMID: 20143431.
446. Das P, Jiang Y, Lee JH, Bhutani MS, Ross WA, Mansfield PF, Ajani JA. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw 8(4):417-25, 2010. PMID: 20410334.
447. Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst 102(8):547-56, 2010. e-Pub 2010. PMID: 20339140.
448. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. J Clin Oncol 28(9):1547-53, 2010. e-Pub 2010. PMID: 20159816.
449. Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy?. J Natl Compr Canc Netw 8(1):135-44, 2010. PMID: 20064295.
450. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. e-Pub 2010. PMID: 20108336.
451. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology 78(5-6):316-22, 2010. e-Pub 2010. PMID: 20699623.
452. Correa MC, Deus HF, Vasconcelos AT, Hayashi Y, Ajani JA, Patnana SV, Almeida JS. AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services. BMC Med Inform Decis Mak 10:65, 2010. e-Pub 2010. PMID: 20977768.
453. Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 5(11):e15074, 2010. e-Pub 2010. PMID: 21152079.
454. Ajani JA. In the ring with a raging bull: unresectable localized esophageal carcinoma. Onkologie 33(5):220-1, 2010. e-Pub 2010. PMID: 20502055.
455. Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol 22(12):1612-21, 2009. e-Pub 2009. PMID: 19734842.
456. Braiteh F, Correa AM, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Mehran RJ, Swisher SG, Ajani JA. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer 115(19):4450-8, 2009. e-Pub 2009. PMID: 19562780.
457. Bolton WD, Hofstetter WL, Francis AM, Correa AM, Ajani JA, Bhutani MS, Erasmus J, Komaki R, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg 138(4):831-6, 2009. e-Pub 2009. PMID: 19660349.
458. Ajani JA. Accomplishments in gastrointestinal oncology in 2008: conclusion. Gastrointest Cancer Res 3(5 Supplement 2):S79, 2009. PMID: 20011571.
459. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 15(18):5744-52, 2009. e-Pub 2009. PMID: 19737949.
460. Al-Batran SE, Ajani JA.. Accomplishments in 2008 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res 3(5 Supplement 2):S58-61, 2009.
461. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 115(16):3609-17, 2009. e-Pub 2009. PMID: 19526592.
462. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer, 2009. e-Pub 2009. PMID: 19685531.
463. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with Esophageal Cancer Radiation Therapy. J Thorac Oncol 4(7):880-8, 2009. e-Pub 2009. PMID: 19458557.
464. Ajani JA. Chemotherapy and radiation resistance: version 2.0. J Clin Oncol 27(16):2735-6; author reply 2737-8, 2009. e-Pub 2009. PMID: 19398570.
465. McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J, Guerrero T. Induction and Concurrent Taxanes Enhance both the Pulmonary Metabolic Radiation Response and the Radiation Pneumonitis Response in Patients with Esophagus Cancer. Int J Radiat Oncol Biol Phys. e-Pub 2009. PMID: 19525073.
466. Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. J Exp Clin Cancer Res 28:94, 2009. e-Pub 2009. PMID: 19566948.
467. Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, Wu X. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila Pa) 2(5):459-65, 2009. e-Pub 2009. PMID: 19401529.
468. Lagaly R, Horak A, Lee JH, Mansfield PF, Ajani JA.. Patient with advanced gastric cancer responds twice to the same systemic therapy. Gastrointest Cancer Res 3(3):115-7, 2009.
469. Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 115(7):1576-85, 2009. e-Pub 2009. PMID: 19156915.
470. Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M, Ajani JA, Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis 30(5):785-92. e-Pub 2009. PMID: 19270000.
471. Jiang Y, Kimchi E, Ajani JA. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach?. Future Oncol 5(2):157-61, 2009. PMID: 19284374.
472. Ajani JA. Future developments in esophageal cancer research. Gastroenterol Clin North Am 38(1):183-8, x, 2009. PMID: 19327575.
473. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 74(2):482-9. e-Pub 2009. PMID: 19289262.
474. Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, Maru D, Mehran RJ, Rice DC, Roth JA, Walsh GL, Vaporciyan AA. Esophageal tumor length is independently associated with long-term survival. Cancer 115(3):508-16, 2009. PMID: 19117343.
475. Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 115(3):624-30, 2009. PMID: 19130466.
476. Brücher BL, Swisher SG, Königsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA. Response to Preoperative Therapy in Upper Gastrointestinal Cancers. Ann Surg Oncol. e-Pub 2009. PMID: 19194759.
477. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs 13(1):49-59. e-Pub 2009. PMID: 19201649.
478. Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 22(2):127-32, 2009. e-Pub 2008. PMID: 19021681.
479. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. US Intergroup Anal Carcinoma Trial: Tumor Diameter Predicts for Colostomy. J Clin Oncol. e-Pub 2009. PMID: 19139424.
480. Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, Ajani J, Huang P. Different redox states in malignant and non-malignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal. e-Pub 2009. PMID: 19187006.
481. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. J Clin Oncol. e-Pub 2009. PMID: 19164214.
482. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience. Oncology 77(2):75-81, 2009. e-Pub 2009. PMID: 19571599.
483. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol 9:77, 2009. PMID: 19835575.
484. Ajani JA, Izzo JG, Lee JS. Chemotherapy and Radiotherapy Resistance: Complexity, Reality, and Promise. J Clin Oncol. e-Pub 2008. PMID: 19047300.
485. Cen P, Correa AM, Le JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. e-Pub 2008. PMID: 19021684.
486. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, Wu X. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) 1(6):460-9, 2008. PMID: 19138993.
487. Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II Randomized Trial of Two Nonoperative Regimens of Induction Chemotherapy Followed by Chemoradiation in Patients With Localized Carcinoma of the Esophagus: RTOG 0113. J Clin Oncol 26(28):4551-6, 2008. e-Pub 2008. PMID: 18574157.
488. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G, Yang G. Esophageal cancer. J Natl Compr Canc Netw 6(9):818-49, 2008. PMID: 18926093.
489. Ajani JA. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw 6(9):813-4, 2008. PMID: 18998257.
490. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 2008. PMID: 18759326.
491. Ajani JA. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. Br J Cancer 99(7):1195; author reply 1196. e-Pub 2008. PMID: 18766183.
492. Ajani JA. Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer?. Nat Clin Pract Gastroenterol Hepatol 5(8):414-5, 2008. PMID: 18560397.
493. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs 12(3):253-68, 2008. PMID: 18501674.
494. Ajani J. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie 31(7):360-1, 2008. PMID: 18596381.
495. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer, 2008. PMID: 18623381.
496. Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer, 2008. PMID: 18623382.
497. Ajani JA. Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer?. Nat Clin Pract Oncol, 2008. PMID: 18628737.
498. Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL. Retrospective Study of Clinicopathologic Features and Prognosis of High-grade Neuroendocrine Carcinoma of the Esophagus. Am J Surg Pathol, 2008. PMID: 18670347.
499. Jiang Y, Kimchi ET, Montero AJ, Staveley-O'Carroll KF, Ajani JA. Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther 8(6):975-91, 2008. PMID: 18533807.
500. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys 71(1):167-72, 2008. PMID: 18406886.
501. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus, 2008. PMID: 18459989.
502. Ajani JA, Schmoll HJ.. Accomplishments in 2007 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res 2(3 Suppl):S47-50, 2008.
503. Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol, 2008. PMID: 18398613.
504. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299(16):1914-21, 2008. PMID: 18430910.
505. Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, Ajani JA. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer 112(5):1020-7, 2008. PMID: 18205187.
506. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 3(3):277-82, 2008. PMID: 18317071.
507. Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs 13(1):135-44, 2008. PMID: 18321153.
508. Baker J, Ajani JA. Proactive nurse management guidelines for managing intensive chemotherapy regimens in patients with advanced gastric cancer. Eur J Oncol Nurs, 2008. PMID: 18329956.
509. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316-23, 2008. PMID: 18323556.
510. Cen P, Hofstetter WL, Lee JH, Ross WA, Wu TT, Swisher SG, Davila M, Rashid A, Correa AM, Ajani JA. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer 112(3):503-10, 2008. PMID: 18072264.
511. Cen P, Tetzlaff ED, Ajani JA. Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results. Ther Clin Risk Manag 4(1):137-40, 2008. PMID: 18728703.
512. Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge!. Ann Surg Oncol 14(12):3290-2, 2007. PMID: 17932722.
513. Ajani JA. The area between the curves gets no respect: is it because of the median madness?. J Clin Oncol 25(34):5531, 2007. PMID: 18048834.
514. Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH. Incidence, Natural History, and Patterns of Locoregional Recurrence in Gastric Cancer Patients Treated with Preoperative Chemoradiotherapy. Int J Radiat Oncol Biol Phys, 2007. PMID: 18164837.
515. Cen P, Ajani JA. Medical treatment for advanced gastroesophageal adenocarcinoma. Curr Opin Gastroenterol 23(6):631-5, 2007. PMID: 17906439.
516. Izzo JG, Ajani JA. Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2. J Clin Oncol 25(31):4865-7, 2007. PMID: 17971580.
517. Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol 31(11):1719-25, 2007. PMID: 18059229.
518. Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 110(10):2186-90, 2007. PMID: 17896785.
519. Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 110(5):989-95, 2007. PMID: 17636525.
520. Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol:1-7, 2007. PMID: 17899453.
521. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg 84(2):365-73; discussion 374-5, 2007. PMID: 17643602.
522. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E, Van Cutsem E. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22):3205-9, 2007. PMID: 17664467.
523. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E, Van Cutsem E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22):3210-6, 2007. PMID: 17664468.
524. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG, Willett CG, Willett CG. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25(24):3719-25, 2007. PMID: 17704421.
525. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 68(3):794-800, 2007. PMID: 17379452.
526. Das P, Crane CH, Ajani JA. Current treatment for localized anal carcinoma. Curr Opin Oncol 19(4):396-400, 2007. PMID: 17545807.
527. Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 16(6):1200-5, 2007. PMID: 17548685.
528. Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer 109(10):1989-95, 2007. PMID: 17397035.
529. Ajani JA. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother?. J Clin Oncol 25(7):906-7; author reply 908-9, 2007. PMID: 17327615.
530. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. Ann Surg Oncol, 2007. PMID: 17342569.
531. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene, 2007. PMID: 17353904.
532. Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 25:698-707, 2007. PMID: 17308274.
533. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 13:912-9, 2007. PMID: 17289885.
534. Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109:658-67, 2007. PMID: 17211865.
535. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109:125-34, 2007. PMID: 17146785.
536. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. Ann Surg Oncol, 2007. PMID: 17253104.
537. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 109:33-40, 2007. PMID: 17133415.
538. Ross WA, Alkassab F, Lynch PM, Ayers GD, Ajani J, Lee JH, Bismar M. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc 65:70-6, 2007. PMID: 17185082.
539. Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA, Swisher SG. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 31:58-64, 2007. PMID: 17197919.
540. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13:234-40, 2007. PMID: 17200360.
541. Ajani JA. Introduction. Semin Oncol 33 Suppl 11:1, 2006. PMID: 17178276.
542. Luthra R, Luthra MG, Izzo J, Wu TT, Lopez-Alvarez E, Malhotra U, Choi IS, Zhang L, Ajani JA. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol 33 Suppl 11:2-5, 2006. PMID: 17178277.
543. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer 107:2576-80, 2006. PMID: 17075877.
544. Shao L, Hittelman WN, Lin J, Yang H, Ajani JA, Wu X. Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutat Res 602:143-50, 2006. PMID: 17011594.
545. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5:2844-50, 2006. PMID: 17121931.
546. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao J, Xie K. Loss of Kruppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res 12:6395-402, 2006. PMID: 17085651.
547. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 12:6565-72, 2006. PMID: 17085672.
548. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-7, 2006. PMID: 17075117.
549. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 107:1475-82, 2006. PMID: 16944539.
550. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 107(5):967-74, 2006. PMID: 16874819.
551. Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA, 3rd, Lebwohl D, Mullaney B. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 24(5):441-6, 2006. PMID: 16586011.
552. Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer, 2006. PMID: 16955509.
553. Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol 12:5501-8, 2006. PMID: 17006988.
554. Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother 7(12):1627-31, 2006. PMID: 16872265.
555. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12(15):4590-7, 2006. PMID: 16899606.
556. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res 12(15):4598-604, 2006. PMID: 16899607.
557. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24(23):3789-98, 2006. PMID: 16785472.
558. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24(24):3953-8, 2006. PMID: 16921048.
559. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 95:450-6, 2006. PMID: 16880795.
560. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107:676-85, 2006. PMID: 16847885.
561. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221-31, 2006. PMID: 16770784.
562. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 24:353-7, 2006. PMID: 16683077.
563. Ajani JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho 33 Suppl 1:117-20, 2006. PMID: 16897985.
564. Ajani JA, Randolph Hecht J, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 106(9):1908-16, 2006. PMID: 16568451.
565. Das P, Fukami N, Ajani JA. Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw 4(4):375-82, 2006. PMID: 16569390.
566. Yasui W, Ajani JA, Nishiyama M, Ohtsu A, Tahara E. Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005. Cancer Sci 97(4):328-31, 2006. PMID: 16630126.
567. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs, 2006. PMID: 16628396.
568. Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64(3):692-9, 2006. PMID: 16242257.
569. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106(5):1017-25, 2006. PMID: 16456809.
570. Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, Ajani JA, Wei Q. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 64(3):700-8, 2006. PMID: 16242255.
571. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24(5):748-54, 2006. PMID: 16401681.
572. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 106(3):552-8, 2006. PMID: 16353210.
573. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24(4):663-7, 2006. PMID: 16446338.
574. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg 131(1):65-72, 2006. PMID: 16399296.
575. Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, Ajani JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus 19(3):152-7, 2006. PMID: 16722991.
576. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24(2):259-67, 2006. PMID: 16344314.
577. Tetzlaff ED, Faust J, Ajani JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer 9(2):140-3, 2006. PMID: 16767371.
578. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 104(11):2365-72, 2005. PMID: 16245310.
579. Das P, Ajani JA. Gastric and gastro-oesophageal cancer therapy. Expert Opin Pharmacother 6(16):2805-12, 2005. PMID: 16318431.
580. Izzo JG, Malhotra U, Wu TT, Ensor J, Babenko IM, Swisher SG, Correa A, Bresalier RS, Hittelman WN, Ajani JA. Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol 32(6 Suppl 9):S11-5, 2005. PMID: 16399423.
581. Song S, Lippman SM, Zou Y, Ye X, Ajani JA, Xu XC. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene 24(56):8268-76, 2005. PMID: 16170369.
582. Wu X, Lu C, Chiang SS, Ajani JA. Pharmacogenetics in esophageal cancer. Semin Oncol 32(6 Suppl 9):S87-9, 2005. PMID: 16399440.
583. Shao L, Lin J, Huang M, Ajani JA, Wu X. Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. Genes Chromosomes Cancer 44(4):415-22, 2005. PMID: 16114035.
584. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 104(7):1349-55, 2005. PMID: 16130133.
585. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590-602, 2005. PMID: 16134179.
586. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23(28):6957-65, 2005. PMID: 16145066.
587. Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs 23(5):479-84, 2005. PMID: 16133799.
588. Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104(8):1620-6, 2005. PMID: 16118804.
589. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23(24):5660-7, 2005. PMID: 16110025.
590. Varadhachary G, Ajani JA. Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev Anticancer Ther 5(4):719-25, 2005. PMID: 16111471.
591. Liu L, Hofstetter WL, Rashid A, Swisher SG, Correa AM, Ajani JA, Hamilton SR, Wu TT. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 29(8):1079-85, 2005. PMID: 16006804.
592. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer,, II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 23(13):3094-103, 2005. PMID: 15860869.
593. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241(5):810-7; discussion 817-20, 2005. PMID: 15849517.
594. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 26(4):785-91, 2005. PMID: 15661803.
595. Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 14(4):826-9, 2005. PMID: 15824151.
596. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103(7):1347-55, 2005. PMID: 15719440.
597. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61(3):656-64, 2005. PMID: 15708243.
598. Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res 11(6):2229-36, 2005. PMID: 15788671.
599. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11(4):1386-93, 2005. PMID: 15746037.
600. Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol 3(2):118-24, 2005. PMID: 16166979.
601. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23(6):1237-44, 2005. PMID: 15718321.
602. Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam JB, Jr, Komaki R, Ajani JA, Roth JA. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg 79(2):391-7; discussionn 391-7, 2005. PMID: 15680801.
603. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, Ajani JA. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer 36(2):69-76, 2005. PMID: 16648656.
604. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 10 Suppl 3:49-58, 2005. PMID: 16368871.
605. Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S, Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 8(1):18-28, 2005. PMID: 15747170.
606. Tetzlaff ED, Ajani JA. Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer 36(1):55-8, 2005. PMID: 16227636.
607. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11(2 Pt 1):656-63, 2005. PMID: 15701853.
608. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 60(5):1484-93, 2004. PMID: 15590179.
609. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22(23):4762-71, 2004. PMID: 15570077.
610. Ajani JA. Irinotecan and other agents in the management of multiple tumor types: highlights from the 6th University of Texas M. D. Anderson Cancer Center Investigators' Workshop. Oncology (Huntingt) 18(14 Suppl 14):7-9, 2004.
611. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(8):1776-85, 2004. PMID: 15386332.
612. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(4):1152-60; discussion 1152-60, 2004. PMID: 15464463.
613. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101(3):518-26, 2004. PMID: 15274064.
614. Whiting J, Sano T, Sasako M, Ajani JA. Report of the Seventeenth International Symposium of the Foundation for Promotion of Cancer Research: Recent Advances in Gastric Cancer. Jpn J Clin Oncol 34(8):481-8, 2004. PMID: 15371468.
615. Harting MT, Blakely ML, Herzog CE, Lally KP, Ajani JA, Andrassy RJ. Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg 39(8):e8-10, 2004. PMID: 15300556.
616. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22(14):2774-80, 2004. PMID: 15254045.
617. Benson AB, 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918-26, 2004. PMID: 15254061.
618. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol 99(7):1258-66, 2004. PMID: 15233663.
619. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100(11):2347-54, 2004. PMID: 15160337.
620. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22(10):1785-96, 2004. PMID: 15067027.
621. Higuchi K, Koizumi W, Tanabe S, Saigenji K, Ajani JA. Chemotherapy is more active against proximal than distal gastric carcinoma. Oncology 66(4):269-74, 2004. PMID: 15218293.
622. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus 17(1):38-43, 2004. PMID: 15209739.
623. Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB, Jr, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 57(5):1317-22, 2003. PMID: 14630268.
624. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9(17):6371-80, 2003. PMID: 14695137.
625. Higuchi K, Phan A, Ajani JA. Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol 4(5):413-9, 2003. PMID: 12941201.
626. Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 57(1):120-7, 2003. PMID: 12909224.
627. Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol 4(8):498-505, 2003. PMID: 12901965.
628. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9(4):261-7, 2003. PMID: 12967136.
629. Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol 26(2):165-70, 2003. PMID: 12714889.
630. Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, Feig B, Skibber J, Janjan N. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 97(5):1195-202, 2003. PMID: 12599225.
631. Schnirer,, II, Yao JC, Ajani JA. Carcinoid--a comprehensive review. Acta Oncol 42(7):672-92, 2003. PMID: 14690153.
632. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 14 Suppl 2:ii41-4, 2003. PMID: 12810457.
633. Wang L, Gong W, Wei D, Peng Z, Wu T-T, Ajani JA, Xie K. Expression of Transcription Factor Sp1 Predicts the Microvessel Density of Human Gastric Cancer: Contribution of Increased VEGF Expression. Clinical Cancer Res, 2003.
634. Zheng L, Wang L, Ajani JA, K Xie. Molecular Basis of Gastric Cancer Development and progression. Gastric Cancer, 2003.
635. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9(1):134-42, 2003. PMID: 12538461.
636. Windham TC, Termuhlen PM, Ajani JA, Mansfield PF. Adenocarcinoma of the stomach in patients age 35 years and younger: no impact of early diagnosis on survival outcome. J Surg Oncol 81(3):118-24; discussion 124-5, 2002. PMID: 12407722.
637. Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, Goldberg RM. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys 54(2):386-96, 2002. PMID: 12243812.
638. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg 236(3):376-84; discussion 384-5, 2002. PMID: 12192324.
639. Hasham-Jiwa N, Kasakura Y, Ajani JA. Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. Int J Clin Oncol 7(4):219-24, 2002. PMID: 12202975.
640. Kasakura Y, Ajani JA, Mochizuki F, Morishita Y, Fujii M, Takayama T. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol 80(4):181-5, 2002. PMID: 12210031.
641. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 16(5 Suppl 5):16-8, 2002. PMID: 12109800.
642. Kasakura Y, Ajani JA, Fujii M, Mochizuki F, Takayama T. Management of perforated gastric carcinoma: a report of 16 cases and review of world literature. Am Surg 68(5):434-40, 2002. PMID: 12013286.
643. Ajani JA. [Is neoadjuvant therapy for locally advanced stomach carcinoma standard?]. Chirurg 73(4):312-5, 2002. PMID: 12063914.
644. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94(3):641-6, 2002. PMID: 11857295.
645. Yao JC, Schnirer,, II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 5(4):208-12, 2002. PMID: 12491078.
646. Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123(1):175-83, 2002. PMID: 11782772.
647. Yao JC Ajani JA. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol 13 Suppl 4:7-12, 2002. PMID: 12401660.
648. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130(6):1078-85, 2001. PMID: 11742342.
649. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725-30, 2001. PMID: 11547741.
650. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8(6):519-24, 2001. PMID: 11456051.
651. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92(2):279-86, 2001. PMID: 11466680.
652. Schnirer,, II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, Ajani JA. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 24(1):91-5, 2001. PMID: 11232959.
653. Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys 51(3 Suppl 2):19-27, 2001. PMID: 11641011.
654. Pro B, Lozano R, Ajani JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs 19(4):341-3, 2001. PMID: 11561696.
655. Ajani JA. The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction. Oncology (Williston Park) 14(12 Suppl 14):17-8, 2000. PMID: 11200142.
656. Komaki R, Janjan NA, Ajani JA, Lynch PM, Fairweather JS, Raijman I, Blumenshein GR, Ho L, Pisters PW, Feig BW, Walsh GL, Pazdur R. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park) 14(12 Suppl 14):34-7, 2000. PMID: 11200147.
657. Ajani JA. [Strategies for preoperative therapy of locoregional cancers: an opportunity for expanding current concepts]. Chirurg 71(12):1431-2, 2000. PMID: 11195060.
658. Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 119(6):1126-32, 2000. PMID: 10838528.
659. Ajani JA, Yao JC. Preoperative therapy for local-regional gastric cancer: rationale and review of trials. Gan To Kagaku Ryoho 27 Suppl 2:392-4, 2000. PMID: 10895184.
660. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 6(2):78-81, 2000. PMID: 11069223.
661. Medgyesy CD, Wolff RA, Putnam JB, Jr, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer 88(2):262-7, 2000. PMID: 10640955.
662. York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol 6(8):771-6, 1999. PMID: 10622506.
663. Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer 86(9):1657-68, 1999. PMID: 10547537.
664. Yao JC, Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Williston Park) 13(11):1485-94; discussion 1497-502 passim, 1999. PMID: 10581599.
665. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 17(8):2403-11, 1999. PMID: 10561303.
666. Partyka S, Dumas P, Ajani J. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. Cancer 85(11):2336-9, 1999. PMID: 10357402.
667. Bold RJ, Ota DM, Ajani JA, Mansfield PF. Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. Gastric Cancer 2(1):1-7, 1999. PMID: 11957063.
668. Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, Ajani J, Rich TA, Goswitz MS, Evetts PA, Allen PK, Lynch PM, Skibber JM. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol 51(2):153-60, 1999. PMID: 10435807.
669. Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am 5(2):112-4, 1999. PMID: 10198733.
670. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229(3):303-8, 1999. PMID: 10077040.
671. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17(2):600-6, 1999. PMID: 10080605.
672. Thomas E, Dumas P, Ajani JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invet New Drugs 16:333-335, 1999.
673. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, Chuang V, Wallace S. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 17(7):474-8, 1999. PMID: 10518191.
674. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339(27):1979-84, 1998. PMID: 9869669.
675. Raijman I, Siddique I, Ajani J, Lynch P. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc 48(2):172-9, 1998. PMID: 9717783.
676. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 16(8):2877-85, 1998. PMID: 9704742.
677. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4(4):269-74, 1998. PMID: 9689986.
678. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16(5):1826-34, 1998. PMID: 9586897.
679. Rivera E Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21(1):36-8, 1998. PMID: 9499254.
680. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol 170(2):339-44, 1998. PMID: 9456942.
681. Ajani JA et al. NCCN Practice guidelines for upper gastrointestinal carcinomas. Oncology (USA) 12(11A):179-213, 1998.
682. Thomas E, Dumas P, Ajani JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 16(4):333-5, 1998. PMID: 10426667.
683. Ajani JA, Pazdur R, Dumas P, Fairweather J. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. Invest New Drugs 16(2):175-7, 1998. PMID: 9848582.
684. Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol 20(6):573-6, 1997. PMID: 9391543.
685. Lowy AM, Mansfield PF, Leach SD, Ajani J. Laparoscopic staging for gastric cancer. Surgery 119(6):611-4, 1996. PMID: 8650600.
686. Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco CH, Dodd GD, Jr. Carcinoid tumors: imaging procedures and interventional radiology. World J Surg 20(2):147-56, 1996. PMID: 8661810.
687. Jeon HM, Lynch PM, Howard L, Ajani J, Levin B, Frazier ML. Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. Hum Mutat 7(4):327-33, 1996. PMID: 8723682.
688. Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol 18(5):436-8, 1995. PMID: 7572763.
689. Rich TA, Skibber JM, Ajani JA, Buchholz DJ, Cleary KR, Dubrow RA, Levin B, Lynch PM, Meterissian SH, Roubein LD, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 32(4):1025-9, 1995. PMID: 7607922.
690. Weinstein GD, Rich TA, Shumate CR, Skibber JM, Cleary KR, Ajani JA, Ota DM. Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys 32(1):197-204, 1995. PMID: 7721616.
691. Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg 19(2):216-20, 1995. PMID: 7754626.
692. Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer 31A(5):665-70, 1995. PMID: 7640036.
693. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 75(2):451-6, 1995. PMID: 7812915.
694. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Jr, Markowitz AB, Abbruzzese JL, Bready B, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12(11):2296-300, 1994. PMID: 7964943.
695. Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus?. Oncology (Williston Park) 8(9):37-42; discussion 44-5, 50-2, 61, 1994. PMID: 7527642.
696. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86(14):1086-91, 1994. PMID: 7912736.
697. Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, Sugarman S, Patt Y, Abbruzzese JL, Levin B. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol 5(5):468-70, 1994. PMID: 7915537.
698. Meterissian S, Skibber J, Rich T, Roubein L, Ajani J, Cleary K, Ota DM. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol 1(2):111-6, 1994. PMID: 7834435.
699. Moore DF, Jr, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL, 3rd, Belt RJ, Mangold C, Bready B, Winn RJ. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol 5(3):286-7, 1994. PMID: 8186177.
700. Vassilopoulou-Sellin R, Ajani J. Islet cell tumors of the pancreas. Endocrinol Metab Clin North Am 23(1):53-65, 1994. PMID: 7913029.
701. Rich TA, Evans DB, Curley SA, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol 5 Suppl 3:75-80, 1994. PMID: 8204533.
702. Rich TA, Ajani JA. High dose external beam radiation therapy with or without concomitant chemotherapy for esophageal carcinoma. Ann Oncol 5 Suppl 3:9-15, 1994. PMID: 8204536.
703. Ajani JA, Winn R, Baez L, Pollock T, Maher T, Hallinan-Fueger B, Newman J. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. Cancer Invest 12(5):488-90, 1994. PMID: 7922705.
704. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 86(1):51-3, 1994. PMID: 7903699.
705. Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, Sellin RV, Fenoglio CJ, Merrell RC, Hickey RC. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114(6):1175-81; discussion 1181-2, 1993. PMID: 7903005.
706. Roubein LD, DuBrow R, David C, Lynch P, Fornage B, Ajani J, Roth J, Levin B. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction. Endoscopy 25(9):587-91, 1993. PMID: 8119209.
707. Jones DV, Jr, Patt YZ, Ajani JA, Abbruzzese J, Carrasco CH, Charnsangavej C, Levin B, Wallace S. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer 72(9):2560-3, 1993. PMID: 8402476.
708. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 85(22):1839-44, 1993. PMID: 8230264.
709. Rich TA, Ajani JA, Morrison WH, Ota D, Levin B. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol 27(3):209-15, 1993. PMID: 8210457.
710. Shumate CR, Rich TA, Skibber JM, Ajani JA, Ota DM. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer 71(11):3690-6, 1993. PMID: 8490919.
711. Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 71(4):1214-8, 1993. PMID: 8435795.
712. Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs 11(1):67-9, 1993. PMID: 8349439.
713. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 11(1):22-8, 1993. PMID: 8418237.
714. Jones DV, Jr, Ajani JA, Winn RJ, Daugherty KR, Levin B, Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest 11(6):667-9, 1993. PMID: 8221199.
715. Ajani JA, Chesnut JR. Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer 29A(16):2332-3, 1993. PMID: 7509166.
716. Ajani JA, Dumas P. Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. Semin Oncol 19(6 Suppl 14):45-7, 1992. PMID: 1488653.
717. Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol 15(6):524-7, 1992. PMID: 1449117.
718. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70(8):2073-6, 1992. PMID: 1394037.
719. Jones DV, Jr, Samaan NA, Sellin RV, Ajani JA. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon. Am J Med 93(3):348-9, 1992. PMID: 1524091.
720. Jones DV, Jr, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs 10(3):211-3, 1992. PMID: 1428730.
721. Grossie VB, Jr, Nishioka K, Ajani JA, Ota DM. Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. J Surg Oncol 50(3):161-7, 1992. PMID: 1619938.
722. Hubbard KP, Daugherty K, Ajani JA, Pazdur R, Levin B, Abbruzzese JL. Phase II trial of fazarabine in advanced colorectal carcinoma. Invest New Drugs 10(1):39-42, 1992. PMID: 1376722.
723. Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, Hallinan R, Levin B. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer 69(4):878-82, 1992. PMID: 1735078.
724. Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WKA, Moser RP, Ajani JA. Differentiation of residual or recurrent tumors from post-treatment changes with PET using 18F-FDG. Radiographics 12:269-275, 1992.
725. Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer 28A(4-5):880-4, 1992. PMID: 1524915.
726. Grossie VB, Jr, Ota DM, Ajani JA, Nishioka K. Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. Invest New Drugs 9(4):321-6, 1991. PMID: 1804805.
727. Linke K, Pazdur R, Abbruzzese JL, Ajani JA, Winn R, Bradof JE, Daugherty K, Levin B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs 9(4):353-6, 1991. PMID: 1804812.
728. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R, Young J, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs 9(4):369-71, 1991. PMID: 1804816.
729. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 68(7):1501-6, 1991. PMID: 1893349.
730. Robey-Cafferty SS, Ajani JA, Ota DM, Roth JA, Bruner JM. Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. Arch Pathol Lab Med 115(8):807-12, 1991. PMID: 1713759.
731. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Wiseman C, Lenado-Lee MA, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs 9(3):257-9, 1991. PMID: 1783525.
732. Nishioka K, Grossie VB, Chang TH, Ajani JA, Ota DM. Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. J Surg Oncol 47(2):117-20, 1991. PMID: 2062082.
733. Ellerbroek NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 20(2):351-5, 1991. PMID: 1846848.
734. Dhingra K, Talpaz M, Dhingra HM, Ajani JA, Rothberg JM, Gutterman JU. A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. Invest New Drugs 9(1):37-9, 1991. PMID: 1851142.
735. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8(12):2027-31, 1990. PMID: 2230894.
736. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Pazdur R, Saks S, Edwards C, Gutterman JU. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod 9(5):522-7, 1990. PMID: 2123922.
737. Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, Abbruzzese JL, Levin B, DeCaro L, Mountain C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 8(7):1231-8, 1990. PMID: 2358838.
738. Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C, Murray JL. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol 8(7):1246-54, 1990. PMID: 2193120.
739. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8(2):147-59, 1990. PMID: 2400936.
740. Ajani JA, Ota DM, Grossie VB, Jr, Abbruzzese JL, Faintuch JS, Patt YZ, Jackson DE, Levin B, Nishioka K. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. Cancer Chemother Pharmacol 26(3):223-6, 1990. PMID: 2113439.
741. Venkatesh S, Ordonez NG, Ajani J, Schultz PN, Hickey RC, Johnston DA, Samaan NA. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 65(2):354-7, 1990. PMID: 2153046.
742. Roth JA, Ajani JA, Rich TA. Multidisciplinary therapy for esophageal cancer. Adv Surg 23:239-60, 1990. PMID: 2403459.
743. Nicaise C, Ajani J, Goudeau P, Rozencweig M, Levin B, Krakoff I. Phase II study of tallysomycin S10b in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 26(3):221-2, 1990. PMID: 1694112.
744. Ajani JA, Abbruzzese JL, Faintuch JS, Patt YZ, Boman BM, Jackson DE, Levin B, Krakoff IH. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest 8(6):619-21, 1990. PMID: 2149834.
745. Ajani JA, Carrasco CH, Samaan NA, Wallace S. Therapeutic options for patients with advanced islet cell and carcinoid tumors. Regional Cancer Treatment 3:235-242, 1990.
746. Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys 17(6):1153-60, 1989. PMID: 2599903.
747. Ajani JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. Gastroenterol Clin North Am 18(4):923-30, 1989. PMID: 2559037.
748. Grossie VB, Jr, Nishioka K, Chang TH, Patenia D, Benitez MM, Ajani JA, Ota DM. Differential effects of parenteral nutrition on tumor growth and erythrocyte polyamine levels in the rat. JPEN J Parenter Enteral Nutr 13(6):590-5, 1989. PMID: 2515305.
749. Ajani JA, Ota DM, Grossie VB, Jr, Levin B, Nishioka K. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. Cancer Res 49(20):5761-5, 1989. PMID: 2507135.
750. Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 87(2):221-4, 1989. PMID: 2527006.
751. Ajani JA, Kanojia MD, Bedikian AY. High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. Am J Clin Oncol 12(4):335-8, 1989. PMID: 2667325.
752. Grossie VB, Jr, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. Cancer Res 49(15):4159-62, 1989. PMID: 2501023.
753. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res 49(14):4057-61, 1989. PMID: 2500234.
754. Ajani JA, Rios AA, Ende K, Abbruzzese JL, Edwards C, Faintuch JS, Saks S, Gutterman JU, Levin B. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod 8(2):140-6, 1989. PMID: 2499663.
755. Tueni EA, Newman RA, Baker FL, Ajani JA, Fan D, Spitzer G. In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells. Cancer Res 49(5):1099-102, 1989. PMID: 2465080.
756. Ajani JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, Kanojia MD. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol 24(1):41-4, 1989. PMID: 2720890.
757. Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, Nicaise C, Levin B. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 6(11):1703-7, 1988. PMID: 3141592.
758. Nishioka K, Grossie VB, Jr, Ajani JA, Patenia D, Chang TH, Ota DM. Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. Int J Cancer 42(5):744-7, 1988. PMID: 3141298.
759. Boman BM, Gagen MM, Bonnem E, Ajani JA, Schmidt S, Dimery IW, Golando J, Neidhart J. Phase I study of recombinant gamma-interferon (rIFN-gamma). J Biol Response Mod 7(5):438-46, 1988. PMID: 3141591.
760. Grossie VB, Jr, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. JPEN J Parenter Enteral Nutr 12(5):441-4, 1988. PMID: 3141639.
761. Fan D, Baker FL, Khokhar AR, Ajani JA, Tomasovic B, Newman RA, Brock WA, Tueni E, Spitzer G. Antitumor activity against human tumor samples of cis-diamminedichloroplatinum(II) and analogues at equivalent in vitro myelotoxic concentrations. Cancer Res 48(11):3135-9, 1988. PMID: 3365698.
762. Ajani JA, Baker FL, Spitzer G. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs 6(2):79-85, 1988. PMID: 3170133.
763. Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs 6(1):47-50, 1988. PMID: 2457566.
764. Baker FL, Ajani J, Spitzer G, Tomasovic BJ, Williams M, Finders M, Brock WA. High colony-forming efficiency of primary human tumor cells cultured in the adhesive-tumor-cell culture system: improvements with medium and serum alterations. Int J Cell Cloning 6(2):95-105, 1988. PMID: 3373036.
765. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 108(3):340-4, 1988. PMID: 2449109.
766. Baker FL, Spitzer G, Ajani JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system (ATCCS). Prog Clin Biol Res 276:105-17, 1988. PMID: 3174675.
767. Ajani JA, Baker FL, Spitzer G, Kelly A, Brock W, Tomasovic B, Singletary SE, McMurtrey M, Plager C. Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol 5(12):1912-21, 1987. PMID: 3681375.
768. Fan D, Ajani JA, Baker FL, Tomasovic B, Brock WA, Spitzer G. Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs. Eur J Cancer Clin Oncol 23(10):1469-76, 1987. PMID: 2890527.
769. Grossie VB, Jr, Ota DM, Ajani JA, Nishioka K. Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma. Cancer Res 47(7):1836-40, 1987. PMID: 3102050.
770. Odaimi M, Ajani J. High-dose chemotherapy. Concepts and strategies. Am J Clin Oncol 10(2):123-32, 1987. PMID: 3551575.
771. Ajani JA, Hortobagyi GN, Frye D, Levin B, Boman BM, Faintuch JS. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. Am J Clin Oncol 10(2):139-40, 1987. PMID: 3551577.
772. Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, Ajani JA, Kelly AM. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 47(2):403-6, 1987. PMID: 3491676.
773. Odaimi M, Ajani JA. Brain metastases and elevated alpha-fetoprotein level in a patient with esophageal carcinoma. South Med J 79(10):1304-6, 1986. PMID: 2429372.
774. Ajani JA, Spitzer G, Tomasovic B, Drewinko B, Hug VM, Dicke K. In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells. Br J Cancer 54(4):607-13, 1986. PMID: 3778805.
775. Patt YZ, Boddie AW, Jr, Charnsangavej C, Ajani JA, Wallace S, Soski M, Claghorn L, Mavligit GM. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol 4(9):1356-64, 1986. PMID: 2943876.
776. Ota DM, Grossie VB, Jr, Ajani JA, Stephens LC, Nishioka K. Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. Int J Cancer 38(2):245-9, 1986. PMID: 3089944.
777. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 147(1):149-54, 1986. PMID: 2424291.
778. Adolphson CC, Ajani JA, Stroehlein JR, Barlogie B, Bodey GP, Korinek J, Bedikian AY. Phase II trial of acivicin in patients with advanced colorectal carcinoma. Am J Clin Oncol 9(3):189-91, 1986. PMID: 3728371.
779. Baker FL, Spitzer G, Ajani JA, Brock WA, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C, et al. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res 46(3):1263-74, 1986. PMID: 3484678.
780. Ajani JA, Dimery I, Chawla SP, Pinnamaneni K, Benjamin RS, Legha SS, Krakoff IH. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. Cancer Treat Rep 70(3):375-9, 1986. PMID: 3955548.
781. Ajani JA, Tomasovic B, Spitzer G, Kavanagh JJ, Thielvoldt D, Baker FL, Gershenson D. Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay. Invest New Drugs 4(2):141-8, 1986. PMID: 2426218.
782. Grossie VB, Nishioka K, Ajani JA, Ota DM, Chang T, Patenia, D. The effect of spontaneous and induced cachexia on hepatic and tumor polyamine metabolism. J Nutrit Growth Cancer 3:143-150, 1986.
783. Grossie VB, Nishioka K, Ota DM, Ajani JA, Chang TH. Ornithine decarboxylase activity of normal tissue from tumor-bearing rats. J Nutr Growth Cancer 3:13-18, 1986.
784. Hortobagyi G, Papadoupoulos N, Frye D, Ajani J, Reuben JM. Phase I clinical studies of Nafazatrom. Invest N Drugs 4:251-255, 1986.
785. Ajani JA, Faintuch JS, McClure RK, Levin B, Boman BM, Krakoff IH. Phase II study of spirogermanium in patients with advanced colorectal carcinoma. Invest New Drugs 4(4):383-5, 1986. PMID: 3583645.
786. Umbach GE, Spitzer G, Ajani JA, Hug V, Thames H, Rudolph FB, Drewinko B. Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate. J Cancer Res Clin Oncol 111(3):273-6, 1986. PMID: 3733857.
787. Feldman LD, Ajani JA. Fluorouracil-associated dermatitis of the hands and feet. Jama 254(24):3479, 1985. PMID: 2933539.
788. Harris WB, Grossie VB, Ota DM, Nishioka K, Ajani JA, Chang T, Patenia D. Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutrition. J Surg Res 38(6):592-8, 1985. PMID: 3925242.
789. Gojobori T, Yokoyama S. Rates of evolution of the retroviral oncogene of Moloney murine sarcoma virus and of its cellular homologues. Proc Natl Acad Sci U S A 82(12):4198-201, 1985. PMID: 2987967.
790. Singletary SE, Umbach GE, Spitzer G, Drewinko B, Tomasovic B, Ajani J, Hug V, Blumenschein G. The human tumor stem cell assay revisited. Int J Cell Cloning 3(2):116-28, 1985. PMID: 3998518.
791. Ajani JA, Kanojia MD, Bedikian AY, Korinek JK, Stein SH, Espinoza EG, Bodey GP. Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncol 8(1):69-71, 1985. PMID: 3993626.
792. Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 42(2):69-71, 1985. PMID: 3921891.
793. Ajani JA, Blaauw AA, Spitzer G, Baker FL, Tomasovic B, Umbach G, Thielvoldt D, Zander AR, Dicke KA. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. Exp Hematol 13 Suppl 16:95-100, 1985. PMID: 2580731.
794. Umbach G, Hug V, Spitzer G, Tomasovic G, Thames H, Ajani JA, Drewinko B. Responses of human bone marrow progenitor cells to fluoro-ARA-AMP, homoharringtonine, and elliptinium. Invest New Drugs 2:263-265, 1985.
795. Umbach GE, Hug V, Spitzer G, Tomasovic B, Thames H, Ajani JA, Drewinko B. Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays. J Cancer Res Clin Oncol 109(2):130-4, 1985. PMID: 3980561.
796. Ajani JA, Kanojia MD, Bodey GP. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma. Cancer Treat Rep 68(12):1507-8, 1984. PMID: 6595058.
797. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 68(9):1085-91, 1984. PMID: 6478448.
798. Ajani JA, Kalter S, Rios A. Oncologic Emergencies: A guide for the practicing physician. Part I Drug Therapy:15-36, 1984.
799. Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, Burgess MA, Benjamin RS, McKelvey E, Krakoff I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 44(8):3608-12, 1984. PMID: 6744283.
800. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer 53(9):1836-40, 1984. PMID: 6231092.
801. Ajani JA, Kalter S, Rios A. Oncologic Emergencies: A guide for the practicing physician. Part II Drug Therapy:54-63, 1984.
802. Legha SS, Ajani JA, Bodey GP. Phase I study of spirogermanium given daily. J Clin Oncol 1(5):331-6, 1983. PMID: 6668504.
803. Kanojia M, Kantarjian H, Ajani J, Barlogie B. High-dose cytosine arabinoside (Ara-C) in colorectal cancer. British J Cancer 48:869-871, 1983.
804. Ajani JA, Burgess MA. Multiple squamous cell carcinoma treated with intra-arterial cisplatin in a patient with rheumatoid arthritis. Cancer Treat Rep 66(11):1987-9, 1982. PMID: 6890408.
805. Ajani JA, Cabanillas FF, Bodey GP. Phase I trial of pentamethylmelamine. Cancer Treat Rep 66(5):1227-8, 1982. PMID: 6805950.

Invited Articles

1. Ajani JA. GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. Gastrointest Cancer Res 4(2):39, 2011. PMID: 21673873.
2. Cohen DJ, Ajani J. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother 12(2):225-39, 2011. PMID: 21226634.
3. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Gastric Cancer Panel. Gastric Cancer. J Natl Compr Canc Netw 8(4):378-409, 2010. PMID: 20410333.
4. Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice!. J Clin Oncol 24(34):5473-4; author reply 5474-6, 2006. PMID: 17135655.
5. Ajani JA. Carcinoma of the esophagus: is biology screaming in my deaf ears?. J Clin Oncol 23(19):4256-8, 2005. PMID: 15781878.
6. Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep 6(3):192-8, 2004. PMID: 15066230.
7. Xiong HQ, Ajani JA. Treatment of colorectal cancer metastasis: the role of chemotherapy. Cancer Metastasis Rev 23(1-2):145-63, 2004. PMID: 15000155.
8. Ajani JA. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. Oncology (Williston Park) 17(9 Suppl 8):10-2, 2003. PMID: 14569840.
9. Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park) 17(9 Suppl 8):20-2, 2003. PMID: 14569843.
10. Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol 21(4):223-7, 2003. PMID: 14648779.
11. Ajani JA. Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus: are we still confused?. Ann Surg Oncol 9(7):605-6, 2002. PMID: 12167571.
12. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park) 16(6 Suppl 6):89-96, 2002. PMID: 12108902.
13. Yao JC Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep 4(3):222-8, 2002. PMID: 11937012.
14. Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. First Line Therapy of Untreated, Advanced Gastric or Gastroesophageal Junction Carcinoma with CPT-11 Plus Cisplatin. Oncology supplement, Cancer 94(3):641-646, 2002.
15. Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric Cancer 5 Suppl 1:31-4, 2002. PMID: 12772885.
16. Ajani JA. Taxotere in Gastric and Esophageal Carcinomas. Semin Oncol, 2002.
17. Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 15(3 Suppl 5):52-4, 2001. PMID: 11301842.
18. Najam A Ajani JA. Anatomic consideration: Uper Gastrointestinal Tract. Atlas of Cancer, 2001.
19. Komaki R, Ajani JA et al. CPT-11 and radiotherapy. Oncology, 2001.
20. Ho L, Rashid A, Kaw M, Ajani J. Predictors of Response to Treatment of Adenocarcinoma of the Stomach. Atlas of Cancer, 2001.
21. Swisher SG, Pisters PW, Komaki R, Lahoti S, Ajani JA. Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol 1(5):387-98, 2000. PMID: 12057146.
22. Ajani JA, Fairweather J, Pisters PW, Charnsangavej C. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 14(12 Suppl 14):19-21, 2000. PMID: 11200143.
23. Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol 16(6):516-21, 2000. PMID: 17031130.
24. Ajani JA. Current Status of Treatment in the Management of Esophageal Carcinoma. Manuscript for distribution. Tampa, Florida. Conference on Esophageal carcinoma, 2000.
25. . Introduction. St croix no 2 (Oncology supplement), 2000.
26. . Introduction. St. Croix no. 3 (Oncology supplement), 2000.
27. . Introduction. St. Croix no. 4 (Oncology supplement), 2000.
28. . Introduction. St. Croix no. 5 (Oncology supplement), 2000.
29. . Introduction: Oncology. Sonoma meeting Oncology Thought Leader Advisory Board Meeting (Oncology supplement), 2000.
30. . Introduction: Paris meeting (to be printed in Seminars in Oncology), 2000.
31. . Introduction: St croix no. 1 (Oncology supplement), 2000.
32. Ajani JA. Cisplaltin plus CPT-11 in Patients with Advanced Gastric or Gastroesophageal Junction Carcinoma. Preliminary Results of an Ongoing Phase II Study. Oncology (USA), 2000.
33. Ajani JA. A Review of Therapy of Colorectal Carcinoma. Ohio Conference. Canton, OH, 2000.
34. Ajani JA. Standard Chemotherapy for Advanced Gastric Carcinoma: Is it a myth?. J Clin Oncol 18:4001-4003, 2000.
35. Ajani JA. Adjuvant Therapy of Gastric Carcinoma. Posted on WebMD.com , 1999.
36. Ajani JA. New Developments in the Treatment of Esophageal and Gastroesophageal Junction Carcinomas. Proceeding Radiology Society of North America meeting, 1999.
37. Ajani JA. New Developments in the Treatment of Esophageal and Gastroesophageal Junction Carcinomas. Refresher’s Course of Radiology Society of North America, Chicago, Illinois, 1999.
38. Ajani JA. An Overview of the treatment of Colorectal Carcinoma. Proceeding 5th Annual Oncology Symposium. Saginaw, MI, 1999.
39. Ajani JA. New Developments in the Treatment of Colorectal and Upper Gastrointestinal Carcinomas. Proceeding Russian Academy of Medical Sciences. (published in Russian in a journal book), 1999.
40. Ajani JA. New chemotherapy agents for gastric and esophageal carcinomas. Proceeding Japan and US Chemotherapy/Radiotherapy Symposium. Hiroshima, Japan, 1999.
41. Ajani JA. The value of chemoradiotherapy in the management of patients with upper gastrointestinal carcinomas. Proc 9th Anticancer Therapy Congress (SOMPS). Paris, France, 1999.
42. Ajani JA. Carcinoma of the esophagus. An update. Cancer Consultant, 1999.
43. Ajani JA. Chemotherapy options for patients with gastric carcinoma. Proceeding Hematology/Oncology Conference, Merida City, Mexico, 1999.
44. Ajani JA Fairweather F. Cisplaltin plus CPT-11 in Patients with Advanced Gastric or Gastroesophageal Junction Carcinoma. Preliminary Results of an Ongoing Phase II Study. Chemotherapy Conference Highlights , 1999.
45. Ajani JA. Current Therapy of Colorectal Carcinoma. Proceeding Texas Society Medical Oncology. Held in Austin:September, 1999.
46. Ajani JA. Esophageal carcinoma. An update on combined modality therapy. Proceeding Hematology/Oncology Conference, Merida City, Mexico, 1999.
47. Ajani JA, Takiuchi H. Recent developments in oral chemotherapy options for gastric carcinoma. Drugs 58 Suppl 3:85-90, 1999. PMID: 10711846.
48. Ajani JA. Carcinomas of the esophagus and stomach: An update. Medical Oncology Board Review. UT M. D. Anderson Cancer Center:23 pp., 50+ refs, 1998.
49. Ajani JA. Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park) 12(10 Suppl 7):44-7, 1998. PMID: 9830625.
50. Ajani JA. Current status of therapy for advanced gastric carcinoma. Oncology (Williston Park) 12(8 Suppl 6):99-102, 1998. PMID: 9726100.
51. Ajani JA. Gastric Carcinoma Update: New drugs, new radiosensitizers, and multimodality therapy. Proceedings Eighth International Congress on Anti-Cancer Treatment. Paris, France, 1998.
52. Partyka S Ajani JA. Chemotherapy of colorectal cancer. Current Treat Options Gastroenterology, 1998.
53. Ajani JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest 113(1 Suppl):112S-119S, 1998. PMID: 9438700.
54. Ajani JA. Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 24(6 Suppl 19):S19-72-S19-76, 1997. PMID: 9427271.
55. Ajani JA. Current options for patients with local-regional gastric carcinoma. Proceeding Gastric Cancer Conference. Yonsai University, Seoul, Korea, 1997.
56. Ajani JA. Esophageal Carcinoma. Proceeding Medical Oncology Board Review. U. T. M. D. Anderson Cancer Center, Houston, TX, 1997.
57. Ajani JA. Gastric Carcinoma. Proceeding Medical Oncology Board Review. U. T. M. D. Anderson Cancer Center, Houston, TX, 1997.
58. Ajani JA. New Chemotherapy agents with properties of radiation sensitization and chemoradiotherapy in patients with gastric carcinoma. Proc Chemoradiotherapy Summit, Yosemite, CA , 1997.
59. Ajani JA. New and old chemotherapy agents for gastric carcinoma. International Gastric Cancer Association News, Newsletter 9, 1997.
60. Diamandidiu E Ajani JA. What treatment for this man with esophageal cancer?. Primary Care and Cancer 17:2 and 6, 1997.
61. Ajani JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 23(5 Suppl 12):55-8, 1996. PMID: 8941411.
62. Ajani JA. Current Status of Chemotherapy of Advanced Gastric Carcinoma. Proceedings WHO Conference on Gastric Carcinoma, Seoul, Korea, 1996.
63. Ajani JA, Ilson D, Kelsen DP. Paclitaxel in the therapy of upper GI carcinomas. Semin Oncol 23(suppl. no. 12):55-58, 1996.
64. Ajani JA. Radiotherapy, chemotherapy, and combined modality therapy of gastric carcinoma. International Gastric Cancer Association News, April Newsletter no. 1:7, 1996.
65. Ajani JA. Too much too late. Case discussion in The Oncology Times. Patient with upper GI tumor and synchronous colon carcinoma. The Oncology Times, 1996.
66. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 22(5 Suppl 12):46-50; discussion 51-3, 1995. PMID: 7481861.
67. Ajani JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol 22(3 Suppl 6):35-40, 1995. PMID: 7541155.
68. Leach SD, Lowy AM, Mansfield PF, Ajani JA. Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. J Infus Chemother 5(3):104-11, 1995. PMID: 8528966.
69. Holmes FA, Kudelka AP, Kavanagh JJ, Ajani JA, Valero V. Clinical Studies of Taxol, in, Taxane Anticancer Agents: Basic Science and Current Status. American Chemical Society Symposium, eds, G. I. Georg, T. C. Chen, I. Ojima, and D. M. Vyas:31-38, 1995.
70. Ajani JA. Current status of biology and therapy of gastric carcinoma. J Infusional Th 5:91-93, 1995.
71. Philip PA, Ajani JA. Gastrointestinal Cancer in the Elderly. Cancer Bulletin, 1995.
72. Raijman I, Wallace S, Ajani JA. Interventional Management of malignant biliary obstruction. Review of an article by MJ Shapiro to appear in Oncology, 1995.
73. Ajani JA, Mansfield P, Ota DM. Potentially resectable gastric carcinoma: Current approaches to staging and preoperative therapy. World J Surg 19:216-220, 1995.
74. Ajani JA. Therapy of carcinoma of the oesophagus: either attempt it not or succeed. Eur J Cancer 31A(5):790-3, 1995. PMID: 7640055.
75. Ajani JA. Etiology and therapy of gastric carcinoma. Proceedings 2nd Oncology Conference on Gastric Carcinoma; Athens, Greece, 1994.
76. Ajani JA, Carrasco CH, Wallace S. Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy. Ann N Y Acad Sci 733:479-87, 1994. PMID: 7978898.
77. Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 21(4):474-82, 1994. PMID: 8042045.
78. Ajani JA. Cancer of the Esophagus. Approaches to Etiology by Valda M. Craddock. Cambridge University Press. Cancer Bulletin 46:284-285, 1994.
79. Ajani JA. Carcinoma of the Esophagus. Carcinoma of the Stomach. Carcinoma of the Colon and Rectum. American College of Gastroenterology Syllabus and Q + A for the Annual Meeting in Sept. San Francisco, 1994.
80. Vassilopoulou-Sellin R, Ajani J. Islet cell tumor of the pancreas. Endocrine Clinics of North America 23:53-65, 1994.
81. Kelsen D, Ajani JA, Ilson D, Daugherty K, Pazdur R. A phase II trial of paclitaxel in advanced esophageal cancer. Preliminary report. Semin Oncol 21:44-48, 1994.
82. Chesnut JR Ajani JA. Role of escalating dose of octreotide in the relief of carcinoid syndorme. Sandoz publication , 1994.
83. Ajani JA. Vascular Occlusion Therapy of Liver Metastases. Review: Soulen MC. Chemoembolization of hepatic malignancies. Oncology 8:90-93, 1994.
84. Ajani JA. What re the therapeutic options for a 60-year old woman with stage II well-differentiated adenocarcinoma of the proximal jejunum?. The Oncology Times. Tumor Board 5:19, 1994.
85. Ajani JA. Carcinoma of the Esophagus. Staging and therapy. Proceedings ACT-AAPI-MCI Symposium. Recent Advances in Oncology. New Delhi, India:pp. 1-11. (an extended abstract), 1993.
86. Ajani JA. American College of Physician Medical Oncology Course. Carcinoma of the Esophagus and GE Junction. UT MDACC Course, 1993.
87. Ajani JA. American College of Physician Medical Oncology Course. Gastric Carcinoma. UT MDACC Course, 1993.
88. Ajani JA. American College of Physician Medical Oncology Course. Hepatocellular Carcinoma. UT MDACC Course, 1993.
89. Ajani JA. American College of Physician Medical Oncology Course. Pancreatic Neuroendocrine Tumors and Carcinoid Tumors. UT MDACC Course, 1993.
90. Ota DM, Ajani JA, Mansfield P. Preoperative Therapy for Gastric Carcinoma. Surgical Clinics of North America 2:493-497, 1993.
91. Ajani JA, Dumas P. Phase II study of oral etoposide in patients with gastric carcinoma: A preliminary report. Semin Oncol , 1992.
92. Ajani JA. Management of Gastric Cancer; edited by PH Sugarbaker, MD; Kluwer Academic Publishers; Boston/Dordrecht/London. JNCI 84:1597, 1992.
93. Ota DM, Mansfield P, Ajani JA. Operative and adjuvant treatment strategies for gastric carcinoma. Cancer Bulletin 44:286-291, 1992.
94. Ajani JA. American College of Physician Medical Oncology Course. Review of Gastric Carcinoma, 1991.
95. Ajani JA. American College of Physician Medical Oncology Course. Review of Carcinoma of the Esophagus and GE Junction, 1991.
96. Ajani JA. American College of Physician Medical Oncology Course (UT MDACC). Review of Carcinoid and Islet Cell Tumors, 1991.
97. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 67(1 Suppl):260-5, 1991. PMID: 1984825.
98. Rich TA, Jessup JM, Ota DM, Ames FC, Hohn DC, Martin RG, Ajani JA, Abbruzzese JL. Conservative management of anal and low rectal cancers with combined modality therapy. Cancer Bulletin , 1989.
99. Ajani JA Spitzer G. Adhesive tumor cell culture system. J Clin Oncol 6:178, 1988.
100. Ajani JA. Adjuvant chemotherapy for colorectal carcinoma. Cancer Bulletin 40:235-237, 1988.
101. Ajani JA. Book review. (Gastric Cancer. Contemporary Issues in Clinical Oncology. H. O. Douglass (ed), Churchill Livingston, New York). Cancer Bull (book review) 40:323, 1988.
102. Ajani JA Jackson DE. Carcinomas of the esophagus and stomach. Consultant 28:93-109, 1988.
103. Ajani JA. Highlights: 1988 Meeting of American Society of Clinical Oncology (ASCO 1988). New Orleans, May 23-25. J Cancer Res Clin Oncol 114:533-535, 1988.
104. Ajani JA. Value of predictive tests for clinical chemotherapy. Cancer Bull 39:263, 1987.
105. Boddie AW, Patt YZ, McBride CN, Wallace S, Ajani JA, Charnsangavej C, Soski M, Levin B. MDAH surgical experience with implantable infusaid pump and Medtronic drug administration device. International conference on Regional Therapy. Giessen, West Germany, 1985.
106. Feldman L Ajani J. 5-Fluorouracil induced dermatitis. JAMA, Dec, 1985.
107. Bodey GP, Yap BS, Ajani JA, Aboud AA, Yap HW, Estey EH. Clinical trials of 4'-epidoxorubicin. 13th International Congress of Chemotherapy. Vienna, Austria, SY 88, part 215, 1983.
108. Ajani JA, Sahu SK, Spitzer G, Hug V, Bodey GP. Cloning of human tumor stem cells in the soft agar - An overview. Cancer Bull 35:16-19, 1983.

Editorials

1. Ajani JA. Crescendos and decrescendos: gastric and esophageal cancers. J Natl Compr Canc Netw 9(8):811-3, 2011. PMID: 21900215.
2. Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie 34(10):499-500, 2011. PMID: 21985847.

Abstracts

1. Jin Z, Shen J, Wang C, Chen D, Zhang B, Zhang J, Ajani JA, Bennouna J, Chao J, Yoon HH, Zhu H, Ruan Y, Zhu C, Xu A.. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. Ann Transl Med 9(14):1189, 2021. PMID: 34430630.
2. Guang Lei 1 2 3 , Yilei Zhang 2 , Pranavi Koppula 2 4 , Xiaoguang Liu 2 , Jie Zhang 2 , Steven H Lin 2 5 , Jaffer A Ajani 6 , Qin Xiao 1 3 , Zhongxing Liao 5 , Hui Wang 7 8 , Boyi Gan 9 10. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res, 2020. e-Pub 2020. PMID: 31949285.
3. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinister M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S.. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). ASCO GI Cancer Symposium, 2009.
4. Ajani JA, Rodriguez W, Bodoky G, Moiseyenk V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J Clin Oncol Suppl 27(15), 2009.
5. Ho L, Phan AT, Jhamb J, Mani M, Tetzlaff E, Lin E, Ajani JA, Abbruzzese JL, Overman MJ. Retrospective review of docetaxel, cisplatin, and 5FU (DCF) given on a weekly basis for the treatment of advanced gastric or esophageal cancer. J Clin Onco. ASCO Annual Mtg Proc 26, 2008.
6. Cen P, Ajani JA, Correa AM, Lee JH, Maru DM, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA. Adenocarcinoma of the lower esophagus with Barrett's or without Barrett's: differences in patients survival after preoperative chemoradiation. J Clin Oncol 26, 2008.
7. Mani MA, Shroff RT, Jacobs C, Wolff RA, Ajani JA, Yao JC, Phan AT. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Onco. ASCO Annual Mtg Proc 26, 2008.
8. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriquez-Bigas MA, Chang GJ, Bhosale P, Krishnan S, Crane CH.. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. GI Cancer Symposium, 2007.
9. Overman MJ, Kopetz S, Morris J, Ajani JA, Hoff PM, Abbruzzese JL, Wolff RA.. A retrospective review of platinum-based versus non-platinum based chemotherapy in the treatment of metastatic adenocarcinoma of the small bowel (SBA). GI Cancer Symposium, 2007.
10. Zachariah B, James J, Gwede CK, Ajani JA, Chin L, Donath D, Kane BL, Rotman M, Berk L.. RTOG 0315: A randomized, double-blind, placebo-controlled phase III study to determine the efficacy of octreotide acetate in preventing or reducing the severity of chemoradiation-induced diarrhea in patients with anal or rectal cancer. J Clin Onc. ASCO Annual Mtg Proc 25(18S), 2007.
11. 60. Ajani JA, Phan A, Ho L, Tetzlaff ED, Baker J, Wei Q. Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer. J Clin Onc. ASCO Annual Mtg Proc 25(18S), 2007.
12. Ajani JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho 33 Suppl 1:117-20, 2006. PMID: 16897985.
13. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas C, Mayer RJ, Haddock MG, Willett C, Rich TA.. Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Onc. ASCO Annual Mtg Proc 24(18S), 2006.
14. Perez RP, Lewis LD, Cohen GI, Hwang J, Malik S, Marshall JL, Baker J, Phan AT, Yao JC, Ajani JA.. First-in-human phase-I pharmacokinetic trial of NS-9, a liposomal poly(I);poly(C), in patients with liver metastases from various primary cancers. J Clin Onc. ASCO Annual Mtg Proc 24(18S), 2006.
15. Lenz H, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara RH, Yao JC, Phan AT, Ajani JA.. Extended saftey and efficacy data on S-1 plus cisplatin in patients with advanced gastric carcinoma in a multi-center phase II study. J Clin Onc. ASCO Annual Mtg Proc 24(18S), 2006.
16. Tetzlaff ED, Baker J, Ajani JA.. Incidence of thrombeombolic events (TEEs) before and during chemotherapy of patients with advanced gastric and gastroesophageal junction carcinoma (AG-GEJC) on clinical trials. J Clin Onc. ASCO Annual Mtg Proc 24(18S), 2006.
17. Falk SJ, Anthoney A, Eatock M, van Custem E, Evans J, Valle J, Chick J, Drolet D, Ferry D, Ajani JA.. Phase II pharmacokietic (PK) and pharmacodynamic (PD) study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction cancer (G/GEJC). J Clin Onc. ASCO Annual Mtg Proc 23(16S), 2005.
18. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter W, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT.. Number of lymph nodes with metastasis predict survival in patients with esophageal or esophagogastric junction adenocarcinoma treated with preoperative chemoradiation. J Clin Onc, ASCO Annual Mtg Proc 23(16S), 2005.
19. Ajani JA, Phan A, Yao JC, Lee F, Singh DA, Haller D, Benson AB, Lenz H, Yanagihara RH, Strumberg D.. Multi-Center Phase II Study of S-1 plus Cisplatin in patients with advanced gastric carcinoma (AGC). J Clin Onc. ASCO Annual Mtg Proc 23(16S), 2005.
20. Mares JE, Worah S, Mathew SV, Charnsangavej C, Chen H, Ajani JA, Hoff PM, Phan AT, Yao JC.. Increased rates hypertension (HTN) among patients with advanced carcinoid treated with bevacizumab. J Clin Onc. ASCO Annual Mtg Proc 23(16S), 2005.
21. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ, Van Custem E.. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients with metastatic gastric adenocarcinoma (MGC). J Clin Onc. ASCO Annual Mtg Proc 23(16S), 2005.
22. Izzo JG, Wu TT, Luthra R, Luthra MG, Swisher S, Aggarwal BB, Bresalier RS, Milas L, Liao Z, Hittelman WN, Ajani JA.. Association of activated transcription factor NF-kappaB with chemo-radiotherapy resistance and porr outcome in esophageal adencarcinoma. J Clin Onc. ASCO Annual Mtg Proc 23(16S), 2005.
23. Okawara GS, Winter K, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willet C, Ajani JA.. A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99-04). J Clin Onc. ASCO Annual Mtg Proc 23(16S), 2005.
24. Izzo JG, Wu TT, Malhotra U, Ensor J, Luthra R, Chao CK, Swisher SG, Liao Z, Aggarwal BB, Hittelman WN, Ajani JA.. Transcription factor NFkB a potential molecular marker predicting and improving treatment efficacy in esophageal cancer. J Clin Onc. ASCO Annual Mtg Proc 23(16S), 2005.
25. Becerra CR, Takimoto C, Ajani JA, Major P, Feit K, Duggal A, De Jagger R.. A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previoulsy untreated metastatic gastric cancer. 2004 ASCO Annual Mtg Proc 22, 2004.
26. Swisher W, Erasmus J, Maish M, Correa AM, Ajani JA, Komaki R, Cox J, Lee HK, Macaplina H, Putnam JB, Rice D, Smythe WR, Vaporciyan AV, Walsh G, Hong D, Wu TT, Roth JA.. PET predicts pathologic response and long-term survival following preoperative chemoradiation in esophageal cancer. Gastrointestinal Cancer Symposium, 2004.
27. Macdonald JS, Smalley S, Benedetti J, Estes N, Haller DG, Ajani JA, Gunderson LL, Jessup M, Martenson JA.. Preoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Undate of the results of Intergroup Study INT-0116 (SWOG 9008). Gastrointestinal Cancer Symposium, 2004.
28. Higuchi K, Koizumi W, Tanabe S, Ajani JA. Chemotherapy is more active against proximal rather than distal gastric carcinoma. Proc ASCO, 2003.
29. Swisher S, Ajani JA, Komaki R, Putnam J, Walsh G, Liao Z, Yao J, Faust J, Wu TT, Roth J. CPT-11-taxotere-5-FU regimen for induction and concurrent chemoradiotherapy prior to surgery in patients with respectable esophageal or GEJ carcinoma. Proc ASCO, 2003.
30. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zuber E, Blattmann A. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a ranfomized phase III trial (V325). . Proc ASCO, 2003.
31. Yao JC, Yeung SJ, Rashid A, Szklaruk J, Baker J, Carr K, Vauthey N, Ellis L, Curley S, Ajani JA. Early results of a phase II trial of imatinib in patients with advanced carcinioid tumor. Proc ASCO, 2003.
32. Hecht JR, Ajani JA, Michaeli D . A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease. Proc ASCO, 2003.
33. Chang BB, Bleyer AW, Faust J, Yao J, Craig C, Ajani JA. Phase II study of bryostatin-1 (NSC 339555) plus paclitaxel in patients with metastatic or unresectabel locally advanced adenocarcinoma of stomach or gastroesophageal junction. Proc ASCO, 2003.
34. Hou Z, Elasmar SA, Lozano R, Hoff P, Wolff RA, Abbruzzese JL, Ajani JA, Carr K, Rashid A, Yao JC. A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc ASCO, 2003.
35. Dabaja B, Suki D, Bonnen, MD, Ajani JA. Adenocarcinoma of the small bowel: presentation, prognostic factors and outcome of 217 patients. Proc. ASCO 21:164a, 2002.
36. Lazo G, Yao JC, Najam AA, Swisher Sg, Putnam JB, Rothe JA, Mansfield PF, Pisters PW, Ajani JA. Clinical risk factors for peritoneal metastases in esophagogastric junction carcinoma (GEJC). . Proc ASCO 21:141a, 2002.
37. Swisher SG, Kelly K, Putnam JB, Ajani JA, Komaki KR, Aggarwal B, Correa AM, Gagneja H, Ho L, Hofstetter W, Kelly JF, Lara A, Liao Z, Lynch PM, Macapinlac HA, Smythe RW, Stevens C, Vaporciyan AA, Walsh GL, Yao JC, Roth JA. Computed Tomography (CT), Endoscopy, Barium Swallow and Positron Emission Tomography (PET) Are Not Predictive of A Complete Pathologic Response Following Preoperative Chemoradiation in Esophageal Cancer Patients. Proceedings Am Assoc Thoracic Surgery , 2002.
38. Phan AT, Najam AA, Yao YC, Mansfield PF, Pisteres PW, Feig BW, Ajani JA. Differences in localization, histology, and pattern of metastasis of gastric cancer among Caucasians, Hispanic, and African-American. Proc ASCO 21:136a, 2002.
39. Moeseyenko V, Van Cutsem E, Tjulanding S, Tchao Y, Sengupta S, Zuber E, Blattmann A, Jacques C, Ajani JA. Docetaxel-cisplatin-5-FU (DCF) versus cisplatin-5-FU (CF) as first line therapy for gastric cancer: interim analyis results on efficacy and safety in multicenter randomized phase III study. Proc ASCO 21:147a, 2002.
40. Shi G, Wang L, Zheng L, Ajani JA, Xie K. Elevated expression of endotheliat nitric oxide synthase correlates with the progression of human gastric adenocarcinoma. Proc. Gastrointestinal Cancer Research:27a, 2002.
41. Zheng L, Le X, Wei D, Wang L, Peng Z, Wu T, Yao J, Ajani JA, Xie K. Expression and regulation of interleukin-8 in human gastric adenocarcinoma. Proc Gastrointestinal Cancer Research:40a, 2002.
42. Alvarez E, Xiong H, Sanchez-Vega B, Vega R, Martin C, Morris J, Hamilton S, Ajani JA, Luthra R. Gene expression analysis of predictive molecular markers in colorectal cancers patients by real time quantitative PCR using RNA from formalin-fixed paraffin embedded tissue. Proc. Gastroinstetinal Cancer Research:15a, 2002.
43. Anthony LB, Vance D, Rubin J, Ajani JA, Stridsberg M. 5-HIAA versus chromogranin A as biochemical marakers in the malignant carcinoid syndrome: results from a randomized multi-institutional clinical trial. Proc ASCO 21:167a, 2002.
44. Najam AA, Yao JC, Lenzi R, Carr K, Giacco G, Mansfield PF, Pisters PW, Feig BW, Ajani JA. Linitis plastica is common in women and in poorly differentiated and signet ring cell histologies: an analysis of 217 patients. Proc ASCO 21:166a, 2002.
45. Ebrahimi B, Phan A, Yao JC, Paul MF, Pisters PW, Feig BW, Ajani JA. Phase II clinical trial of Rubitecan against advanced gastric adenocarcinoma. Proc ASCO 21:150a, 2002.
46. Hecht JR, Ajani JA, Michaeli D. Phase II study of G17DT immunogen in combination with cisplatin (CDDP) and 5-fluorouracil (5-FU) in subjects with metastatic or locally recurrent gastric or gastroesophageal cancer previously untreated with chemotherapy for advanced disease. Proc ASCO 21:154a, 2002.
47. Boyer MJ, Boore M, Leichman L, Walpole E, Bjarnason GA, Butts CA, Haller DG, Berlin JD, Hidalgo M, Wilcken N, Stephenson J, Romeyer F, Guld T, Gustafson N, Gallant G, Ajani JA. Phase II study of novel taxane BMS-184476 in previously treated patients with advanced adenocarcinoma involving the stomach or gastroesophageal (GE) junction. Proc ASCO 21:148a, 2002.
48. Ajani JA, Shah MA, Bokemeyer C, Lenz HJ, Burris HA, Van Cutsem E, Usakewicz J, Peeters O, Voi M, Lebwohl D, Safran H. Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane. Proc ASCO 21:155a, 2002.
49. Baker J, Schnirer II, Yao JC, Carr K, Ho L, Ajani JA. Phase II trial of irinotecan in patients with advanced carcinoid tumor. Proc ASCO 21:166a, 2002.
50. Ukropec J, Pro B, Lozano R, Ajani JA. Refractory CPT-11 induced diarrhea in cancer patients: resolution with octreotide, foru case studies. Proc. ASCO 21:271a, 2002.
51. Phan A, Nasham N, Yao J, Schnirer I, Najam A, Reddy S, Chang S, Wu T, Ajani JA. Role of phospholipase A2 in the pathogenesi of surgically induced adhensions. Proc. Gastrointestinal Cancer Research:22a, 2002.
52. Liao Z, Cox JD, Jin J, Zhen Z, Ajani JA, Swisher SG, Kelly JD, Stevens C, Roth JA, Vaporciyan AA, Smythe WR, Walsh GL, Putnam JB, Ho L, Allen P, Komaki R. Surgical resection may have increased survival of patients with clinical stage II and III esophageal cancer treated with concurrent chemoradiation. Proceedings American Radium Society , 2002.
53. Wang L, Zheng L, Wei D, Le X, Peng Z, Wu T, Yao J, Ajani JA, Xie K. Unique expression paterns of transcription factor Sp1 and normal and malignant gastric tissues implication of its role in gastric cancer development and progression. Proc. Gastrointestinal Cancer Research:31a, 2002.
54. Ajani JA. Preoperative Approaches Iincluding Preoperative Chemoradiation Therapy in Paitnets with Potentially Resectable Gastric Carcinoma. Proceeding TTD, Alicante, Spain, 2001.
55. Ajani JA. Therapy of Advanced Gastric Cancer. Proceedings International Gastric Cancer Symposium. Cairns, Australia, 2001.
56. Ajani JA, Ho L, Carr KL, Baker J. Phase II Study of G17DT with Concurrent 5-Fluorouracil and Cisplatin in Patients with Advanced Untreated Gastric Carcinoma. Proceedings Symposium on Gastrin. A key promoter of GI malignancies. Results of immunotherapy trials. San Francisco, 2001.
57. Ajani JA. Predicting response to therapy in local-regional gastric carcinoma. Proceedings 4th International Gastric Cancer Congress. New York, 2001.
58. Ajani JA, Pro B, Lozano R. Therapeutic Response to Octreotide in Patients with Refractory CPT-11 Induced Diarrhea. Proceedings Treatment of Chemotherapy-induced Diarrhea and Carcinoid Syndrome. New Orleans , 2001.
59. Ajani JA, Komaki R, Walsh G, Putnam J, Swisher S, Lahoti S, Ho L, Faust J, Ro J, Smythe R, Vaporcian A, Pisters P, Kelly J, Stevens C, Roth J. CPT-11 Plus Cisplatin as Induction Chemotherapy Followed by Chemoradiotherapy in Resectable Carcinoma of the Esophagus and GE Junction. Proc ASCO 20:131a, 2001.
60. Baker J, Ajani JA, Ho L, Mansfield P, Feig B, Keith M, Charnsangavej C. CPT-11 Plus Cisplatin as Second Line Therapy of Advanced Gastric or GE Junction Adenocarcinoma. Proc ASCO 20:163a, 2001.
61. Yao JC, Chiang S, Yu C, Giacco G, Hess K, Carr KL, Mansfield PF, Pisters PW, Feig BW, Ajani JA. The Effects of Gender and Ethnicity on Gastric Cancer Localization. Proc ASCO 20:165a, 2001.
62. Najam AA, Yao JC, Giacco G, Carr KL, Schnirer II, Ajani JA. The Effects of Gender, Race, Histology, and Tumor Location on Patterns of Metastases in Gastric Cancer. Proc ASCO 20:2166a, 2001.
63. Xiong Q, Yao JC, Phan A, Giacco G, Hess K, Roth JA, Putnam JB, Walsh GL, Swisher SG, Mansfield PF, Pisters PW, Feig BW, Ajani JA. Frequency of Esophagogastric Junction Involvement Among Upper Gastrointestinal Cancers. Proc ASCO 20:430a, 2001.
64. Swisher S, Ajani JA, Komaki R, Walsh G, Nesbitt J, Martin F, Lahoti S, Smythe WR, Vaporicyan A, Putnam J, Roth JA. Improved survival in esophageal cancer following taxol based induction chemotherapy, concurrent chemoradiation and surgery. American Association of Thoracic Surgery Abstract , 2001.
65. Swisher S, Wynn P, Mosheim M, Putnam JB, Komaki R, Ajani JA, Smyth WR, Vaporciyan A, Roth J, Walsh G. Is Surgical Resection Indicated for Recurrent Esophageal Tumors Following Definitive Chemoradiation? . American Association of Thoracic Surgery Abstract , 2001.
66. Ajani JA. Therapy of Advanced Gastric Carcinoma. Proceedings International Oncology Foundation. On the Internet , 2001.
67. Ajani JA. CPT-11 in GI cancers. Tel Aviv Conference. Israel, 2000.
68. Mansfield PF, Newman RA, Dougherty T, Ajani JA. Intraperitoneal hyperthermia perfusion using mitomycin. Drug absorption altered by treatment temperature. Proc ASCO, 2000.
69. Ajani JA. Chemotherapy of Advanced Gastric Carcinoma. Orlando, 2000.
70. Gopal R, Janjan N, Ajani JA, Ho L, Hamilton S, Cleary K, Dubrow R, Feig B, Pisters P, Lowy A, Mansfield P, Crane C. Comparison of pathologic response among three pre-operative chemoradiation regimens for resectable, locally advanced stomach cancer. Proc ASTRO I J Rad Onc Bio Phy 48(3 Supplement):118, 2000.
71. Yao JC, Schnirer II, Chiang SS, Kothari A, John R, Cooksley C, Ajani JA. Different Patterns of Gastric Cancer Localization in Men and Women. Proc ASCO 19:652a, 2000.
72. Swisher SG, Wynn P, Mosheim MP, Putnam JB, Komaki R, Ajani JA, Smythe RW, Vaporciyan AA, Roth JA, Walsh GL. Is Surgical Salvage Indicated for Recurrent Esophageal Tumors Following Definitive Chemoradiation?. . Proc Am Assoc Thoracic Surgery , 2000.
73. Ajani JA, Fodor M, Van Cutsem E, Tjulandin S, Moiseyenko V, Cabral F, Majlis A, Chao Y, Zuber E, Blattmann A, Garay C, Jacques C. Multinational Randomized Phase II Trial of Docetaxel and Cisplatin with or without 5-Fluorouracil in Patients with Advanced Gastric or GE Junction Adenocarcinoma. Proc ASCO 19:247a, 2000.
74. Blumenshein G, Ajani JA, Fairweather J, Komaki R, Janjan NA, Ho L, Pisters PW, Walsh GL, Raijman I, Lahoti S, Crane C, Feig BW. Phase I Study of CPT-11 Plus Radiotherapy in Patients with Locally Advanced Upper GI Carcinomas. Proc ASCO 19:322a, 2000.
75. Macdonald JS, Smalley S, Benedetti J, Estes N, Haller DG, Ajani JA, Gunderson LL, Jessup M, Martenson JA. Postoperative Combined Radiation and Chemotherapy Improves Disease-Free Survival and Overall Survival in Resected Adenocarcinoma of the Stomach and GE Junction. Results of Intergroup Study INT-0116 (SWOG 9008). Proc ASCO 19:1a, 2000.
76. Mansfield PF, Lowy AM, Feig BW, Janjan N, Pisters PW, Rich TA, Ajani JA. Preoperative Chemoradiation for Potentially Resectable Gastric Cancer. Proc ASCO 19:246a, 2000.
77. Ajani JA. Recent Advances in Chemotherapy of Gastric Carcinoma. Taiwan , 2000.
78. Schnirer II, Komaki R, Yao JC, Swisher SG, Putnam J, Pisters PW, Roth JA, Yan M, Janjan N, Mansfield PF, Feig BW, Ajani JA. A Study of Concurrent 5FU/Paclitaxel and Radiotherapy in Patients with Carcinoma of the Upper Gastrointestinal Tract. Proc Asco 19:472a, 2000.
79. Ajani JA. Phase II Study of CPT-11 and Cisplatin in Patients with Advanced Gastric Carcinoma. Proceeding Mount Sainai Chemotherapy Symposium, New York, NY, 1999.
80. Ajani JA. New chemotherapy agents and new strategies for local-regional esophageal carcinoma. Proceeding U of Chicago. 1st symposium on Head & Neck and Chest Malignancies, 1999.
81. Ajani JA. Combined Modality Approaches to Gastric Gastric Cancer. Proceedings Asian Society of Clinical Oncology. Bali, Indonesia, 1999.
82. Ajani JA. An update on systemic chemotherapy and value of chemoradiotherapy for gastric carcinoma. Proceeding 71st meeting of Japanese Gastric Cancer Association, Tokyo, Japan, 1999.
83. Crane CH, Janjan NA, Ajani JA, Hunt K, Feig B, Skibber J. Adenocarcinoma of the anus. Is chemoradiotherapy effective?. Proceeding American Radium Society. Big Island, Hawaii, 1999.
84. Ajani JA. Preoperative and postoperative approaches to locally advanced gastric carcinoma. Proceeding 3rd International Gastric Cancer Congress, Seoul, Korea, 1999.
85. Ajani JA, Hargraves K, Fairweather J. Phase I study of taxol, carboplatin and UFT plus leucovorin in patients with advanced upper GI carcinomas. Proc Fox Chase Cancer Center Symposium, Lanai, Hawaii, 1999.
86. Janjan N, Crane CH, Ajani JA, Goswitz M, Hunt K, Feig B, Chapman J, Tich TR, Skibber J, Dong L. 30 Gy is a sufficient dose to control local recurrence from anal cancer. Dosimetric evaluation of N0 patients undergoing chemoradiation. Proc. Radium Society , 1999.
87. Fairweather J, Ajani JA, Komaki R, Janjan NA, Pisters P, Walsh GL, Delclos ME, Lynch PM, Raijman I, Feig BW, Hargraves K. Phase I study of CPT-11 plus radiotherapy in paitents with locally advanced upper GI carcinomas. Proc ASCO , 1999.
88. Pro B, Ajani JA, Dabaja B, Hargraves K, Fairweather J. A phase I study of Taxol, carboplatin, and UFT plus leucovorin in patients with advanced upper gastrointestinal carcinomas. Proc ASCO , 1999.
89. Ajani JA, Fairweather J, Pisters PW, Feig BW, Hargraves K, Charnsangavej C. Phase II study of CPT-11 plus cisplatin in patients with advanced gastric and GE junction carcinomas. Proc ASCO , 1999.
90. Dabaja B, Ajani JA, Pro B, Abi-Said D, Nasr F, Cooksley C, Campos LT. Small bowel adenocarcinoma: 20-year M. D. Anderson Cancer Center esperience. Proc ASCO , 1999.
91. Medessey. Small cell lung. Asco, 1999.
92. Ajani JA. Current status of chemotherapy of colorectal carcinoma. Proc. Radiology Society of North America, 1998.
93. Ajani JA. Preoperative approaches and preoperative chemoradiation therapy in patients with potentially resectable gastric carcinoma. Proceedings Fifth Annual International Conference on Gastrointestinal Oncology. Bordeaux, France, 1998.
94. Ajani JA. Gastric Cancer. Tokyo. Japan proceedings on Comprehensive Conference on Gastric Carcinoma, 1998.
95. Lynch P, Raijman I, Pazdur, Delclos M, Martin F, Roth J. three-step taxol-based therapy in patients with resectable esophageal carcinoma. Proceedings, Investigators of Taxol Workshop. St. Thomas, Virgin Island, 1998.
96. Raijman I, Siddique I, Skibber J, Ajani JA, Lahoti S, Lynch P. Palliation of malignant colorectal strictures with expandable metallic stents: Experience with 20 patients. Proceeding DDW, 1998.
97. Raijman I, Siddique I, Ajani JA, Evans D, Abbruzzese J, Lahoti S, Lynch P. Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents. Proceedings DDW, 1998.
98. Anthony L, Ajani JA, Schimer S, Venook A, Bukowsky R, Pommier R, Saltz L, Dandona P, Rubin J. Phase IV open-label long-term trial of the safety, tolerability, and efficacy of octreotide acetate LAR injected at 4-week intervals in malignant carcinoid syndrome. Proc ASCO 17:268a, 1998.
99. Nesbitt J, Ajani JA, Komaki R, Walsh G, Putnam J, Swisher S, Pisters P, Lynch P, Raijman I, Pazdur R, Delclos M, Matine F, Roth J. Preoperative taxol-based chemotherapy followed by chemoradiation therapy in patients with potentially resectable esophageal carcinoma. Proc ASCO 17:282a, 1998.
100. Ajani JA, Mansfield PF, Janjan N, Pisters P, Lynch P, Raijman I, Pazdur R, Goswitz M, Feig B, Hargraves K, Myerson R, Gunderson L. Properative chemoradiation therapy in patients with potentially resectable gastric carcinoma. Proceeding ASCO 17:283a, 1998.
101. Ajani JA. Hepatic arterial chemotherapy is investigational for patients with liver metastases from colorectal carcinoma. Proceedings 8th International Conference. Regional Cancer Treatment September 1997. Ulm, Germany:Supplement, page: 71, 1997.
102. Wallace S, Yang D, Li C, Ajani JA, Chuang VP, Lawrence D, Richli W, Carrasco CH. Polymer drug delivery system. Proceedings 8th International Conference. Regional Cancer Treatment September 1997. Ulm, Germany:Supplement, page: 4, 1997.
103. Ajani JA. Paclitaxel studies in GI malignancies at M. D. Anderson Cancer Center using a variety of schedules. Proc Taxol Workshop. Atlanta, GA, 1997.
104. Ajani JA. Paclitaxel in the treatment of gastric and esophageal carcinomas. Bristol-Myers Proc Investigators Meeting, Puerto Rico, 1997.
105. Kelsen DP, Ginsberg R, Qian C, Gunderson L, Mortimer J, Estes N, Haller D, Ajani JA, Kocha W, Roth J, Minsky B. Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer. A preliminary report of intergroup study 113 (RTOG 89-11). . Proc ASCO 16:276a, 1997.
106. Raijman I, Siddique I, Ajani JA. How much luminal dilatation (if any) is necessary prior to palcement of an esophageal wallstent?. Proc ASGE, 1997.
107. Swisher S, Hu M, Holmes EC, Hunt K, Ajani J, McFadden D, Nelson S, Nesbitt J, Putnam JB, Vaporcian A, Walsh G, Zinner M, Roth J. Impact of number of involved lymph nodes on long-term survival in esophageal cancer. Proceeding SSO, 1997.
108. Raijman I, Siddique I, Ajani JA, Lynch P. Large experience in a cancer center in the palliation of malignant dysphagia and fistulae with the wallstent. Proc ASGE, 1997.
109. Raijman I, Siddique I, Ajani JA, Lynch P. Management of a rectovesical malignant fistula with the coated wallstent. Proc ASGE, 1997.
110. Anthony L, Ajani JA, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, Rubin J. Octreotide acetate long acting release (OALAR): 5-HIAA response in a randomized multi-center double-blind trial in carcinoid syndrome. Proceedings 79th Annual Meeting of the Endocrine Society, 1997.
111. Raijman I, Siddique I, Ajani JA, Lynch P. The palliation of malignant dysphagi with chemoradiation therapy does not increase the rate of potentially fatal complications from coated wallstent. Proc ASGE, 1997.
112. Ajani J, Fiarweather J, Dumas P, Pazdur R, Mansfield PF. A phase II study of Taxol in patients with advanced untreated gastric carcinoma. Proc ASCO , 1997.
113. Pazdur R, Patt Y, Ajani JA, Dumas P, Sonnichsen D, Ferreira I, Birkhofer M. Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cancer patients. Proc ASCO 16:959a, 1997.
114. Rubin J, Ajani JA, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Results of a randomized study of the safety, tolerability, and efficacy of multiple double-blind dose levels of octreotide acetate LAR given subcutaneous Sandostatin in malignant. Proc ASCO 16:A997, 1997.
115. Raijman I, Siddique I, Ajani JA, Lynch P. Tumor factors that may affect the outcome after palliation with the esophageal wallstent. Proc ASGE, 1997.
116. Feig BW, Lowy AM, JanJan N, Ajani JA, Charnsangavej C, Rich TA, Mansfield PF. Alteration of nodal staging by preoperative chemoradiotherapy for potentially resectable gastric cancer. Proceedings WHO conference on Gastric Cancer. Athens, Greece, 1996.
117. Ajani JA. Multidisciplinary Approaches to Carcinoma of the Stomach and Esophagus. Proceedings International Symposium on Gastroenterology. Shanghai, China, 1996.
118. Ajani JA. Current status of chemotherapy of advanced gastric carcinoma. Proceeding WHO-CC for Gastric Cancer (12th International Seminar. 6Th General Assembly). Seoul, Korea:108-109, 1996.
119. Ajani JA. Pharmacokinetics, dosing, schedule, toxicity and activity of Taxol. Oncology Symposium (Bristol-Myers Oncology). Istanbul, Turkey, 1996.
120. Ajani JA. Medical therapy of resected and advanced colorectal carcinoma. Proc Sixth International Congress on Anti-Cancer Treatments. Paris, France, 1996.
121. Ajani JA, Mansfield P, Dumas P, Pazdur R, Evans D, Curley S, Pisters P, Lynch P, Ota D. All chemotherapy preoperatively with cisplatin, 5-FU, Intron in patients with potentially resectable gastric carcinoma. Proc ASCO 15:208, 1996.
122. Ajani JA. Current therapeutic approaches in patients with potentially resectable gastric carcinoma. Proc. Symposium on GI Malignancies. Zaragosa, Spain, 1996.
123. Mansfield PF, Dougherty T, Ajani JA, Madden T, Newman RA. Intraperitoneal hyperthermic perfusion using mitomycin C: effect of temperature on systemic drug absorption. Proc ASCO 15:473, 1996.
124. Ajani JA. New agents and combined modality therapy for carcinoma of the esophagus. Proceeding International Symposium on Thoracic Malignancies. Pittsburgh, Pennsylvania, 1996.
125. Rivera E Ajani JA. New chemotherapy regimen with doxorubicin, streptozotocin, and 5-fluorouracil for patients with metastatic islet cell carcinoma. Porc ASCO 15:232, 1996.
126. Duanabdudiy E, Ajani JA, Yang D, Chuang V, Brown C, Carrasco C, Lawrence D, Wallace S. Phase I-II evaluation of vascular embolization with microencapsulated cisplatin (C-HAE) in neuroendocrine tumors (NET) metastatic to the liver. Proc. ASCO , 1996.
127. Diamandidou E, Ajani JA, Yang D, Chuang V, Brown C, Carrasco C, Lawrence D, Wallace S. Phase I-II study of vascular embolization with microencapsulated cisplatin in neuroendocrine tumors metastatic to the liver. Proc ASCO 15:192, 1996.
128. Lowy AM, Feig BW, JanJan N, Ajani JA, Rich TA, Mansfield PF. A pilot study of preoperative chemoradiation for potentially resectable gastric cancer. Proc SSO , 1996.
129. Ajani JA. Carcinoma of the esophagus. (Extended abstract). . Chilean Socienty of Internal Medicine. Santiago, Chile, 1995.
130. Ajani JA. Carcinoma of the Stomach. (Extended abstract). . Chilean Socienty of Internal Medicine. Santiago, Chile, 1995.
131. Ajani JA. Carcinomas of the Colon and Rectum. (Extended abstract). . Chilean Socienty of Internal Medicine. Santiago, Chile, 1995.
132. Ajani JA. Combined modality therapy of carcinoma of the esophagus and stomach. Proc Combined Modality Therapy in the 21st Century organized by Rowell Park Cancer Institute held in Buffalo, NY, 1995.
133. Ajani JA, Ilson D, Kelsen D. Therapy of carcinoma of the esophagus with Taxol. Proceedings ECCO, Paris, France, 1995.
134. Ajani JA. Therapy of carcinoma of the esophagus. Operate or not to operate. Proceeding Europeon School of Oncology Course. Milano, Italy, 1995.
135. Ajani JA. Approaches to patients with resectable gastric carcinoma. First International Gastric Conference. Kyoto, Japan, 1995.
136. Lynch PM, Jeon HM, Howard L, Ajani J, Levin B, Frazier M. Common hMSH2 mutation in unrelated families with variable family history of colorectal cancer. Proc. AGA , 1995.
137. Lowy J, Ajani JA, Mansfield PF. Peritoneal staging of patients with resectable gastric carcinoma. Proc SSO, 1995.
138. Pazdur R, ERivera, Diaz-Canton E, Lassere Y, Bready B, Ajani JA. Phase I trial of UFT (uracil:tegafur) with leucovorin: 14-day schedule. Proc ASCO 14:482, 1995.
139. Pazdur R, Diaz-Canton E, Meyers C, Abbruzzese J, Patt Y, Rivera E, Touroutoglou N, Edwards K, Bready B, Ajani JA. Phase II trial of CI-980 in metastatic colorectal carcinoma patients. ASCO 14:208, 1995.
140. Mansfield PF, Dougherty T, Ajani JA. A prospective study of thermal distribution during intraperitoneal hyperthermic perfusion. Proc. SSO, 1995.
141. Lowy AM, Leach PF, Mansfield D, Ota D, Pazdur R, Dumas P, Ajani JA. Repsonse to neoadjuvant chemotherapy predicts outcome in resectable gastric cancer. ASCO 14:211, 1995.
142. Pazdur R, Bready B, Diaz-Canton E, Gray R, Belt R, Goodwin W, Dakhil SR, Fueger R, Winn R, Ajani JA. Sequential modulation of fluorouracil with leucovorin, PALA, and alpha-interferon: Phase II trial in advanced colorectal carcinoma. Proc ASCO 14:208, 1995.
143. Ajani JA, Ilson D, Bhalla K, Forastiere A, Pazdur R, Martin R, Daugherty K, Kelsen DP. Taxol, cisplatin, 5-FU: A multi-institutional phase II study in patients with carcinoma of the esophagus. ASCO 14:203, 1995.
144. Ajani JA. New agents in the treatment of advanced upper gastrointestinal cancers. Proceedings 5th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies. Salzburg, Austria, 1994.
145. Ajani JA, Ilson D, Daugherty K, Pazdur R, Kelsen DP. Phase II trial of paclitaxel (Taxol) in patient with carcinoma of the esophagus. Proceedings Taxol Symposia in Madrid, Spain and Rome, Italy, 1994.
146. Ajani JA, Ilson D, Daugherty K, Pazdur R, Kelsen DP. Paclitaxel (Taxol) is active against carcinoma of the esophagus. Report of a phase II trial. Proceeding ASCO 13:192, 1994.
147. Ajani JA. Paclitaxel in therapy of esophageal and head & neck carcinomas. Taxol Symposia in Beijing, China, 1994.
148. Lowy AM, Ajani JA, Mansfield PF. Peritoneal cytologic staging in gastric adenocarcinoma. Proc ASCO , 1994.
149. Pazdur R, Lassere Y, Bready B, Rhodes V, Soo E, Ajani JA, Abbruzzese JL, Patt Y, Sugarman S, Levin B. Phase II clinical trial of UFT plus oral folinic acid: A potentially effective oral treatment regimen for metastatic colorectal carcinoma. Proc 8th EORTC Symposium, 1994.
150. Pazdur R, Lassere Y, Bready B, Soo E, Ajani JA, Sugarman S, Patt Y, Abbruzzese JL, Raber MN. Phase II trial of docetaxel in metastatic colorectal carcinoma. Proc 8th EORTC Symposium, 1994.
151. Sugarman SM, Pazdur R, Brown C, Vosika GJ, Jones DV, Markowitz A, Ajani JA, Bready B, Soo E, Levin B. A phase II trial of Immther for previously untreated patients with metastatic colorectal cancer to the liver. Proc ASCO , 1994.
152. Sugarman SM, Ajani JA, Daugherty K, Winn R, Lanzotti V, Bearden JD, Abbruzzese JL. A phase II trial of tototecan for the treatment of advanced measurable colorectal cancer. Proc ASCO , 1994.
153. Rich T, Skibber J, Ota D, Ajani JA, Buchholz D, Cleary K, Dubrow R, Levin B, Lynch P, Meterssian S, Pearce A, Roubein R. Pre-operative radiotherapy plus 5-FU continuous infusion in highly proliferative tumors. Proc ASTRO, 1994.
154. Pazdur R, Rhodes V, Lassere Y, Bready B, Soo E, Ajani JA, Abbruzzese JL, Sugarman S, Jones D, Markowitz A, Patt Y, Ho D, Levin B. UFT plus leucovorin. A potentially effective oral regimen in colorectal carcinoma. Proc ASCO , 1994.
155. Ajani JA, Mayer R, Ota D, Steele G, Evans D, Roh M, Sugarbaker J, Dumas P, Gray C, Vena D, Stablein D. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. Proceedings Fourth International congress on Anti-Cancer Chemotherapy; Paris, France, 1993.
156. Ajani JA. Approaches to therapy of potentially resectable gastric carcinoma. Proc Sixth Advances in Oncology Symposium, Mexico City, 1993.
157. Ajani JA. Chemotherjapy of metastatic gastric carcinoma. Proc Sixth Advances in Oncology Symposium, Mexico City, 1993.
158. Kelsen DP, Ajani JA, Ilson DH. Clinical activity of Taxol in patients with adenocarcinoma and squamous carcinoma of the esopha;gus and gastroesophageal junction: A preliminary report. Proc. ECCO, Jarusalem, 1993.
159. Ajani JA, Dumas P, Pazdur R, Mansfield P, Ota D. Phase II trial of oral etoposide in untreated patients with advanced gastric carcinoma. Proc ASCO 12:217a, 1993.
160. Weinstein GD, Rich TA, Shumate CR, Skibber JM, Ajani JA, Ota DM. Preoperative chemoradiation and complete surgical excision with or without intraoperatative electron beam boost (EB-IORT) for advanced primary rectal cancer. Proc ASTRO, 1993.
161. Ajani JA, Grossie VB, Ota D, Nishioka K. Clinical Experience with alpha-difluoromethyl ornithine in advanced colon carcinoma and its pharmacology. International Symposium on Polyamine in Cancer; Montgomery, Texas, 1992.
162. Ajani JA, Roth JA, Ota DM. Current therapy of upper gastrointestinal carcinomas. Proc 10th Congress on Future Directions in Chemotherapy, Geneva, Switzerland, 1992.
163. Ajani JA. Approaches to therapy of potentially resectable gastric carcinoma. . Proc. International Conference on Biology and Treatment of Gastrointestinal Malignancies. Frankfurt, Germany, 1992.
164. Rich TA, Ota DM, Skibber JM, Schumate CR, Morrison WH, Ajani JA, Levin B, Cleary K, Roubein L. Preoperative radiotherapy and 5-FU concomitant infusion for low rectal adenocarcinoma. Proc. International Conference on Biology and Treatment of Gastrointestinal Malignancies. Frankfurt, Germany 407, 1992.
165. Ajani JA. Systemic chemotherapy for potentially resectable adenocarcinoma of the esophagus and gastroesophageal junction. Proc. International Conference on Biology and Treatment of Gastrointestinal Malignancies. Frankfurt, Germany, 1992.
166. Ajani JA, Roth J, Putnam B, Ryan B, Walsh G, Lynch P, Gould P. Feasibility of five preoperative chemotherapy courses for resectable adenocarcinoma of the esophagus and GE junction. Proc AACR 33:218, 1992.
167. Kim Y, Ajani JA, El-Naggar A, Roth J, Lynch P, Ota D. Potentially resectable upper gastrointestinal adenocarcinomas: Evaluation of prognostic factors. Proc ASCO 11:181, 1992.
168. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena D, Stablein D. Preoperative and postoperative chemotherapy (CT) for patients with potentially resectable gastric carcinoma (PRGC). . Proc ASCO 11:165, 1992.
169. Rich TA, Ota DM, Skibber JM, Schumate CR, Morrison WH, Ajani JA, Levin B, Cleary KR, Roubein LD. Preoperative radiotherapy and 5-FU concomitant infusion for low rectal adenocarcinoma. Proc Am Soc Surg Oncol, 1992.
170. Rich TA, Terry NA, Meistrich ML, Brown BW, Cleary KR, Ajani JA, Ota DM, Peters LJ. Tumor cell kinetics of human rectal cancer: Relationship between potential doubling time, response to irradiation and chemotherapy, and patterns of failure. Proc ASTRO, 1992.
171. Grossie B, Ajani JA, Ota D, Nishioka K. Tumor growth recovery after BCNU treatment is delayed by difluoromethylornithine (DFMO). Proc AACR 33, 1992.
172. Evans D, Byrd R, Rich T, Ajani JA, Ames F. Preoperative chemoradiotherapy and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Proc. Southwester Surgical Society, 1991.
173. Ajani JA, Ota D, Jessup J, Ames F, Faintuch J, Jackson D. Pilot study of pre- and postoperative chemotherapy for resectable gastric carcinoma. Proc Third International Congress on Neo-Adjuvant Chemotherapy. Paris, France, 1991.
174. Shumate CR, Rich TA, Hohn DC, Ajani JA, Ota DM. Advanced rectal cancer. Improved tumor response with preoperative chemotherapy and radiotherapy. Proc SSO, 1991.
175. Ajani JA, Roth J, Ryan B, Putnam J, Pazdur R, Faintuch J, Dumas P, Levin B, McMurtrey M, Gutterman J. High-dose chemotherapy with GM-CSF for resectable adenocarcinoma of the esophagus. Proc ASCO 10, 1991.
176. Gomez J, Pazdur R, Ajani JA, Winn R, Abbruzzese JL, Patt YZ, Pilat S, Levin B. Phase II study of 5-fluorouracil and recombinant alpha-2A interferon in the treatment of advanced gastric carcinoma. Proc ASCO 10, 1991.
177. Derderian P, Pazdur R, Ajani JA, Winn R, Abbruzzese JL, Patt YZ, Pilat S, Levin B. Phase II study of 5-fluorouracil and recombinant alpha-2A interferon in the treatment of advanced pancreatic carcinoma. Proc ASCO 10, 1991.
178. Jaiyesimi I, Pazdur R, Patt YZ, Ajani JA, Abbruzzese JL, Daugherty K, Levin B. Phase II study of recombinant interferon alpha 2A and continuous infusion 5-fluorouracil for metastatatic colorectal carcinoma. Proc ASCO 10, 1991.
179. Linke K, Pazdur R, Ajani JA, Abbruzzese J, Patt Y, Levin B. Phase II trial of amonafide in advanced pancreatic carcinoma. Proc ASCO 10, 1991.
180. Abbruzzese J, Pazdur R, Ajani JA, Daugherty K, Tarassoff P, Levin B. A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc ASCO , 1991.
181. Rich T, Ames F, Roh M, Ajani JA. Post-operative irradiation (XRT) and protracted 5-fluorouracil infusion for biliary tract cancers. Proc ASCO 10, 1991.
182. Meistrich ML, Terry NHA, Rich TA, White RA, Brown BW, Ota DM, Ajani JA, Cleary KR, Peters LJ. Potential doubling times of human rectal carcinomas and treatment response. Proc International Society for Analytic Cytology (ISAC), 1991.
183. Rich T, Meistrich M, Terry N, White A, Peters L, Cleary K, Ajani JA, Ota D. Pre-treatment tumor cell kinetics in patients with advanced primary and recurrent rectal adenocarcinomas are associated with treatment response to pre-operative chemoradiotherapy. Proc 9th International Congress of Radiation Research, 1991.
184. Roth J Ajani JA. Multidisciplinary therapy for esophageal cancer. Proc UICC, Hamburg, W. Geramany, 1990.
185. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Proceeding of University of Maryland Symposium: Recent Advances in Etoposide Therapy. Alexandria, Virginia, 1990.
186. Rich TA, Ajani JA, Ellerbroek NA, Ota DM, Hohn DC, Levin B. Low dose continuous infusion 5-fluorouracil (5-FU) with or without cisplatin (CDDP) during external beam radiotherapy (XRT) for adenocarcinomas of the gastrointestinal (GI) tract. Proc Third International Conference on Interaction of Radiation and Systemic Therapy, Monteray, California, 1990.
187. Ellerbroek, NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatinum combined with external beam irradiation for advanced colorectal adenocarcinoma and for unresectable non-small cell lung carcinoma. Proc The Third International Conference on the Interaction of Radiation Therapy and Systemic Therapy, Monteray, CA, 1990.
188. Ajani JA, Roth JA. Pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus. Proc 6th International Conference on the Adjuvant Therapy of Cancer. Tucson, Arizona, 1990.
189. Ajani JA, Ota DM, Jackson DE. Resectable gastric carcinoma (RGC). Pre- and postoperative chemotherapy. Proc 6th International Conference on the Adjuvant Therapy of Cancer. Tucson, Arizona, 1990.
190. Ajani JA Jackson DE. Therapeutic approaches to locoregional and metastatic carcinoma of the stomach. Symposium: Recent Advances in Etoposide Therapy. Proc Future Trends in Chemotherapy. Geneva, Switzerland, 1990.
191. Ajani JA, CCarrasco, DJackson, NSamaan, DLawrence, SWallace. Biochemical response to SMS-201-995 given prior to chemoembolization for neuroendocrine tumors. Proc AACR 31:185, 1990.
192. Nishioka K, Ajani JA, Ota DM, Grossie VB, Patenia T, Rotriguez T, Wagle JR. Clinical and experimental studies of DFMO on human colorectal carcinoma. Proc 1990 International Symposium on Polyamines in Molecular and Medical Biology:84-85, 1990.
193. Grossie B, Nishioka K, Ajani JA, Ota D. Control of TPN-enhanced tumor growth by substituting ornithine for arginine. J Parent Enter Nutrition 14, 1990.
194. Baker FL, Sanger LJ, Spitzer G, Ajani JA, Brock WA. Drug sensitivitiy of normal and malignant tissue in vitro. Proc AACR , 1990.
195. Grossie VB, Thompson CW, Nishioka K, Ajani JA, Ota DM. Enhanced antitumor activity of difluoromethylornithine (DFMO) when administered with essential amino acid-based TPN. J Parent Enter Nutrition 14:105, 1990.
196. Ajani JA, Roth J, Ryan B, Putnam W, Pazdur R, Faintuch J, Jackson D, Rodriguez A, Levin B, DeCaro L, McMurtrey M, Gutterman J. Feasibility and toxicities of GM-CSF given with high-dose chemotherapy for resectable adenocarcinoma of the esophagus. Proc ASCO 9:118, 1990.
197. Robey-Cafferty S, Ajani JA, Ota D, Roth J, Bruner et al. P-glycoprotein in patients with upper gastrointestinal tumors. Proc Society of Pathology, 1990.
198. Pazdur R, Abbruzzese J, Faintuch J, Ajani JA, Patt Y, Jackson D, Markowitz A, Winn R, Gutterman J, Levin B. Phase II study of recombinant interferon-alpha (rIFN) and 5-Fluorouracil (5-FU) in patients (pts) with advanced colorectal carcinoma. Proc ASCO 9:117, 1990.
199. Gressot L, Pazdur R, Markowitz A, Abbruzzese J, Faintuch J, Patt Y, Ajani JA, Edwards C, Levin B, Gutterman J. Phase I-II studies of recombinant interleukin-2 and 5-flurouracil plus folinic acid for patients with advanced colorectal carcinoma. Proc ASCO 9:118, 1990.
200. Dhingra K, Talpaz M, Dhingra HM, Ajani JA, Rothberg J, Gutterman JU. Recombinant alpha interferon (Roferon) and weekly cisplatinum (CDDP) combination therapy. A phase I trial. Proc ASCO 9:193, 1990.
201. Grossie B, Ota D, Ajani JA, Nishioka K. Reduction of difluoromethylornithine-induced thrombocytopenia with ornithine. J Cell Biochem 14c(suppl):97, 1990.
202. Ajani JA, Ota D, Ames F, Jackson D, Boddie A, Abbruzzese J, Hohn D, Roh M, Faintuch J, Levin B, Jessup J. Pre- and postoperative chemotherapy for operable gastric carcinoma. Proc Sixteenth International Congress of Chemotherapy. Jerusalem, Israel, 1989.
203. Ajani JA, Carrasco C, Charnsangavej C, BLevin, SWallance. Systemic and regional therapy of neuroendocrine tumors of the gastrointestinal tract. Proc IV International conference on Advances in Regional Cancer Therapy. Berchtesgaden, West Germany, 1989.
204. Faintuch JS, Ajani JA, Abbruzzese J, Edwards C, Raber M. Combination chemotherapy of metastatic carcinoma of unknown primary with etoposide, cisplatin, and 5-fluorouracil. Phase II study. Proc ASCO 8:123, 1989.
205. Rich TA, Ajani JA, Abbruzzesse J, Ames F, Roh M, Hohn D. Combined modality therapy for cancer of the biliary tract. Proceeding Gilbert Fletcher Society Meeting , 1989.
206. Baker FL, Spitzer G, Ajani JA, Brock WA, Sanger LJ, Wike J. Enrichment of tumor stem cells by short term high density (STHD) incubation in the adhesive tumor cell culture system (ATCCS). . Proc AACR 30:606, 1989.
207. Perez-soler R, Khokhar AR, Lautersztain J, Ajani JA, Dexeus F, Raber M, Lopez-Berenstein G. Phase I clinical and pharmacology study of liposome entrapped cis-bis-neodecanoato trans-R,R-1,2 diamino cyclohexane platinum (II) (L-NDDP). . Proc ASCO 8:67, 1989.
208. Perez-soler R, Khokhar AR, Lautersztain J, Ajani JA, Dexeus F, Raber M, Lopez-Berenstein G. Phase I clinical and pharmacology study of liposome entrapped cis-bis-neodecanoato trans-R,R-1,2 diamino cyclohexane platinum (II) (L-NDDP). . Proc EORTC, 1989.
209. Abbruzzese J, Ajani JA, Faintuch J, Patt Y, Pazdur R, Blaustein A, Braud E, Edwards C, Levin B. Phase II study of iproplatin (CHIP) in patients with advanced gastric and pancreatic carcinomas. . Proc ASCO 8:123, 1989.
210. Roth JA, Ajani JA, McMurtrey M, Ryan B, Natarajan G, Rodriguez A, Levin B, Faintuch J. Pilot study of pre- and postoperative combination chemotherapy for resectable adenocarcinoma of the esophagus. Proc International Conference on Diseases of the Esophagus, Chicago , 1989.
211. Ajani JA, McMurtrey M, Ryan B, DeCaro L, Rich T, Abbruzzese J, Jackson D, Rodriguez A, Faintuch J, Levin B, Mountain C, Roth J. Pre- and postoperative chemotherapy for operable adenocarcinoma of the esophagus. Proc ASCO 8:121, 1989.
212. Ajani JA, Kavanagh J, Patt Y, Levin B, Edwards C, Gutterman J. Roferon and doxorubicin combination active against advanced islet cell or carcinoid tumors. Proc AACR 30:293, 1989.
213. Nishioka K, Ota DM, Grossie VB, Abbruzzese JL, Levin B, Ajani JA. Clinical and pharmacological effects of continuous infusion of DFMO in patients with advanced colorectal carcinoma. Proc 1988 Internat Symposium on Polyamines in Biochemical and Clinical Research. Sorrento, Naples (Italy). , 1988.
214. Grossie VB, Ota DM, Ajani JA, Nishioka K. Selective elimination of DFMO-induced thrombocytopenia by ornithine in tumor-bearing rats. Proc 1988 Internat Symposium on Polyamines in Biochemical and Clinical Research. Sorrento, Naples (Italy). , 1988.
215. Ajani JA, MMcMurtrey, Rich T, Roth J, Blackburn R, DeCaro L, Faintuch J, Levin B, Ryan B, Mountain C. Prolonged chemotherapy (CT) of locally advanced squamous carcinoma of the esophagus (SCCE). . Proc 2nd Internat Congress on Neo-Adjuvant Chemotherapy; Paris, France, 1988.
216. Ajani JA, Baker F, Tueni E, Spitzer G. Activity and patterns of corss sensitivity of recombinant alpha interferon against primary human tumors in vitro. Proc AACR 29:492, 1988.
217. Roubein L Ajani JA. Brain metastases in patients with colorectal carcinoma. Proc ASGE, 1988.
218. Grossie B, Ota D, Nishioka, Ajani JA. Control of TPN-enhanced tumor-growth with polyamine-directed chemotherapy. Proc ASPEN, 1988.
219. Patt Y, Lamki L, Jessup J, Levin B, Ajani JA, Halverson C, Schweighardt S, Shanken J, Murray L. Detection of occult metastases adenocarcinoma in patients with rising serum CEA by 111-In labeled monoclonal anti-CEA ZCE-025. Proc AACR 29:425, 1988.
220. Ajani JA, Ota D, Grossie B, Abbruzzese J, Faintuch J, Levin B, Goudeau P, Nishioka K. Difluoromethylornithine in patients with advanced colorectal carcinoma: Toxicity, response, pharmacology, and polyamine levels. Proc AACR 29:201, 1988.
221. Tueni E, Spitzer G, Ajani JA, Baker F, Fan D. In vitro chemosensitivity of fresh lung tumors in the adhesive tumor-cell culture system (ATCCS) vs lung tumor cell lines in the tetrazolium assay (MTT): Implications for drug screening. Proc AACR 29:487, 1988.
222. Baker F, Ajani JA, Spitzer G, Brock W. Mechanism of action of alpha interferon. Proc AACR 29:414, 1988.
223. Grossie B, Ota D, Ajani JA, Nishioka K. Modulation of difluoromethylornithine toxicity by concomitant ornithine treatment in tumor-bearing rats. Proc AACR 29:346, 1988.
224. Spitzer G, Baker F, Ajani JA. Patterns of pleiotropic drug resistance of primary human lung tumors in vitro. Proc AACR 29:316, 1988.
225. Weeks A, Abbruzzese J, Raber M, Gravel D, Ajani JA, Levin B, Grem J, Chun H. Phase I study of MeCCNU given in combination with 5-FU plus high-dose folinic acid in patients with metastatic colorectal carcinoma. Proc AACR 29:203, 1988.
226. Ajani JA, Abbruzzese J, Blackburn R, Faintuch J, Boman B, Levin B. Phase II evaluation of trimetrexate in patients with advanced colorectal carcinoma. Proc ASCO 7:115, 1988.
227. Abbruzzese J, Ajani JA, Blackburn R, Faintuch J, Patt Y, Levin B. Phase II study of didemnin-B in advanced colorectal cancer. Proc AACR 29:203, 1988.
228. Grossie B, Nishioka K, Medley R, Ajani JA, Ota DM. Role of arginine in total parenteral nutrition (TPN)-enhanced tumor growth in the rat. Proc FASEB, 1988.
229. Baker F, Spitzer G, Ajani JA, Brock W. ATCCS. Assay of primary human tumor cells for drug sensitivity using the adhesive-tumor-cell culture system (ATCCS). Proceedings of Prediction of Tumor Treatment Response, Banff, Canada, 1987.
230. Faintuch JS, Abbruzzese J, Ajani JA, Raber M, Goudeau P, Frost P, Levin B. Combination chemotherapy of metastatic carcinoma of unknown primary origin with etoposide (VP-16), cisplatin (CDDP), and 5-fluorouracil (5-FU): A preliminary report. Proc ASCO 6:130, 1987.
231. Rios A, Levin B, Ajani JA, Abbruzzese J, Faintuch J, Ende K. Combination of recombinant human interferon gamma (rIFNgamma) and 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma (CRC). Proc ASCO 6:84, 1987.
232. Ajani JA, McMurtrey M, Rich T, Blackburn R, Chang-Tung E, Faintuch J, Levin B, Mountain C. Combined modality therapy with effective prolonged systemic component for locally advanced squamous cell carcinoma of the esophagus (SCE). . Proc ASCO 6:82, 1987.
233. Fan D, Baker F, khokhar AR, Spitzer G, Tomasovic B, Ajani JA, Newman RA, Finders M, Joe T, Brock WA. Comparison of cisplatinum and its analogs at equivalent in vitro doses in a primary adhesive human tumor cell culture assay (ATCCS). . Proc AACR 28:421, 1987.
234. Grossie VB, Ota DM, Ajani JA, Nishioka K. Differential effects of difluoromethylornithine (DFMO) on hepatic and tumor polyamine metabolism in sarcoma-bearing rats. Proc AACR 28:319, 1987.
235. Ajani JA, Baker F, Spitzer G, Kelly A, Tomasovic B, Fan D, Brock W. Differential in vitro activity of biologics and chemotherapy drugs compared in human tumors. . Proc 15th International Congress of Chemotherapy, Instanbul, Turkey, 1987.
236. Baker F, Ajani JA, Spitzer G, Brock W. Evidence for cell cycle retardation of human tumors by recombinant alpha interferon (IFNRA) in vitro. Proc Second Conference on Immunity to Cancer; Williamsburg, Virginia:26, 1987.
237. Baker FL, Tomasovic B, Spitzer G, Ajani JA, Williams M, Finders M, Tofilon P, Brock WA. High colony forming efficiency (CFE) of primary human tumor cells cultured in the adhesive-tumor-cell culture system (ATCCS). Proc AACR 28:28, 1987.
238. Rich TA, Ajani JA, Goudeau P, Ende K. High dose radiotherapy (XRT) with protracted venous 5-fluorouracil (PV 5FU) radiosensitization for advanced gastrointestinal cancer. Proc ASCO 6:79, 1987.
239. Spitzer G, Ajani JA, Baker F, Brock W, Fan D, Tomasovic B. In vitro comparison of antitumor efficacy of investigational and standard drugs at the equitoxic concentrations in the adhesive tumor cell culture system (ATCCS): An in vitro method of drug screening. Proceedings of Prediction of Tumor Treatment Response, Banff, 1987.
240. Ajani JA, Baker F, Brock W, Spitzer G, Kelly A, Tomasovic B, Fan D. In vitro comparison of radiation therapy (RT) and chemotherapy (CT) response in primary human tumors. Proc AACR 28:447, 1987.
241. Ajani JA, Baker F, Kelly A, Spitzer G, Brock W, Tomasovic B, Joe T, Fan D. In vitro drug response of primary human tumor cells in the adhesive tumor culture system (ATCCS) predicts for clinical response. Proceedings Conference on Prediction of Tumor Treatment Response, Banff, Canada, 1987.
242. Smith E, Ajani JA, Blackburn R, Rich T, Roth J, Levin B. Oral nutrition support of patients with esophageal cancer. Proc Am Dietetic Assoc , 1987.
243. Nishioka K, Grossie VB, Ota DM, Ajani JA. Polyamine directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. Proc AACR 28:317, 1987.
244. Ajani JA, Baker F, Spitzer. Relationship of antitumor response between recombinant gamma interferon (IFNRG) and cytotoxic drugs against human tumors in vitro. Proc Second Conference on Immunity to Cancer; Williamsburg, Virginia:38, 1987.
245. Carrasco CH, Ajani JA, Samaan NA, Charnsangavej C, Boman B, Wallace S. Sequential hepatic artery embolization (HAE) for metastatic islet cell carcinoma. Proc ASCO 6:83, 1987.
246. Ota D, Grossie B, Ajani JA, Chang T, Patenia D, Goudeau, Nishioka K. Toxicity and erythrocyte (RBC) polyamine levels of cancer patients receiving continuous i.v. difluoromethylornithine (DFMO). Proc AACR 28:230, 1987.
247. Baker F, Spitzer G, Ajani JA, Fan D, Tomasovic B, Finders M, Brock W. Application of the adhesive-tumor-cell culture (ATCCS) in the testing of chemotherapy drugs. Proc Texas Anticancer Drug Development Consortium, Topatio Springs, Boerne, Texas, 1986.
248. Wallace S, Carrasco CH, Charnsangavej C, Ajani JA, Samaan NA. Embolization of neuroendocrine metastases. Proceedings of Current Approaches for the Diagnosis and Treatment of Gastrointestinal Cancer. Houston, Texas:38, 1986.
249. Wallace S, Carrasco CH, Charnsangavej C, Ajani JA, Samaan NA. Hepatic artery embolization in the carcinoid syndrome. proceeding of Gastrointestinal Endocrine Tumors. Houston, Texas, 1986.
250. Ajani JA, McMurtrey MJ, Rich TA, Levin B, Mountain CF. Role of chemotherapy in squamous cell carcinoma of the esophagus. Proceedings of Current Approaches for the Diagnosis and Treatment of Gastrointestinal Cancer. Houston, Texas:26, 1986.
251. Nishioka K, Grossie VB, Ota DM, Ajani JA, Harris WB, Chang T, Patenia D. Effect of total parentaral nutrition and intravenous infusion of DFMO on polyamine metabolism in tumor-bearing hosts. Proc International Conference on Polyamines in Life Sciences, Japan, 1986.
252. Ajani JA, Baker F, Spitzer G, Brock W, Thielvoldt D, Tomasovic B, McMurtrey, Plager C. Adhesive tumor-cell culture system (ATCCS): Preliminary results of clinical correlations. Proc AACR 27:411, 1986.
253. Ajani JA, Levin B, Goudeau P, Kanojia M, Faintuch J, Boman B. Adriamycin with sequential methotrexate and 5-fluorouracil (AMF) for advanced gastric cancer. Proc ASCO 5:93, 1986.
254. Grossie VB, Ota DM, Stephens LC, Ajani JA, Nishioka K. Antitumor activity of host toxicity of continuous intravenous (IV) alpha-difluoromethylornithine (DFMO). Proc AACR 27:292, 1986.
255. Chawla SP, Benjamin RS, Hortobagyi GN, Ajani JA, Bodey GP. Decreased cardiotoxicity of 96-hr continuous infusion Adriamycin compared with Epirubicin. Proc ASCO 5:44, 1986.
256. Baker F, Brock W, Spitzer G, Ajani JA, Tomasovic B, Williams M, Boch S. Design consideration of an in-vitro drug and radiation sensitivity assay for human tumor cells. . Proc AACR 27:411, 1986.
257. Singletary E, Baker F, Thielvoldt D, Spitzer G, Ajani JA, Tomasovic B, Benjamin R, Ames F. Influence of prior chemotherapy (PT) on in-vitro drug response in melanoma and sarcoma. Proc ASCO 5:128, 1986.
258. Grossie B, Benitez M, Ota D, Ajani JA, Nishioka K. Influence of total parenteral nutrition (TPN) on tumor growth and erythrocyte (RBC) polyamine levels of colon tumor-bearing (TB) rats. Proceeding ASPEN , 1986.
259. Grossie B, Nishioka K, Ota D, Ajani JA. Influence of TPN on polyamine biosynthesis in tumor bearing (TB) rats. JPEN 10:3S, 1986.
260. Ajani JA, Tomasovic B, Spitzer G, Kavanagh J, Thielvoldt, Baker F, Gershenson D. In-vitro activity of 2-fluoro-ara AMP against gynecologic malignancies in the soft agar assay. Proc 14th International Cancer Congress, Budapest, Hungry 1:407, 1986.
261. Spitzer G, Ajani JA, Baker F, Thielvoldt D, Tomasovic B. In-vitro comparison of response to interferon and chemotherapy of human tumors. Proc AACR 27:313, 1986.
262. Reichardt P, Baker F, Ajani JA, Spitzer G, Tomasovic B, Nelson R. In-vitro drug combinations for human tumor cells in the adhesive tumor-cell culture system (ATCCS). . Proc AACR 27:371, 1986.
263. Reichardt P, Baker F, Ajani JA, Spitzer G, Tomasovic B. In-vitro drug combinations for human tumor cells in the adhesive tumor-cell culture system (ATCCS). . 14th International Cancer Congress, Budapest, Hungry 3:1073, 1986.
264. Boman B, Gagen M, Ajani JA, Dimery IW, Bonnen E, Golando J, Neidhart J. Phase I study of Schering recombinant gamma interferon. Proc ASCO 5:236, 1986.
265. Spitzer G, Baker F, Ajani JA, Tomasovic B, Thielvoldt D. Activity of investigational agents: Caracemide(CA), Taxol (TA), and Spirogermanium (SP) in the adhesive tumor cell culture system. Proceedings AACR 26:334, 1985.
266. Baker F, Spitzer G, Ajani JA, Lukeman J, Pathak S, Brock W, Tomasovic B, Thielvoldt D. Adhesive tumor cell culture system: Successful primary culture of human tumor cells on an adhesive substrate. Proceedings AACR 26:367, 1985.
267. Grossie B, Nishioka K, Martin S, Ajani JA, Ota D. Amino acid (AA) precursors of erythrocyte (RBC) polyamines in tumor bearing rats. Proceedings JPEN 9(1):117, 1985.
268. Patt Y, Ajani JA, Boddie A, Charnsangavej C, Claghorn L,Soski M. Arterial cisplatin (CDDP) and floxuridine (FUDR) for colorectal cancer metastases to liver. Recent Advances in Cancer, Proceedings 14th International Congress of Chemotherapy, Kyoto (University of Tokyo Press), Japan:1168-1167, 1985.
269. Patt Y, Boddie A, Ajani JA, Charnsangavej C, Claghorn L, Soski M, Mavligit G. Arterial cisplatin (CDDP) and floxuridine (FUDR) for colorectal cancer metastatic (CRC) to the liver. . Proceedings ASCO 4:94, 1985.
270. Ajani JA, Baker FL, Spitzer G, Mountain C, Tomasovic B, Thielvoldt D. Chemosensitivity of lung cancer according to the stage: An assessment in the adhesive tumor cell culture system (ATCCS). . Proceedings ASCO 4:179, 1985.
271. Singletary E, Romsdahl M, Spitzer G, Baker F, Ajani JA, Tomasovic B, Thielvoldt D. Epidermal growth factor (EGF) induced proliferation and increased chemosensitivity with hormonal interactions in the human stem cell assay (HTSCA) and in the newly developed adhesive human tumor culture system. Proceedings AACR 26:200, 1985.
272. Patt YZ, Boddie A, Charnsangavej C, Ajani JA, Soski M, Claghorn L, Mavligit GM. Hepatic arterial cisplatin and FUDR for colorectal cancer in the liver. Proceedings 2nd International Conference on Advances in Regional Cancer Therapy, Giessen, W. Germany, 1985.
273. Boddie AW, Patt YZ, McBride CM, Wallace S, Ajani JA, Charnsangavej C, Soski M, Levin B. MDAH experience with implantable Infusaid pumps and Medtronic drug administration devices. Proceedings 2nd International Conference on Advances in Regional Cancer Therapy, Giessen, W. Germany, 1985.
274. Harris W, Ota D, Grossie B, Ajani JA, Nishioka K. Monitoring difluoromethyl ornithine (DFMO) inhibition and tumor polyamine.(PA) synthesis. Proceedings AACR 26:374, 1985.
275. Ajani JA, Carrasco C, Charnsangavej C, McClure R, Patt Y, Benjamin R, Samaan N, Wallace S. Regional therapy of endocrine tumors metastatic to the liver. Proceedings 2nd International Conference on Advances in Regional Cancer Therapy. Giessen, W. Germany, 1985.
276. Umbach GE, Tomasovic B, Spitzer G, Umbach U, Merchant N, Ajani JA, Hug V. Chemosensitivity testing of human malignancy at drug concentrations based on dose survival curves of bone marrow progenitor cells. Proceedings AACR 25:373, 1984.
277. Harris WB, Grossie VB, Ota DM, Nishioka K, Ajani JA, Chang T. Effect of continuous infusion difluoromethyl ornithine (DFMO) in tumor bearing rats receiving total parenteral nutrition (TPN). Proceedings AAS , 1984.
278. Ajani JA, Wallace S, Charnsangavej C, Carrasco CH. Percutaneous portal vein chemotherapy infusion for metastatic colorectal carcinoma. Proceedings Intra-arterial and Intra-cavitary Chemotherapy. San Diego, 1984.
279. Ajani JA, Kantarjian H, Kanojia M, Karlin D. Phase II trial of cis-platinum in advanced upper gastrointestinal cancer. Proceedings ASCO 3:147, 1984.
280. Ajani JA, Baker FL, Spitzer G, Tomasovic B, Umbach GThielvoldt D. Relative in vitro activity of chemotherapy agents on colony forming cells from human tumors and normal bone marrow. Proceedings International symposium on Myelosuppressive Effects of Antineoplastic Drugs, Miami, Florida , 1984.
281. Hairston DL Ajani JA. Therapy of carcinoma of the appendix. Proceedings ASCO 3:142, 1984.
282. Harris W, Ajani JA, Hickey R, Stroehlein J. Therapy of islet cell tumors: A review of the M.D. Anderson experience. Proceedings ASCO 3:146, 1984.
283. Stein SH, Ajani JA, Karlin DA, Nelson RS. Combination chemotherapy of hepatocellular carcinoma with 5-fluorouracil, Adriamycin, mitomycin-C, and methyl CCNU (FAMMe). . Proceedings ASCO 2:120, 1983.
284. Ajani JA, Legha SS, Karlin DA, Hill CS. Combination chemotherapy of metastatic carcinoid tumors with 5-FU, Adriamycin, and cytoxan (FAC) and 5-FU, Adriamycin, mitomycin-C, and methyl CCNU (FAMMe). Proceedings ASCO 2:124, 1983.
285. Kanojia MD, Ajani JA, Barlogie B, Zander A. Combination chemotherapy of metastatic colorectal carcinoma with vinblastine, bleomycin, and cis-platinum (VBP). Proceedings ASCO 2:124, 1983.
286. Mahajan SL, Ajani JA, Kanojia MH, Vellekoop L, Bodey GP. Comparison of tow schedules of sequential high methotrexate (MTX) and 5-fluorouracil (5-FU) for metastatic colorectal carcinoma. Proceedings ASCO 2:122, 1983.
287. Feun LG, Yap BS, Benjamin RS, Savaraj N, Burgess MA, Ajani JA, McKelvey E, Bodey GP. Phase I trial of 1,4,5,6,8-pentazacenaphylene, 3-amino, 1,5-dihydro-5-methyl-1-B-D-ribofuranosyl-5'-phosphate ester (TCN-P, NSC 280594) on a 5-day continuous infusion schedule. Proceedings AACR 24:144, 1983.
288. Ranginani RR, Ajani JA, Bedikian AY, Mckelvey EM, Bodey GP. Sequential conventional dose methotrexate (MTX) and 5-fluorouracil (5-FU) in the primary therapy of metastatic colorectal carcinoma. Proceedings ASCO 2:122, 1983.
289. Ajani JA, Legha SS, Burgess MA, Bodey GP. Phase I study of spirogermanium given for 5 consecutive days per week. Proceedings ASCO 1:16, 1982.

Book Chapters

1. Phan A, Ajani JA. Chemoradiotherapy of Gastric, Esophageal, Pancreatic, and Biliary Carcinomas, 2002.
2. Ajani JA. Multimodality therapy of local-regional gastric carcinoma. In: Book of Japanese Gastric Cancer Surgical Society. Tokyo, Japan. June, 1999.
3. Ajani JA. Adjuvant therapy of colon and rectal carcinoma. In: Progress in Anti-Cancer Chemotherapy. Blackwill Science, 135-142, 1997.
4. Ajani JA. Current approaches to local-regional gastric carcinoma. In: Polish Society of Gastric Carcioma, 1997.
5. Ajani JA. Current therapy of advanced gastric carcinoma. In: Polish Society of Gastric Carcioma, 1997.
6. Touroutoglou N, Arcenas AG, Ajani JA. Biology and Therapy of neuroendocrine tumors of the gastrointestinal tract. RPR, 285-298, 1996.
7. Philip PA, Ajani JA. Carcinoma of the Esophagus. In: Medical Oncology: A Comprehensive Review. RPR, 225-234, 1996.
8. Nishioka K, Mitchell MF, Ajani JA. Clinical studies of polyamines and their anti-metabolite. In: Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. Chapman and Hall Publishing Company, 251-278, 1996.
9. Philip PA, Ajani JA. Gastric Carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 235-246, 1996.
10. Ajani JA, Kelsen DP, Rich TA, Roth JA. Chemotherapy and radiation therapy for squamous cell carcinoma and adenocarcinoma of the esophagus and gastroesophageal junction. In: Thoracic Oncology. W. B. Saunders Company, 433-441, 1995.
11. Arcenas AG, Ajani JA, Carrasco CH, Levin B, Wallace S. Vascular occlusive therapy of pancreatic endocrine tumor metastatic to the liver. In: Frontiers of Gastrointestinal Research, Endrocrine Tumors of the Pancreas-Recent Advances. Karger, 1994.
12. Ajani JA Rich TA. Combination of chemotherapy and radiotherapy in the treatment of colorectal carcinomas. In: Chemoradiation Therapy of Gastrointestinal Tract. Lea & Febiger, 330-336, 1993.
13. Soh LT, Ajani JA. Gastric carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 175-184, 1993.
14. Soh LT, Ajani JA. Pancreatic carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 163-174, 1993.
15. Arcenas AG, Ajani JA. Pancreatic Islet Cell and Carcinoid Tumors. In: Medical Oncology: A Comprehensive Review. RPR, 185-198, 1993.
16. Rich TA Ajani JA. Radiotherapy plus concomitant chemotherapy for cancers of the stomach, pancreas, and biliary system. In: Chemoradiation Therapy of Gastrointestinal Tract. Lea & Febiger, 303-314, 1993.
17. Rich TA, Ajani JA. Chemoradiation therapy for Rectal cancer. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 151-162, 1991.
18. Rich TA, Ajani JA. Chemoradiotherapy approaches for treatment of loco-regional bile duct carcinoma. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 135-142, 1991.
19. Rich TA, Ajani JA. Chemoradiotherapy approaches for treatment of loco-regional pancreatic carcinoma. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 143-1150, 1991.
20. Rich TA, Ochran T, Boyer A, Ames F, Ota D, Evans D, Ajani JA. Electron bean intraoperative radiotherapy at M. D. Anderson Cancer Center: Preliminary results. In: Intraoperative Radiation Therapy. Paragamon Press, 81-83, 1991.
21. Roth JA, Ajani JA, Rich TA. Multidisciplinary therapy for esophageal cancer. In: Advances in Surgery. Year Book Medical Publishers, 239-260, 1990.
22. Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA. Resectable Adenocarcinoma of the Esophagus:A Study of Pre- and Postoperative Chemotherapy. In: Adjuvant Therapy of Cancer VI. W.B. Saunders, 396-404, 1990.
23. Hall JT, Wallace S, Carrasco CH, Charnsangavej C, Richli W, Ajani JA, Samaan N, Dodd GD. Gastrointestinal and pancreatic endocrine tumors. In: FL Chan and C Wang. Baillere Tindall, 121-152, 1989.
24. Ajani JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. In: Gastrointestinal Endocrinology, The Gastroenterology Clinics of North America. W. B. Saunders, 923-930, 1989.
25. Ajani JA, McMurtrey M, Rich TA, Blackburn R, Chang-Tung E, Levin B, Roth J A, Mountain CF. Carcinoma of the esophagus: Contribution of chemotherapy. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 272-281, 1988.
26. Baker FL, Spitzer G, Ajani JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system. In: Prediction of Response to Chemotherapy. Alan R. Liss, Inc, 1988.
27. Wallace S, Carrasco C, Ajani J, Charnsangvej C, Samaan N. Embolization of neuroendocrine hepatic metastases. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 337-349, 1988.
28. Rich TA Ajani JA. Radiotherapy of esophageal carcinoma. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 261-271, 1988.
29. Ajani JA Samaan NA. Carcinoids and Islet Cell Neoplasms. (Selected abstracts) . In: ONCOLOGY OVERVIEW NCI/ICRDB, December, 1987.
30. Nishioka K, Grossie VB, Ota DM, Ajani JA. Changes in polyamine metabolism in tumor-bearing hosts with total parenteral nutrition and intravenous infusion of alpha-difluoromethylornithine. In: The Physiology of Polyamines. CRC Press Inc, 1987.
31. Bodey GP Ajani JA. Chemotherapeutic and hormonal approaches to treatment of carcinoma of the pancreas. In: Surgical Diseases of the Pancreas. Lea and Febiger, 748-761, 1987.
32. Ajani JA. Diagnosis and treatment of esophageal carcinoma (selected abstracts). In: ONCOLOGY OVERVIEW NCI/ICRDB, June, 1987.
33. Stroehlein JR Ajani JA. Gastric carcinoma. In: Current Therapy in Gastrointestinal and Liver Diseases. B. C. Decker, Inc, 120-123, 1986.
34. Patt Y, Ajani JA, Boddie A, Charnsangavej C, Claghorn L, Soski M. Arterial cisplatin and floxuridine for colorectal cancer metastatic to the liver. In: Recent Advances in Chemotherapy. University of Tokyo Press, 1166-1167, 1985.
35. Umbach GE, Spitzer G, Ajani JA, Thames H, Hug V, Rudolph F, Drewinko B. Factors determining methotrexate cytotoxicity in human bone marrow progenitor cells: Implications for in vitro drug testing of human tumors. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 443-450, 1984.
36. Spitzer G, Baker F, Umbach G, Hug V, Tomasovic B, Ajani JA, Haynes M, Sahu SK. Growth factor enhancement of the in vitro stem cell assay. In: Predictive Test in Human Cancer; Recent Results in Cancer Research. Springer-Verlag, 1984.
37. Ajani JA, Spitzer G, Baker F, Umbach GE, Tomasovic B, Sahu SK. Human tumor cloning assay with prospective clinical correlations and association between in vitro sensitivity and the number of drugs tested. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 595-604, 1984.
38. Spitzer G, Singletary E, Tomasovic B, Umbach G, Merchant N, Hug V, Ajani JA. Human tumor cloning culture supplements. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 215-228, 1984.

Letters to the Editor

1. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or Calibrate? We Say Calibrate. J Clin Oncol 29: 2732, 2011.
2. Ajani JA. Reply to D. Vordermark. J Clin Oncol.
3. Hofstetter W, Ajani J, Swisher SG. Author reply. Cancer 109: 1449, 2007.
4. Ajani JA. Operate on my stomach cancer? Oh, no--not you, or not yet!. J Clin Oncol 22: 1763-4; author reply 1764-5, 2004.
5. Vauthey JN, Ajani JA. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. J Clin Oncol 21: 4265-7, 2003.
6. Ajani JA. It's the poison that killed him, you say!. J Clin Oncol 21: 3885, 2003.
7. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth?. J Clin Oncol 18: 4001-3, 2000.
8. Ajani JA. In rectal carcinoma, colostomy or no colostomy: is this the question?. J Clin Oncol 11: 193-4, 1993.
9. Rich TA, Hughes L, Ajani JA, Brock W. Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer. Int J Radiat Oncol Biol Phys 18: 710, 1990.
10. Ajani JA. Bolus fluorouracil for metastatic colorectal carcinoma?. J Clin Oncol 7: 1366-7, 1989.